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ABSTRACT
Introduction: Coronary heart disease (CHD) is the major cause of death and disability in the 
Western society. Much is known about the disease process and its contributing risk factors. This, 
and evidence from clinical pharmaceutical trials has been used to develop clinical guidelines for 
best practice. Despite this, the healthcare literature repeatedly demonstrates sub optimal CHD 
risk factor and medical management of patients. More effective measures of health promotion, 
care management directed to achieve risk factor targets and education are recommended.
Study aims and objectives: The research has two main aims. First to investigate the extent to 
which secondaiy prevention measures for CHD patients are managed in a contemporary West of 
Scotland settmg and, second to evaluate a new healthcare model for the secondaiy prevention of 
CHD, with the care to be provided by a cardiac nurse specialist (CNS) working with patients and 
the healthcare team across the primary and secondaiy care interface.
The specific objectives of this thesis are:
• To identify the extent to which evidence based practice is applied to the management of 
patients with CHD.
• To examine the perceived health status of CHD patients and their motivation to make 
healthy lifestyle changes.
• To evaluate the impact of a CNS in the management of patients with CHD.
Patients and Study Design:
The study was undertaken in two phases. The CNS, in partnership with the primaiy care team, 
undertook both phases of the research. Patients (n=531) in phase I (part A) were identified using 
computerised database disease registers. The collection of data consisted of a retrospective 
casenote review of the presence of coronary risk factors and appropriate evidence based medical 
treatments. Following casenote review, patients (n-475), a sub group of phase I (part A), were 
identified for their suitability to participated in phase I (part B), a prospective observational study. 
Patients were sent a postal questiomiaire which examined both the perceived health status of 
patients with CHD, and, the presence of current coronary risk factors. The postal questiomiaire 
also identified those indicating motivation to make healthy lifestyle changes. In phase II, a subset 
of motivated patients from the original cohort of phase I patients, were recaiited to a randomised 
control trial (RCT) (n=91). The RCT was designed to evaluate the impact of a new care model. 
The intervention group (n=45) were recruited to a new nurse-led inteivention, versus, the control 
group (n^46), who were assigned to usual care from their GP practice team.
Results
Phase I -  Part A
The analysis from the retrospective casenote review identified the following percentage of 
patients who had documentation of the main CHD risk factors recorded within the previous 12 
months:
• Blood pressure 40%, weight 59.5% and cholesterol 62% were recorded in patients 
casenotes over a 12 month period.
• Smoking status, ever recorded, was available in 98% of patients casenotes, with a 
documented 23.5% current smokers
• Aspirin 77.5%, beta blockers (post MI) 46% and statin 56% were recorded in casenotes as 
being prescribed
Phase I -  Part B
The postal questionnaire achieved the following results:
• 76% of patients responded, with the majority (66%) indicating motivation to make 
healthy lifestyle changes
• Patients were well informed of their past and present medical histoiy and had received or 
obtained relevant education about their health
Phase II
• Baseline levels for cholesterol, blood pressure, smoking, BMI, SF36 and prophylactic 
medication were similar with no statistically significant difference
At 12 months:
There was a significant difference in the changes in cholesterol between the inteiwention 
group (0.74nunol/l) and control group (0.19mmol/l) p=0.018.
The percentage of patients with a target cholesterol (< 5.0mmol/l) was 79% in the 
intervention group versus 45% in the control group (p=0.002).
At 12 months there was a significant difference in the changes in systolic blood pressure 
between the intervention group (17.97mmHg) and control group (5.43mmHg) p=0.009. 
Similarly at 12 months there was a significant difference in the changes in diastolic blood 
pressure between the intervention group (13.13mmHg) versus control group (6.36mmHg) 
p-Q.006
The percentage of patients with a target blood pressure (< 140/85mmHg) was 97% in the 
intervention group versus 61% in the control group for the same period (p=0.000).
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At 12 months there was no significant difference observed between the groups for the 
number of patients achieving smoking cessation (p=0.519). However the total number of 
cigarettes smoked by patients was significantly reduced in the intervention group 
compared to control group (p=0.004).
At 12 months a greater percentage of patients within the intervention group (42%) 
reached target body mass index (BMI) versus control group (19%) (p=0.025).
Some improvements within the inteivention group were made to quality of life, as 
measured by the Short form 36 questionnaire, however these were not statistically 
significant.
At 12 months differences in prescribing of Aspirin 95% versus 93% (p>0.5). Statin 87% 
versus 71% (p=0.092) ACE inliibitor 42% versus 14% (p=0.005) and Beta blocker 47% 
versus 50% (p>0.5), intervention versus control respectively were observed.
Conclusion: Sub-optimal risk factor documentation and management of patients with CHD
continues to exist in current practice. The CNS significantly improved outcomes in secondary 
prevention management of motivated patients with CHD. Further research may wish to examine 
whether this model of care can be effective in patient groups considered to be poorly motivated 
with higher levels of risk factors present. This thesis has proved that this model of care is 
effective in improving risk factor modification in a group most likely to benefit from such 
intervention. In addition to this, the new model of care demonstrates a structured comprehensive 
care pathway, which could be reproducible.
IV
Acknowledgements
The completion of this thesis would not have been possible without the help and support of 
several people. First, and foremost, I would like to thank the patients for their incredible 
dedication to the study. I thank them for their time, humour and motivation.
I would like to thank my supeivisors. Dr Grace Lindsay, for her support and expertise in guiding 
me through the research process and her incredible patience and friendship. Dr Frank Dunn, for 
his trust in me to undertake this thesis, also his forward thinking to support the research project.
A thank you to the Nursing and Midwifery School, University of Glasgow, in particular my 
advisor. Professor Lorraine Smith for her advice and understanding.
In addition I would like to take tlris opportunity to thank the following colleagues for their 
contribution. Dr Aim Doubal, Dr Maiy Harris and Dr William Johnstone, who were kind enough 
to invite me into their practices and offer me support and encouragement. The entire practice staff 
team who made me feel veiy welcome and provided me with assistance, tea and laughter. Dr 
Haiper Gilmour, Patricia Meldrum and Neil O’Shauglmessy for their statistical advice. Special 
thanks to Dr Kerry Jane Hogg, Dr Nicholas Goodfield, Dr Mitchell Lindsay, Dr Joanne Lindsay 
and Aim Wright for their practical advice and unwavering support.
A very sincere thanks to Dr Andrew McGavigan for his endless nagging, I know it was meant 
with the kindest of intention.
I would like to thank all my family for their constant encouragement. My parents, especially my 
Dad, for his time, travelling hundreds of miles on a regular basis to provide childcare. My 
husband Joe has made incalculable sacrifices, without his love and support, this thesis would still
be on the '‘To do” list. And finally, my children Ethan and Noah, who I love dearly, without them 
I would have completed this thesis a long time ago!
I would like to dedicate this thesis to my parents, Jim and Sheena.
VI
Declaration
The work presented in this thesis was performed solely by the author, except where the
assistance o f others is acknowledged.
Vll
List of contents
1.0 INTRODUCTION................................................................... i
1.1 Burden of Coronary Heart Disease............................................................................ 1
1.2 CHD risk factors and management.............................................................................1
1.3 The changing face of Primary Care........................................................................... 3
1.4 The role of Nurse Specialist..........................................................................................3
1.5 Purpose and rationale of the research............................................................................ 4
1.6 Layout of the thesis..............................................................................................................4
2.0 LITERATURE REVIEW.......................................................5
2.1 Search Parameters......................................................................................................  5
2.2 Introduction..........................................................................................................................5
2.3 Epidemiology of coronary heart disease.........................................................................6
2.3.1 W orldwide............................................................................................................................. 6
2.3.2 United Kingdom (U K )........................................................................................................7
2.3.3 Scotland.................................................................................................................................. 8
2.3.4 G lasgow .................................................................................................................................8
2.4 Pathophysiology of Coronary Heart Disease................................................................. 9
2.4.1 Coronary Atherosclerosis................................................................................................... 9
2.4.2 Myocardial ischaem ia....................................................................................................... 10
2.4.3 Manifestations o f myocardial ischaem ia...................................................................... 10
2.4.4 Angina.................................................................................................................................. 11
2.4.5 Myocardial infarction (MI)/Acute Coronary Syndrome.............................................11
2.5 Coronary Risk Factors.....................................................................................................13
2.5.1 Sm oking...............................................................................................................................13
2.5.2 Diabetes................................................................................................................................16
2.5.3 H ypertension.......................................................................................................................16
2.5.4 Hypercholesterolaemia.....................................................................................................18
2.5.5 O besity.................................................................................................................................21
2.5.6 Inactivity............................................................................................................................. 22
2.5.7 A lcohol.................................................................................................................................23
2.5.8 Extent to which risk factors and intervention impact on CHD m ortality...............24
2.6 Management of patients with CH D.............................................................................. 25
2.6.1 Joint British Guidelines.....................................................................................................25
2.6.2 Scottish Intercollegiate Guidelines Network (SIGN).................................................27
2.6.3 National Service Framework (N SF).............................................................................. 27
Vlll
2.7 Overview of current practice......................................   28
2.7.1 Surveys o f secondary prevention management........................................................... 29
2.8 Prophylactic medication..........................   31
2.8.1 Antiplatelet therapy .......................................................................................................... 31
2.8.2 Beta adrenergic blocking agents (|3 blockers)...................  33
2.8.3 Statins...................................................................................................................................34
2.8.4 Angiotensin Converting Enzyme Inhibitors................................................................34
2.9 Implementation of prophylactic medications..........................       36
2.10 Quality of Life (QOL)...................................   36
2.11 Behavioural change........................................................................................................40
2.11.1 Motivational interviewing............................................................................................. 40
2.12 Nurse-led Intervention............................................................................................... 41
2.12.1 Introduction......................................................................................................................41
2.12.2 Advanced nursing roles..................................................................................................42
2.12.3 Nurse Consultants............................................................................................................43
2.12.4 Cardiac Nurse Specialist R o le s ....................................................................................43
2.13 Conclusion.................................................................................................................... 48
3.0 LITERATURE PERTAINING TO METHODS................. so
3.1 Introduction....................................................................................................................... 50
3.2 Research Design.................................................................................................................50
3.3 Ethical considerations......................................................................................................51
3.4 Subject recruitment and consent.........................................................................  52
3.5 Randomisation............................................................................................................. .....53
3.6 Randomised Control Trials....................................................................   54
3.7 Data collection methods.................................................................................................. 54
3.7.1 Reliability and Validity.....................................................................................................54
3.7.2 Retrospective and Prospective D a ta .............................................................................. 55
3.7.3 Quantitative and Qualitative R esearch ..........................................................................56
3.8 Introduction to Data Collection Tools..........................................................................57
3.8.1 Questionnaires....................................................................................................................57
3.8.2 Postal questionnaires...................................................................... '................................. 58
3.8.3 Interview Schedules.......................................................................................................... 59
3.9 Construction of questions................................................................................................ 59
3.9.1 Open questions.........................................................................   60
3.9.2 Closed questions................................................................................................................ 60
IX
3.9.3 Rating scales..................................................................................................................... 61
3.10 Pre validated research tools....................................................................................... 63
3.10.1 Introduction..............................................................  63
3.10.2 Short form 36 (SF36)......................................................................................................63
4.0 MATERIALS AND METHODS..................................
4.1 Introduction............................................................................................................
4.9 Research Setting
4.14 Phase I -  part B
65
65
65
65
66
66
67
68
.69
.69
69
,70
71
.71
,72 d:
.72 Î
.72
.73
.73 f
.74 i
.74
.74 /i
,.74
..76 ...I'
.76 :
77
..77
..78 5
..78 Î
___
4.17 Pilot study of intervention.........................................................................................   78
4.17.1 Evaluation of intervention method following pilot study..................................... 79
4.18 Phase II Main study..................................................................................................  80
4.18.1 Baseline V isit............................................................................................................ 80
4.18.2 Clinical Measures......................................................................................................82
4.18.3 Blood Pressure........................................................................................................... 82
4.18.4 Body Mass Index.......................................................................................................82
4.18.5 Venous blood sampling.............................................................................................83
4.18.6 Randomisation for phase II...................................................................................... 84
4.19 Inteivention group.......................................................................................................... 84
4.20 Control group  .......................................................................................................86
4.21 Data Management and Analysis..................................................................................87
4.21.1 Phase 1........................................................................................................................ 87
4.21.2 Phase II....................................................................................................................... 87
4.22 Data Analysis...................................................................................................................88
4.22.1 Variables.................................................................................................................... 88
4.22.2 Summary Statistics................................................................................................... 88
4.22.3 Normal distribution................................................................................................... 90
4.22.4 Hypothesis..................................................................................................................90
4.22.5 Intention to Treat.......................................................................................................91
4.22.6 Presentation of results...............................................................................................91
5.0 RESULTS -  PHASE 1........................................................... 93
5.1 Introduction....................................................................................................................... 93
5.2 Patient selection...........................................................................................   94
5.2.1 Age and gender.......................................................................................................... 95
5.3 Past Medical History...............................................................................   95
5.4 Risk factors.......................  96
5.5 Prophylactic evidence based medication......................................................................98
5.6 P artB ...................................................................................................................................99
5.7 Patient selection.................................................................................................................99
5.8 Questionnaire responses....................................................................   101
5.9 Medication........................................................................................................................102
5.10 Perceptions of general health and fitness................................................................. 102
5.11 Motivation to change....................................................................................................103
XI
5.12 Education...........................   105
5.13 Conclusion..............   106
6.0 RESULTS -  PHASE II.........................................................107
6.1 Introduction......................................................................................................................107
6.2 Patient selection...............................................................................................................107
6.3 Questionnaire A response rate..................................................................................... 108
6.4 Patient selection...............................................................................................................109
6.5 Summary of baseline characteristics for randomised control trial...................... I l l
6.6 Follow up of patients......................................................................................................113
6.7 Changes from baseline to 12months.........................   114
6.8 Percentage of patients reaching target levels in accordance with current 
guidelines.................................................................................................................................116
6.9 Prophylactic evidence based medication....................................................................118
6.10 Short Form 36 health survey (SF-36).......................................................................121
6.12 Analysis by Intention to Treat................................................................................... 124
6.13 Trends in risk factors over 12 months for the intervention group only............ 125
6.13.1 Blood pressure...............................................................................................................125
6.13.2 Body mass index (BM I).............................................................................................. 127
6.13.3 Cholesterol.....................................................................................................................128
6.14 Conclusion.....................................................................................................................129
CHAPTER 7.0 DISCUSSION...................................................................... i30
7.1 Introduction..................................................................................................................... 130
7.2 Research Aims and Questions...................................................................................... 130
7.3 Answering the research questions................................................................................131
7.4 Observed levels of coronary risk factor documentation in medical casenotes for 
those patients with known CHD...............................................................  131
7.5 To what extent are patients with CHD managed in relation to reaching 
recommended target levels for coronary risk factors?.................................................133
7.6 Prescribing trends for the implementation of evidence based prophylactic 
medication in patients with CH D..................................................................................... 135
Xll
7.7 Sub optimal management does not appear to affect patients perceptions of 
general health......................................................................................................................... 136
7.8 Patient motivation to make healthy lifestyle changes...............................................137
7.9 The impact of the CNS in improving and managing CHD in those patients 
motivated to make healthy lifestyle changes....................................................................138
7.10 Study limitations............................................................................................................143
7.11 Recommendation for further research.....................................................................144
7.12 General conclusions.....................................................................  145
7.13 Full Circle.......................................................................................................................146
Appendix I: Coronary event rates per country from the WHO MONICA Project for 
(a) men and (b) women......................................................................................................... 161
Appendix II: ABCD to hypertension.................................................................................163
Appendix HI: Body Mass Index Calculation............................................   165
Appendix IV: Proposal for Ethical Approval................................................................167
Appendix V: Proforma.........................................................................................................174
Appendix VI: GP consent forms for contacting patient by postal questionnaire.... 178
Appendix VH: Postal questionnaire................................................................................. 180
Appendix VHI: Interview Schedule.................................................................................. 188
Appendix IX: Patient held record cards......................................................................... 197
Appendix X: Abstract accepted for poster presentation at the European Society of 
Cardiology 2000, Amsterdam, The Netherlands 26-30 August 2000..........................199
Appendix XI: Professional Nurse: Nurse-led interventions contribute to cutting the 
risks for heart disease...........................................................................................................201
Xlll
List of tables
TABLE 1 T r e a t m e n t  ta r g e ts  f o r  m o d if ia b l e  r is k  f a c t o r s .................................................. 26
T a b l e  2 T im e p l a n  o f  s t u d y ..................................................................................................................67
T a b l e  3 N u m b e r s  id e n t ified  b y  m e a n s  o f  p o w e r  c a l c u l a t io n  f o r  R C T.....................68
T a b l e  4 Su m m a r y  sta t ist ic s  f o r  m o d if ia b l e  r is k  f a c t o r s  P h a se  I pa r t  A ...............97
T a b l e  5 P o st a l  q u e s t io n n a ir e  r e s po n se  in  a c t u a l  n u m b e r s ...........................................109
T a b l e  6 C o n tr o l  a n d  in t e r v e n t io n  g r o u ps  a t  b a s e l in e .................................................... I l l
T a b l e  7 B a se l in e  ci-ia r a c t e r ist ic s  f o r  in t e r v e n t io n  a n d  c o n t r o l  in  r e l a t io n  to
RISK FACTOR TARGETS AND PRESCRIBING..................................................................................112
TABLE 8 B r e a k d o w n  o f  %  o f  p a t i e n t s  d o c u m e n te d  in  b o t h  g r o u p s  w i th  o n e  o r  
m o r e  IH D  d i a g n o s i s ..................................................................................................................... 113
T a b l e  9 Il l u st r a t e s  t h e  c h a n g e s  f o u n d  b e t w e e n  tpie t w o  g r o u ps  a t  12 m o n t h s  115
T a b l e  10 D e m o n st r a t e s  sta tistic a l  sig n ific a n c e  f o u n d  b e t w e e n  g r o u ps  a t  0 a n d  
12 m o n t h s ...........................................................................................................................................118
Ta b l e  11 C i-ia n g es  f o u n d  in  p r e sc r ib in g  b e t w e e n  th e  t w o  g r o u ps  a t  b a s e l in e  a n d
12 MONTH FOLLOW UP...................................................................................................................... 121
T a b l e  12 M e a n  (SD ) Sh o r t  F o r m  36 h e a l t h  su r v e y  (SF-36) sc o r e s  a t  b a s e l in e  a n d  
12 m o n t h s  a n d  m e a n  c h a n g e s  in  sc o r es  b e t w e e n  b a s e l in e  a n d  12 MONTHS IN 
in t e r v e n t io n  a n d  CONTROL GROUPS.......................................................................................122
T a b l e  13 T r e n d s  in  a l c o h o l  c o n s u m p t io n  o v e r  e h e  s t u d y  p e r io d  - f i g u r e s  a r e
PRESENTED IN ACTUAL NUMBERS................................................................................................ 123
T a b l e  14 Su m m a r y  o f  re su lt s  o f  tw o  sa m pl e  t -tests  (u sin g  a n a l y sis  b y  in t e n t io n  
TO t r e a t ) ..............................................................................................................................................124
XIV
List of figures
F ig u r e  1 m e t h o d s  e m p l o y e d  in  t h e  id e n t ific a t io n  a n d  s el e c t io n  o f  pa t ie n t
NUMBERS FOR PHASE I - PART A .....................................................................................................94
F ig u r e  2 P e r c e n t a g e  o f  pa t ie n t s  w it h  d o c u m e n t a t io n  of  o n e  o r  m o r e  IH D
DIAGNOSIS, AS RETRIEVED FROM CASENOTE ANALYSIS.......................................................... 95
F ig u r e  3 C o m p a r is o n  o f  th e  %  o f  pa t ie n t s  f o u n d  in  A SPIR E  a n d  in  th e  c u r r e n t
STUDY WITH DOCUMENTATION OR CORONARY RISK FACTORS.............................................. 96
F ig u r e  4 M eth o d s  e m p l o y e d  in  id e n t ific a t io n  a n d  sel e c t io n  o f  p a t ie n t  n u m b e r s  
f o r  P h a se  I - pa r t  B ....................................................................................................................... 100
FiGUiTE 5 C o m p a r is o n  o f  p a t ie n t  %  w it h  d o c u m e n t a t io n  o f  d ia g n o s is  in  c a s e n o t e  
r e t r ie v a l  v e r s u s  pa t ie n t s  o w n  r e p o r t in g  in  po st a l  q u e s t io n n a ir e .................102
F ig u r e  6 D ist r ib u t io n s  o f  r e s po n se s  o f  pa t ie n t s  pe r c e pt io n s  o f  l e v e l  o f  h e a l t h , 
fit n e ss  AND DIET............................................................................................................................... 103
F ig u r e  7 P e r c e n t a g e  o f  pa t ie n t s  r e s p o n d in g  to  po sta l  q u e s t io n n a ir e  in d ic a t in g  
AREAS OF l ife st y l e  THEY WISH TO ADDRESS..........................................................................104
F ig u r e  8 A c t u a l  n u m b e r s  o f  pa t ie n t s  r e p o r t in g  r e a s o n s  f o r  w is h e ig  t o  m a k e
LIFESTYLE CHANGES..........................................................................................................................104
FIGURE 9 In d ic a t e s  w h e r e  pa t ie n t s  so u r c e  t h eir  e d u c a t io n a l  in f o r m a t io n , d a t a  
ARE pr e se n t e d  AS %  AND PATIENTS MAY HAVE IDENTIFIED MORE THAN ONE AREA 105
F ig u r e  10 M eti-iod s  e m p l o y e d  in  id e n t if ic a t io n  a n d  fo l l o w  u p  o f  pa t ie n t  n u m b e r s  
FOR P h a se  I I ........................................................................................................................................ 108
F ig u r e  11 M eth o d s  e m p l o y e d  in  th e  id e n t ific a t io n  a n d  s el e c t io n  o f  p a t ie n t
n u m b e r s  f o r  P h a se  n  - r a n d o m is e d  c o n t r o l  t r ia l ..................................................... 110
F ig u r e  12 D e t a il s  o u t c o m e  of  pa t ie n t s  u n a b l e  to  c o m pl e t e  12 m o n t h  R C T  114
F ig u r e  13 P e r c e n t a g e  o f  pa t ie n t s  in  b o t h  g r o u ps  r e a c h e ^g  t a r g e t  b l o o d
p r e s s u r e  a t  0 AND 12 MONTHS...................................................................................................116
F ig u r e  14 P e r c e n t a g e  o f  pa t ie n t s  in  b o t h  g r o u ps  r e a c h in g  t a r g e t  c h o l e st e r o l
AT 0 AND 12 MONTHS....................................................................................................................... 117
FIGURE 15 P e r c e n t a g e  o f  pa t ie n t s  in  b o t h  g r o u ps  r e a c h in g  t a r g e t  B M I a t  0 a n d  
12 MONTHS...........................................................................................................................................117
F ig u r e  16 P e r c e n t a g e  o f  pa t ie n t s  pr e sc r ib e d  A spirin  a t  0 a n d  12 m o n t h s .............119
XV
F ig u r e  17 P e r c e n t a g e  o f  pa t ie n t s  p r e sc r ib e d  B e t a  B l o c k e r  a t  0 a n d  12 m o n t h s  
...................................................................................................................................................119
F ig u r e  18 P e r c e n t a g e  o f  pa t ie n t s  p r e sc r ib e d  St a t in  a t  0 a n d  12 m o n t h s .............. 119
F ig u r e  19 P e r c e n t a g e  o f  p a t i e n t s  p r e s c r ib e d  A c e  In i- iib ito r  a t  0 a n d  12 m o n th s  
 120
F ig u r e  20 P r e se n t s  th e  m e a n  r e c o r d in g  o f  sy sto lic  b l o o d  p r e s s u r e  (SBP) in  th e  
in t e r v e n t io n  g r o u p  AT 3, 6, 9 AND 12 MONTHS.................................................................125
F ig u r e  21 P r e s e n t s  th e  m e a n  r e c o r d in g  o f  d ia sto lic  b l o o d  p r e s s u r e  (D B P) in  th e  
in t e r v e n t io n  g r o u p  AT 3, 6, 9 AND 12 MONTHS.................................................................126
F ig u r e  22 P r e se n t s  tite m e a n  r e c o r d in g  o f  b o d y  m a ss  in d e x  (BMI) in  tfie
INTERVENTION GROUP AT 3, 6, 9 AND 12 MONTHS.................................................................127
F ig u r e  23 P r e se n t s  th e  m e a n  r e c o r d in g  o f  to ta l  c h o l e st e r o l  in  tfie in t e r v e n t io n  
GROUP AT 3, 6, 9 AND 12 MONTHS................................................................................................ 128
XVI
( 'h(ip!n- One - liiirotliH non
1.0 Introduction
1.1 Burden of Coronary Heart Disease
The incidence of Coronary Heart Disease (CHD) in the United Kingdom (UK) accounts for 
approximately 268,000 new cases of myocardial infarction (MI) and 338,000 new cases of angina 
each year. Further, the most recent CHD statistics from the British Heart Foundation (BHF) 
estimate the prevalence to be around 2.6million people (British Heart Foundation 2005).
Epidemiological evidence has observed a fall in the mortality from CHD, which may be attributed 
to a greater understanding of the disease and advances in medical therapy. Flowever, CHD 
remains the UKs leading cause of death, responsible for in excess of 110,000 lives in 2003. In 
Scotland alone, the rate of premature death from CHD was reported to be 84% higher than that 
found in the south west of England (BHF 2005). A distinct north to south divide is known to exist 
witliin the UK, but it would appear from epidemiological work that the gap is widening.
1.2 CHD risk factors and management
CHD is a multifactorial disease. Evidence from large epidemiological studies such as the 
Framingham Study (Woodbuiy, et al 1979) have improved our understanding of coronaiy risk 
factors and their relationship to coronary event rates. Several modifiable risk factors have been 
identified. Risk factors such as hypertension, hypercholesterolaemia and diabetes once 
established and identified can be treated with a combination of lifestyle changes and medical 
therapy. Other modifiable risk factors include smoking, poor diet, inactivity and excess alcohol 
(Lindsay 1997).
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In addition to addressing lifestyle issues, medical therapy is an important factor in the 
management of CHD. Landmark clinical pharmaceutical trials, for example the Scandinavian 
Simvastatin Suivival Study (4S) (Scandinavian Simvastatin Survival Study Group 1994) and the 
First International Study of Infarct Survival (ISIS 1) (First International Study of Infarct Survival 
Collaborative Group 1986) have clearly demonstrated the positive impact that the initiation of the 
appropriate evidence based medication can have on outcomes.
Guidelines outlining the evidence base for best practice in CHD management are widely 
accessible within both primary and secondary care, yet surveys continue to report sub optimal 
management (Aspire Steering Group 1996;Brady, et al 2001). It is likely that a combination of 
patient motivation and the model of care delivery may be responsible for this,
It cannot be overlooked that patients themselves have a large role to play in the management of 
CHD, and should be encouraged to share this responsibility with their healthcare team. Making 
appropriate lifestyle changes to address coronary risk factors and adhering to recommended 
medical therapy has been shown to significantly improve not only coronaiy event rates but all 
vascular event rates (British Cardiac Society 1998;Tunstall-Pedoe et al 1994).
Issues surrounding patient motivation to change have been examined. Motivational interviewing 
(Prochaska, et al 1992) is a psychological model which has been tested in a variety of areas, and 
attempt^ to motivate patients to make positive changes. With regard to CHD management, 
patients who lack motivation may be less inclined to seek medical advice and attempt lifestyle 
changes, and as such may be at higher risk of sustaining a coronary event.
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1.3 The changing face of Primary Care
In 1999 the Scottish Executive, following on from the Acute Services Review (Scottish Office 
1998) published the "Introduction o f Managed Clinical Networks within the NHS in 
'(Scottish Executive 1999). The aims of the Managed Clinical Networks (MCN) are to 
integrate service provision across primary, secondary and tertiary care. In a similar vein to the 
Joint British Societies Guidelines (British Cardiac Society et al. 2005) in cardiology, the MCN’s 
aim to move away from centers working in isolation and join forces to ensure patients are 
provided with the best possible care. Highlighted in the report is a recommendation that the MCN 
concept could prove effective in CHD management. One way of tackling this may be with the 
establisliment of nurse led secondary prevention clinics for management of patients with CHD. 
Some work has been undertaken in this area examining different models of care (Campbell et al. 
1998b; Jolly et al. 1999).
1.4 The role of Nurse Specialist
A number of nurse specialist and advanced nursing posts exist in the United Kingdom, although 
little attention has been given to evaluating these roles in terms of clinical effectiveness. Nurse 
specialist posts exist in almost every area of nursing, within both primary and secondary care, and 
this has predominantly arisen as a result of changes in junior doctors hours, increased demands on 
clinical practice and a recognition of unmet health care needs. Within the cardiology setting 
examples of advanced nursing practice can be seen in both primaiy and secondary care. First, 
nurse led thrombolysis significantly improved ‘door to needle time’ for patients presenting to 
hospital with myocardial infarction (MI), thus improving suiwival rates (Armstrong 2003;Potts 
2002). Heart failure liaison nurses, which originated from Glasgow have been established 
throughout the UK with evidence of effectiveness (Blue et al. 2001). Finally, nurse led chest pain
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clinics are now widely established for the investigation of patients with suspected cardiac chest 
pain.
1.5 Purpose and rationale of the research
Taking all of the above factors into consideration, in addition to Glasgows poor coronaiy heart 
disease record (Tunstall-Pedoe et al 1994), the idea of integrating a cardiac nurse speeialist 
(CNS), with secondary care experience into primary care was conceived. This thesis initially set 
out to examine how well patients with coronary heart disease were managed in primary care. 
Once this initial research question was answered the next phase in the research was to explore the 
impact a specialist cardiac nurse could have in managing patients with coronary heart disease. 
Exploration of the current literature has suggested the need for better assessment and management 
of coronary risk factors and evidence based treatment.
1.6 Layout of the thesis
The thesis begins with a review of the current literature in chapter 2 outlining the main research 
aims. Literature pertaining to the methods employed is discussed in chapter 3, and the materials 
and methods chosen are detailed in chapter 4. Results from the thesis are presented in two 
separate chapters. Chapter 5 presents the results for phase I parts A and B, chapter 6 presents the 
results of the randomised control trial undertaken in phase II. Chapter 7 completes the thesis with 
a broad discussion of the findings and concludes with the main outcomes of the thesis, discussing 
implications of the research, study limitations and considerations for the future.
2.0 Literature Review
2.1 Search Parameters
The literature search undertaken for this thesis was conunenced in 1998 and updated on a 
continuous basis. The following databases were searched: MEDLINE (Index Medicus and the 
International Nursing Index) 1966-March 2006, CINAHL (the Cumulative Index of Nursing and 
Allied Health Literature) 1982-March 2006, BNI (British Nursing hidex) 1985-March 2006 and 
the Cochrane Database.
Key words and phrases used were coronaiy heart disease, secondary prevention, risk factors, 
evidence based medication, prophylactic medication, quality of life, health belief model, and 
advanced nursing practice. In addition grey literature, computerised databases and a variety of 
other sources were also reviewed.
2.2 Introduction
Over the last fifteen years more people have died through coronaiy heart disease (CHD) than any 
other disease or cause (Mackay & Mensah 2004), This chapter explores what has been described 
as a “global epidemic” (World Health Organisation 2005) and also examines the impaet CHD has 
both internationally and nationally. The chapter discusses the pathophysiology and 
manifestations of the disease, and examines its contributing factors. In addition, the evolution of 
advanced nursing roles is described with specific focus given to the role of the Cardiac Nurse 
Specialist (CNS).
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2.3 Epidemiology of coronary heart disease
Data collected from large epidemiological surveys (Potts 2002;Timstall-Pedoe et al 
1994;Woodbiii'y, et al 1979) over the last few decades has improved our understanding of 
coronary risk factors. In addition, these data provide useful infonnation on the incidence, 
prevalence and mortality of CHD.
2.3.1 Worldwide
In 2002 coronary heart disease alone accounted for 7,353,000 deaths in all World Health 
Organisation (WHO) (World Health Organisation 2005) member states. Data pertaining to 
worldwide CHD mortality is not available for all populations and in some areas of the world 
figures are based on crude assumptions (Asplund 2004). Wliat is known from the WHO is that 
variations from death rates as a result of CHD are striking, with the highest incidence reported in 
the ex Union of Socialist Soviet Republics (World Health Organisation 2005). In Europe and 
other countries there appears to be an obvious east to west gradient, however there are also 
observed inter-countiy variations. In the example of tire UK, a distinct north to south gradient 
exists. Epidemiology for the UK is discussed below in section 2,2.2.
Over the last few decades trends in CHD morbidity and mortality have fluctuated (World Health 
Organisation 2005) and there are a number of possible explanations for this. Developing 
countries tend to adopt a western lifestyle, with increased smoking habits and changes in diet 
(Kitamura et al. 2002). There have also been a number of medical advances over this period, 
some examples are; the advent of thrombolytic therapy (The GUSTO Investigators 1993), more 
advanced medical interventions in coronary care units and coronary revascularisation (Charnier et 
a/.;Guerci & Ross 1989;Hillegass & Brott;The GUSTO Investigators 1993), and implementation 
of evidence based medical treatment (Goldman & Cook 1984;Tunstall-Pedoeef al 1994). As a 
result, individuals are living longer.
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Despite what is known about the disease process and its contributing factors the worldwide 
burden of CHD is forecast to worsen and further action must be taken (Asplund 2004;Goldman & 
Cook 1984;Tunstall-Pedoe et al 1994;World Health Organisation 2005).
2.3.2 United Kingdom (UK)
In 2003 CHD alone was the most common cause of premature death in the UK population, 
resulting in just fewer than 114,000 adult deaths (Peterson et a l 2005), (appendix I). In the same 
year CHD was responsible for approximately 38,000 premature deaths in the UK (Peterson , et al 
2005).
The World Health Organisation (WHO) MONICA project (Tunstall-Pedoe et al 1994) published 
results of a large international epidemiology study. The MONICA project was undertaken over a 
10-year period and monitored trends and determinants of approximately 170,000 heart attacks, 
and risk factors in 35 pre-defined populations across 21 countries. One of the main aims of the 
research was to identify what factors were responsible for the decline of CHD. One explanation 
given for the decline in CHD was that event rates were dependent on the driving force behind the 
disease. For example, in populations where changes to improving lifestyle were made, an 
expected decline in CHD death would be expected.
Recent statistics published by the British Heart Foundation (BHF) (Peterson et al 2005) clearly 
show that mortality from CHD is declining. Although there is concern that the number of patients 
with a diagnosis of CHD is rising, this could in part be due to an increasing percentage of people 
sui*viving an acute event and an ageing population. It is also important to note that although death 
rates as a result of CHD in the UK are falling, it would appear to be at a slower rate than in other 
parts of the world (Asplund 2004). For example, between 1989 and 1999 the death rate in men 
aged 35-74 years fell by 39%, however in Norway and Australia it fell by 47% (Peterson et al
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2005). No explanation is given for this but it could be hypothesized that a greater level of health 
flmding in these countries has contributed to these changes.
2.3.3 Scotland
Data observed for the UK indicates a distinct north to south gradient. In Scotland CHD continues 
to be one of the top tliree causes of death (General Register Office for Scotland 2005) with 22% 
of male and 17% of female deaths attributable to CHD in 2003 (Scottish Executive 2005). Death 
rates in Scotland from CHD are declining and this trend is forecast to continue (Peterson et al 
2005). Saving Lives: our healthier nation (Department of Health 1999), a white paper published 
in 1999 set a target of a 40% reduction in cardiovascular disease mortality in 2010. This target 
was not felt to be unrealistic if advances in medical and surgical intervention continue and current 
trends in coronary risk factors are maintained (Critchiey & Capewell 2002). As previously 
discussed mortality rates have declined in other countries, some at a faster rate than others. 
Addressing known coronary risk factors has been reported to reduce CHD mortality by as much 
as 60% to 80% (Capewell, et al 1999).
2.3.4 Glasgow
The UK women in the MONICA (Tunstall-Pedoe,e7 al 1994) study were found to have the 
highest rates of coronary events, with the UK men studied found to have the second highest. The 
UK site was in fact Glasgow, and as a result a number of health initiatives targeting CHD have 
been undertaken in Glasgow in an attempt to impact on this. Over the last 5 years Greater 
Glasgow National Health Service Board (GGNHSB) has been working witli both primaiy and 
secondaiy care to tackle the problem of CHD and address a number of key areas, namely coronary 
risk factors and socio-economic inequalities. In February 1999, the Scottish Executive, 
Department of Health published a report outlining the introduction of Managed Clinical Networks 
(MCN) in Scotland (Scottish Executive 1999). The aim of this concept is to integrate care 
between primaiy, secondary and tertiary care in an attempt to provide patients with the best 
evidence based care. Within the Greater Glasgow National Health Service Board (GGNHSB) a
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MCN has been established specifically to address CHD. General Practices are being encouraged 
to establish secondaiy prevention clinics for the management of patients with CHD.
Surveys have demonstrated that social deprivation plays an important role in the levels of 
coronaiy heart disease found around the world (Marmot 2001b;Tiinstall-Pedoe et al 1994;Yamell 
et al. 2005). Statistics in Public Health, reporting the level of social deprivation by postcode, are 
often measured by means of deprivation category scores (DEPCAT) (McLoone 2004). DEPCAT 
1 refers to the most affluent areas by postcode and DEPCAT 7, the most deprived. In McLoones 
report 30% of the Greater Glasgow National Health Seiwice Board (GGNHSB) population are to 
be found in DEPCAT 7, this represents 7% of the population of Scotland.
2.4 Pathophysiology of Coronary Heart Disease
Coronaiy Heart Disease (CHD) can present as angina, myocardial infarction (MI), heart failure or 
sudden death. The underlying pathophysiology of CHD involves a process called coronary 
atherosclerosis. The following subsections will describe the process of coronary atherosclerosis.
2.4.1 Coronary Atherosclerosis
Atherosclerosis comes from the Greek “athero” (meaning gmel or paste) and “sclerosis” 
(hardness). Atherosclerosis is a slow and complex disease process, which post mortem studies 
has shown to start as early as childliood (Topol et al. 2002). It significantly affects the lumen of 
the coronaiy arteries and is characterized by the accumulation of lipids and fibrous tissue. This 
accumulation of materials (known as atherosclerotic plaque) builds up in the inner layer of the 
coronaiy arteiy (endothelium), causing obstructions to varying degrees. These plaques most 
commonly affect the large and medium-sized coronary arteries and progress as a result of both
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age and other contribnting factors (Sanderson & Kurth 1983). Due to damage to the endothelium, 
fats, cholesterol, platelets, cellular waste products, calcium and other substances are deposited in 
the artery wall (Ross 1999). These cells and surrounding material thicken the endothelium 
significantly, the coronary arteiy's diameter narrows and blood flow decreases, reducing oxygen 
supply. Plaques can grow large enough to significantly reduce the blood's flow through an artery, 
however most of the damage occurs when they become fragile and mpture (Davies 1987).
2.4.2 Myocardial ischaemia
The oxygen supply to the myocardium is supplied by the coronaiy arteries and is dependent on a 
number of haemodynamic factors (Klabunde 2004). The heart unlike other organs in the body 
demands a greater oxygen supply and for this reason experiences the problems related to coronaiy  ^
artery obstruction. Even at rest the heart extracts a maximum amount of arterial blood supply 
(Sanderson & Kurth 1983) and as such has little safety margin in its oxygen extraction. For this 
reason in order for tlie heart to receive more oxygen it must increase the blood flow to the 
myocardium, instead of increasing the oxygen extraction. In normal coronaiy arteries the 
autonomic neiwous system would allow the arteries to dilate therefore increasing oxygen to the 
myocardium in times of stress. However, changes in the vascular pressure as a result of 
atherosclerosis can affect the oxygen supply to the myocardium (Klabunde 2004). The arteries 
have less ability to dilate and are therefore unable to meet the demands of the myocardium. This 
insufficiency results in what is known as myocardial ischaemia (Crossman 2004).
2.4.3 Manifestations of myocardial ischaemia
The symptoms of myocardial ischaemia vary between individuals, and the term angina is used as 
an umbrella term to describe one or more symptoms. Angina was historically first recorded in 
1768, and was described by an English physician in a lecture to the College of Physicians of
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London (Heberden 1802). Angina can be described as stable or unstable and can present in a 
number of ways.
2.4.4 Angina
Classically, patients may complain of central chest discomfort, with possible radiation to their left 
arm and associated shortness of breath (Jackson 2000). In stable angina the symptoms occur as a 
result of coronary ischaemia and will tend to be related to exertion, however, anything, which 
potentially increases the oxygen demand to the myocardium, may result in symptoms (Crossman
2004). Other symptoms of ischaemia exist and include right arm discomfort, jaw discomfort, 
sweating and nausea, however these are usually accompanied with one or more of the main 
presenting features (Jackson 2000).
Unstable angina (UA) is an indication of atheromatous plaque instability and patients should be 
admitted to hospital for monitoring and treatment as there is concern over plaque fissuring and 
embolism (Wallentin et al 2004). Patients with unstable angina may experience symptoms at rest 
or with very little exertion and often symptoms are increased in both frequency and severity 
(Jackson 2000).
2.4.5 Myocardial infarction (MI)/Acute Coronary Syndrome
Rupture of an unstable atheromatous plaque reveals the lipid rich core, which encourages 
thrombin fonnation leading to partial or complete occlusion of the coronary after)/ (Ross 1999). 
This mpture of the plaque leads to myocardial ischaemia and where myocardial necrosis occurs, 
this is commonly referred to as myocardial infarction (MI). With the introduction of newer 
biochemical markers, such as, cardiac Troponins, it has become increasingly more difficult to 
detemrine MI ftom an unstable coronaiy event (Jaffe et al 2004) and as such newer classifications 
of MI have been fomiulated.
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Cardiac chest pain is now differentiated as stable angina and Acute Coronary Syndromes (ACS) 
(Pollack, et a/.;Roe et al. 2005;Wallentin et al 2004). Under the umbrella term of ACS are Non 
ST Elevation Myocardial Infarction (NSTEMI) and ST elevation Myocardial Infarction (STEMI), 
In both circumstances plaque mpture occurs, however the main difference is whether thrombi 
result in partial or total occlusion of the arteiy.
Non ST elevation MI
Patients presenting with NSTEMI tend to have a ‘gmmbling’ course of pain with an increase in 
frequency and severity of a symptoms over a matter of days to hours, this is due to the partial 
occlusion of thrombi. Presentation in NSTEMI involves no ST elevation on the 
electrocardiogram (ECG), symptoms, myocardial necrosis (damage) can occur, however this 
tends to be less and is often not at a level detectable by standard cardiac markers, such as creatine 
kinase (CK).
Risk stratification for this group of patients is important. Patients considered to be at higher risk 
include those with previous MI, diabetes, those requiring urgent coronaiy revascularisation, heart 
failure and hypotension (Boersma et al. 2000). For those patients deemed at higher risk there is 
an increased mortality rate of as much as 9% (Antman et a l 1996) and a combined rate of death, 
MI or revascularisation of 40.9% (Altman 2002).
ST elevation MI
Patients presenting with STEMI tend to have a more sudden onset of pain, due to the occlusion of 
thrombi. As a result of this, STEMI involves ST elevation on the electrocardiogram, symptoms, 
myocardial damage and resultant cardiac enzyme rise.
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Patients sustaining either a STEMI or NSTEMI should ideally be managed in hospital and should 
be offered a cardiac rehabilitation programme in addition to their medical treatment.
2.5 Coronary Risk Factors
Evidence from laboratoty, clinical and epidemiological research has led to major advances in the 
understanding and pathogenesis of atherosclerosis and its major clinical manifestations, CHD. A 
number of modifiable risk factors relating to the progression of coronaiy atherosclerosis and the 
risk of clinical CHD events are known, and reduction of these risk factors has resulted in a 
commensurate reduction in non-fatal and fatal CHD and an increase in life expectancy (British 
Cardiac Society 1998). Thus, there is considerable potential for prevention of CHD. The main 
modifiable risk factors are smoking, diabetes, hypertension, hypercholesterolaemia, obesity, 
inactivity and excess alcohol (Lindsay 1997;Styies & McIntyre 1997). It is accepted that genetic 
factors contribute to CHD, however the World Health Organisation reports that 80%-90% of 
people dying from CHD were found to have one or more risk factor (World Health Organisation 
2005). The following subsections will discuss the extent to which the above risk factors 
contribute to CHD progression and highlight interventions, which could significantly decrease 
coronary event rates.
2.5.1 Smoking
Amongst the general population, smoking is probably the most commonly associated risk factor 
for many different diseases. Over the last fifteen to twenty years smoking has been publicised as 
being detrimental to individuals health. However, it is only really in the last seven years that the 
government has taken action to change the profile of smoking (Department of Health 1998).
Smoking rates in the UK have been falling over the last few decades (Office for National 
Statistics 2003), however there is concern that the number of young females taking up the habit is
13
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increasing (ASH 2004;Depaitment of Health 1998). Smoking is responsible for in excess of
100,000 preventable deaths in the UK eveiy year (The University of Portsmouth for HAD 2002), 
with the highest rates in the North; North East and West England and Scotland. This figure has 
reduced significantly over the last ten years with 120,000 deaths related to smoking reported in 
1995 (The Health Education Authority 1997). This reduction in smoking related deaths is thought 
to be due to the continuous reduction in the percentage of current smokers.
People who smoke (ASH 2004) or who are subjected to secondliand smoke (Chen et al 
2004;Janirozik 2005), are at increased risk of smoking related illness, such as, cancer, heart 
disease and stroke (Doll & Peto 1976). The precise mechanism of the effects of smoking and 
heart disease are still unclear, however it is reported that smokers have higher levels of fibrinogen, 
and platelets become ‘stickier’. Levels of carbon monoxide, found in tobacco smoke increase the 
movement of lipoproteins fi’om the blood stream to the vessel walls, contributing to 
atherosclerosis (Mosca 2004).
In Scotland alone 32% of males and 30% of females were reported to be current smokers in 2001 
with 20% of all deaths from CHD attributed to smoking (Peterson et al 2005). Targets set out in 
the governments ‘White Paper’ Smoking Kills (Department of Health 1998), clearly identify key 
areas of service development to be achieved by 2010. Included in the white paper were proposals 
to employ specialist NHS smoking cessation services, the introduction of nicotine replacement 
therapy (NRT) on prescription and a commitment to ban tobacco advertising. In addition, more 
emphasis was focused on smoke free public areas, which is obviously of current significance with 
the introduction of the recent smoking ban in Scotland. Despite all the above initiatives a great 
deal is dependent on the individual’s own motivation to stop smoking and this will be discussed 
further in section 2.10.
In a study examining the long-term effects on mortality of stopping smoking after Unstable 
Angina (UA) and Myocardial Infarction (MI) (Daly et al 1983), 555 men aged 60 and under who 
had survived a first episode of UA or MI were followed up over 13 years. This study assessed
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498 of the original cohort of patients who were alive two years after their initial event. 124 were 
non-smokers at entry (ex-smokers and never smoked) and 374 were smokers at entiy. Those 
smoking five or more cigarettes for the six months prior to the initial event were defined as 
smokers and all the others including ex-smokers were defined as non-smokers. The results 
showed that mortality in those who continued to smoke was significantly higher (82.1%) than in 
those who stopped smoking (36.9%). In teiins of average annual follow up over the 13 year 
period, those who continued to smoke had a mortality 2.8 times higher than those who stopped 
(p<0.01). The results also suggested that ceasing to smoke is the single most effective action in 
management of patients with CHD.
There is evidence to suggest that addressing smoking cessation in hospitalised patients is effective 
and may result in patients achieving abstinence for longer(Vemon et al 1999). This group of 
patients may be more amenable to the idea due to their current health situation. It is likely that 
owing to a heightened awareness of ill health and probable restrictions on smoking, it may be 
easier to undertake the task of quitting.
A number of methods of smoking cessation interventions exist, for example, nicotine replacement 
therapy (NRT) (Russell 1993), acupuncture (Wliite 2006) and behavioural counselling (Agency 
for Health Care Policy and Research 1996). The literature would suggest that patients attempting 
to quit might be more successful if they seek the assistance of one or more smoking cessation 
intervention (Agency for Health Care Policy and Research 1996). Wliether or not the actual 
interventions are responsible for success is debatable, as perhaps those who seek such methods are 
in fact more highly motivated individuals willing to try anything in an attempt to achieve their 
goal.
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2.5.2 Diabetes
Diabetes mellitus (DM) affects approximately 2 million people in the UK, of these 1.8 million 
have type II diabetes (non insulin dependent) (Diabetes UK & All-party Parliamentary Group for 
Diabetes and supported by the Hansard Society 2005), which represents 3% of the population. 
Diabetes UK forecast a further one million people within the UK have diabetes, which is currently 
undiagnosed (Diabetes UK & All-party Parliamentary Group for Diabetes and supported by the 
Hansard Society 2005). Over the last eight years the incidence of diabetes has risen dramatically 
with an increase of 400, 000 people, (0.7% of the total population).
In Scotland, it was estimated that 210,000 people had diabetes in the year 2000 (Scottish 
Intercollegiate Guidelines Network 2001), representing 4% of the Scottish population, indicating 
that figures in Scotland are indeed higher than the rest of the UK.
Patients with a diagnosis of DM, type I or type II, have a two -  three fold increased likelihood of 
developing CHD (Kanters et al 1999). Patients with type II diabetes are more likely to experience 
macrovascular complications, such as coronary atherosclerosis, although patients with type I 
diabetes are still at risk (Sweeney & Orchard 2004). Of those patients with diabetes 80% will die 
from CHD (Barnet & OGara 2003) .
Diabetes as with CHD is often a multifactorial disease and addressing known risk factors such as 
obesity, smoking, and cholesterol may reduce coronaiy events (British Cardiac Society 
1998;Lindsay 1997).
2.5.3 Hypertension
Blood pressure is the result of cardiac output and peripheral resistance (Chalmers et al 1999). As 
the heart beats and the left ventricle contracts and blood empties into the aorta, this is known as 
the ‘systolic’ blood pressure and is the maximum pressure. As the left ventricle refills this resting 
pressure is known as the ‘diastolic’ blood pressure, blood pressure is measured in mniHg (Watson 
& Royle 1987). Cardiac output is influenced by a number of factors; heart rate, rhytlun, left 
ventricular function, valvular ftinction, preload and autonomic neiwous activity.
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The current WHO definition of hypertension is a systolic blood pressure of > MOminHg and/or a 
diastolic blood pressure of > 90ininHg(World Health Organisation for the Eastern Mediterranean
2005). This is infact higher than the targets set out in the Joint British Societies 
Guidelines(British Cardiac Society, British Hypertension Society, Diabetes, HEART, Primary 
Care Cardiovascular Society, & Stroke Association. 2005) of 140/85mmHg, however the WHO 
definition is aimed at primary prevention.
The causes of hypertension remain unclear (Mayet & Hughes 2003). In approximately 95% of 
cases of hypertension the cause is unknown. This is referred to as ‘essential’ or ‘primaiy’ 
hypertension (Carretero & Oparil 2000). However, it is probable that patients have coexistent risk 
factors, for example, smoking, obesity. In ‘secondary’ hj/pertension a number of causes are 
thought to contribute to hypertension. Renal and endocrine disorders, medication, pregnancy and 
coarctation of the aorta are the main documented causes in secondaiy hypertension (Sinclair et al 
1987). Elevation of both systolic and diastolic blood pressure is associated with an increased 
morbidity and mortality, risk of cardiovascular disease and renal dysfiinction. It is reported that 
an increase of blood pressure of only lOnunHg reduces life expectancy. Elevated blood pressure 
results in the thickening of arteries, with hypertrophied smooth muscle. Larger dilated vessels are 
unable to cope with the increased pressure. The heart is put under strain and can lead to left 
ventricular hypertrophy, atrial fibrillation, and angina (Kannel et al 1998).
Commonly patients are documented to as having “white coat hypertension”. This is normally 
associated with normotensive patients. Evidence demonstrates that patients attending a clinic will 
have elevated blood pressure recordings, however during ambulatoiy recordings at home they are 
entirely normotensive. The reason for this is thought to be due to a stress response, although this 
theoiy is often debated. Some clinicians do not believe that stress affects blood pressure (Jhalani 
et al 2005;Little et al 2002). Similarly, some hypertension patients are thought to have “white 
coat effect”. The patient is known to have hypertension, however is normally well controlled 
when monitored at home. Clinic readings again demonstrate elevated readings(Mansoor et al
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1996). Wliite coat syndrome is important to keep in mind when managing patients blood 
pressure. If this is suspected then a 24 hour blood pressure monitor may be of particular use.
Management of hypertension is often suboptimal with many patients being intolerant to treatment 
and not complying with recommended regimens. Evidence would suggest that suboptimal 
monotherapy may be partly to blame. In a survey undertaken by Sharma et al a reported 60% of 
patients were found to be on only one antihypertensive medication (Sharma et al 2004). In 2004 
the British Hypertension Society published an AB/CD treatment algorithm, (appendix II) to 
improve blood pressure management. Each letter refers to an antihypertensive diiig class. By 
instituting a defined protocol it is hoped that blood pressure will be better controlled and the use 
of monotherapy will be a thing of the past. As yet, there is no evidence to support whether or not 
this is being implemented in clinical practice.
Moreover, as with CHD, risk factors should be documented and addressed. Addressing known 
risk factors such as obesity (Bramlage et al 2004), inactivity , excessive salt intake (LAW 1991) 
and dietary habits (Appel et al 1997) can be effective in reducing blood pressure. Adopting 
lifestyle changes may control blood pressure sufficiently to avoid the commencement of 
antihypertensive medications. This is perhaps not often reinforced to the patient.
2.5.4 Hypercholesterolaemia
The significance of elevated cholesterol as a risk factor for CHD is now well documented. The 
mechanisms by which atherosclerotic plaques are fonned has been studied for over 150 years. In 
1856 a German pathologist, Rudolf Virchow (Virchow 1856) hypothesised a link between 
cholesterol and lipids in the atherosclerotic process. Many years later (1913), further studies 
undertaken confirmed this relationship, and observed artheromatous plaque fonnation in rabbits, 
wliich was identical to that identified in human patients (Anitschkow 1913).
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Despite this knowledge, little emphasis appeared to be directed in addressing cholesterol as a risk 
factor for CHD. This could in part be due to limited epidemiological evidence higWighting this as 
an area of importance. However, in 1970, the ‘Seven Countries Study’ (Keys 1970) demonstrated 
that in countries with high incidence of CHD median cholesterol levels were elevated. 
Conversely, countries with a low median cholesterol level had a lower incidence of CHD,
Studies evaluating the impact of diet on lowering plasma cholesterol concentrations have been 
undertaken, however, the results appear to be variable. Early dietaiy trials in the 1960’s using 
reduced fat did not convincingly demonstrate reduction in cardiac events or mortality (Baker et al 
1963;Greeii et al 1963).
The ‘Diet and Reinfarction Trial’ (DART) (Burr et al 1989), examined changes in fat, fish and 
fibre intakes on death and myocardial infarction. 2,033 men with a history of MI were 
randomised into a three-arm study. Men randomised were allocated to receive advice on each of 
three dietary factors: a reduction in fat intake and an increase in the ratio of polyunsaturated to 
saturated fat, and increase in fatty fish intake, and an increase in cereal fibre intake.’ Total 
cholesterol and HDL cholesterol total were monitored. At six months and at two years patients 
given dietary fat adviee tended to have lower plasma cholesterol levels than the other patients, 
however the differences were not significant. It is possible that during dietary trials there may be 
issues with compliance. Patients in the inteiwention group may not eat exactly what they are 
advised to eat, while patients in the control groups may spontaneously change to that diet being 
tested.
Probably the most convincing evidence to support lowering cholesterol has emerged as a result of 
studies examining the benefits of statins. The publication of landmark trials, such as 4S 
(Scandinavian Simvastatin Survival Study Group 1994) and LIPID (The Long-Term Intervention 
with Pravastatin in Ischaemic Disease (LIPID) Study Group 1998) has radically changed how 
cholesterol is managed in patients with CHD.
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Results from the 4S (Scandinavian Simvastatin Survival Study Group 1994) study demonstrated 
that lowering cholesterol in patients with CHD improved total and CHD mortality. A total of 
4,444 patients aged 35-70 years with Angina or previous Myocardial Infarct (MI) with serum total 
cholesterol of 5.5 -  8.0mmol/l were studied. The study involving both men and women, was a 
double-blind randomised control trial was undertaken with patients receiving either Simvastatin or 
placebo. Patients were stratified for location and previous MI. Groups were well matched for 
age, sex and CHD risk factors. This study demonstrated in a large number not only a reduction in 
cardiovascular mortality (8% in Simvastatin group versus 12% in placebo group, (p= 0.0003) but 
also a non statistically significant difference in non cardiac mortality, disproving previous 
concerns about the safety of Statin therapy. Over the five-year follow up Simvastatin reduced 
total cholesterol by 25%.
In 1989 the Long-Teim Intervention with Pravastatin in Ischaemic Heart Disease (LIPID) (The 
Long-Term Inteiwention with Pravastatin in Ischaemic Disease (LIPID) Study Group 1998) Study 
Group also demonstrated a reduced mortality from CHD and overall mortality. This study 
involved 9,014 male patients aged 31-75 years of age with a past medical history of myocardial 
infarction or hospitalisation for unstable angina. Patients with a broader range of starting 
cholesterol levels 4.0 -  7.0mmol/l were recmited. A double-blind randomised control trial was 
carried out comparing the effects of Pravastatin 40mg once daily with placebo. Groups were 
again equally matched for smokers, hypertensives, etc, with 4,512 patients randomised to be 
treated with Pravastatin and 4,502 to the placebo. Results from the study revealed that mortality 
from CHD causes was 24% lower (p<0.001) in the Pravastatin group. This was attributed to a 
reduction in total cholesterol that was 18% greater than in the placebo group (p<0.001).
As new evidence emerges from clinical trials, the target cholesterol level changes and is widely 
debated. In 1998, the Joint British Guidelines (British Cardiac Society 1998) recommended a 
target cholesterol level of < 5.2mmol/l. This has subsequently been changed and even more 
aggressive target levels are desired. Recommendations from the Heart Protection Study (Heart
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Protection Study Collaborative Group. 2002) reported patients with known CHD should have a 
target cholesterol level of < 3,5inniol/l and medical management with Simvastatin 40mg OD 
should be sufficient to achieve this goal.
Undoubtedly as with the other coronary risk factors, patients should be encouraged to make 
appropriate lifestyle changes. There is evidence to support that in addition to the recognised 
benefits of lifestyle changes, good dietary habits, smoking cessation and increased exercise may 
contribute to reducing semm cholesterol levels (Gotto 1986).
2.5.5 Obesity
Obesity in adults is defined as a body mass index (BMI) >30. The BMI is specifically called the 
Quetelet BMI, named after its creator Lambert Quetelet in 1869 (Sucharda 1989). Quetelet 
observed that in adults of normal build, weight was proportional to height squared. A hundred 
years later Keys et al made a similar finding and named the relationship BMI, see appendix III. In 
order to maintain a healthy weight (BMI 18.5-25) energy intake should be equivalent to energy 
expenditure. It is perhaps obvious that excessive sways in either direction will lead to individuals 
becoming underweight or obese.
A number of factors are considered to contribute to obesity, honnones, genetics and metabolic 
rate. However, it cannot be overlooked that a number of socio-economic forces also exist 
(Stunkard & Sorensen 1993). As a nation our current economic growth continues to rise. 
Modernisation has led to individuals undertaking less physical jobs, increased machinery and 
computerisation. Globalisation of food markets, introducing a wide range of convenience 
products, which are foods high in saturated fats and sugars. These factors are likely to have 
contributed to the incidence of obesity. In addition to this, a higher percentage of households are 
car owners (63-85%) (Office for National Statistics 2003) and as a result may undertake less 
physical activity, if any.
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There are approximately 300 million obese people worldwide with an emerging epidemic of 
obesity in the UK (World Health Organisation 2006). A further one billion are thought to be 
overweight (BMI 25-30). The UK has the fastest growing rate of obesity in the developed world. 
Over the last ten years there has been an eight percent (14-22%) increase in the obese adult UK 
population. It is also of concern that one in four children in the UK are overweight or obese with 
a resultant growing incidence of type II diabetes emerging in adolescents (Diabetes UK & All­
party Parliamentary Group for Diabetes and supported by the Hansard Society 2005).
Obese individuals have a two-fold increase of developing CHD (HEA 1990) and it is well 
recognised that dietary modification has a key role to play in not only obesity but in altering other 
CHD risk factors.
2.5.6 Inactivity
Industrialisation, urbanisation and mechanised transport have, as previously mentioned, 
significantly reduced the amount of physical activity we undertake today. Growing evidence is 
emerging demonstrating that regular exercise such as walking, swimming, cycling and dancing 
are of benefit in reducing the risk of coronary events in both primaiy and secondaiy prevention of 
CHD (Williams et al 1987). Despite this knowledge currently more than 60% of the worldwide 
population is not sufficiently active (World Health Organisation 2006) and this may be reflected 
in the growing incidence of obesity in the UK (section 2.4.5).
Regular physical exercise has proven to lower coronaiy risk factor profiles (Taylor et al 2002), 
however debate remains around whether or not it alters the presence or extent of atherosclerosis. 
There is evidence to suggest that reductions in fibrinogen and blood viscosity are observed in 
those who undertake regular exercise (Connelly et al 1992;Elwood et al 1993). Moreover, those 
who regularly undertake moderate to vigorous exercise are shown to lower BMI and insulin 
resistance (Taylor et al 2002), lower blood pressure and increase HDL cholesterol (Despres et al
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1995). Individuals who have previously been physically active are not at less risk, as the benefits 
of physical activity cannot be saved and it is reported that individuals who do not undertake 
regular exercise have a two-fold increase in developing CHD (Morris et al 1990).
A Cochrane review of both men and women of all ages with known CHD demonstrated that 
exercise only cardiac rehabilitation reduced ail cause mortality by 27%, cardiac death by 31% and 
a combined endpoint of mortality, non fatal MI and revascularisation by 19% (Cochrane 4, 2004). 
It is recommended in primary and secondary prevention of CHD that people should undertake 
regular exercise in order to benefit from the cardio-protective effects. How much exercise and in 
what form is unclear. Recommendations from the SIGN guidelines would suggest 30mins of 
moderate to vigorous exercise on most days may be beneficial (Scottish hitercollegiate Guidelines 
Network (SIGN) 2001). Other guidelines (British Cardiac Society, British Hypertension Society, 
Diabetes, HEART, Primary Care Cardiovascular Society, & Stroke Association. 2005) advocate 
the benefits of regular exercise, but do not state the quantity of exercise that should be undertaken.
2.5.7 Alcohol
Perhaps in contrast to other coronaiy risk factors, alcohol is reported to have an inverse 
association with CHD (Marmot 2001a) at low to moderate levels of consumption. Studies 
conducted have demonstrated that at such levels there may indeed be beneficial effects on the 
heart, lowering CHD risk. This is thought in part to be due to changes in platelet aggregation 
(Renaud et al 1992) and an increase in HDL cholesterol levels . But what is light to moderate 
drinking? Reviewing the literature there does not appear to be a clear definition of drinking 
levels. Even published guidelines are not consistent when defining recommended levels. SIGN 
(Scottish Intercollegiate Guidelines Network (SIGN) 2003) guidelines suggest that one “unit” of 
alcohol is approximate to 8g of ethanol. No definition of light or moderate drinking is given 
however it is specified that in excess of 5 units of alcohol a day for men and over 3 units of 
alcohol a day for women is hazardous.
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It cannot be ignored that drinking excessive amounts and “binge” drinking are reported to 
increase coronary risk and can lead to sudden death (Corrao ei al 2000). In addition, the effects of 
excessive or heavy drinking may contribute to increased mortality and morbidity from liver 
disease, hypertension and cancer.
2.5.8 Extent to which risk factors and intervention impact on CHD mortality
Determining the extent to which risk factor changes and medical and surgical interventions 
reduced Scottish CHD mortality was examined by Capewell et al (Capewell et al 1999). Using a 
validated mortality model (Critchiey & Capewell 2002) developed by Capewell et al, data were 
collected over three decades from 1974 to 1994. A model combining effectiveness data from 
meta-analysis of treatment uptake in specific patient categories in Scotland was employed. Data 
from large epidemiological surveys, for example MONICA (Tunstall-Pedoe et al 1994), national 
health seivice sources and local audit were used to estimate how the above factors influenced 
CHD mortality. Where possible the absolute mortality benefit of specific treatments was 
determined. Patient categories examining medical interventions included; 1) initial treatment for 
acute myocaridial infarction, eg, thrombolytic therapy; 2) secondary prevention following 
myocardial infarction, eg, treatment with Aspirin; 3) Treatment of angina in hospital, eg heparin ; 
4) Angina in Primaiy care, eg, patients given Aspirin; 5) Treatment of hypertension, eg, 
antiliypertensive therapy. Surgical interventions being examined included Primary Coronary 
Intervention (PCI), for example, angioplasty, and cardiac surgery, such as coronary arteiy bypass 
graft (CABG). Consideration was made for potential overlaps in the above groups and this was 
addressed using analysis of MONICA data (Tunstall-Pedoe et al 1994).
Trends in coronary risk factor changes were also examined, these included smoking, cholesterol, 
deprivation and blood pressure. Using mean values of these a regression analysis was imdertaken.
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An estimated benefit from the cumulative effects of treatments has been reported and this was 
factored into the analysis.
Following analysis of the data in 1994, the number of deaths from CHD within Scotland was 
actually 6,205 fewer than expected. Concurring with other similar work, Capewell et al attributed 
60% of this CHD mortality reduction to changes in risk factors, with approximately a third related 
to smoking cessation.
2.6 Management of patients with CHD
Prior to 1998 individual British societies representing healthcare professionals worked 
independently, publishing separate guidelines specific to their field, but much of their goals were 
the same. For example, the British H)/perlipidaemia Association compiled and published 
guidelines on the management of hyperlipidaemia (Betteridge et al 1993). In an attempt to 
acliieve a common approach it was felt necessary to include all cardiovascular risk factors, rather 
than focusing on single risk factors and treating them in isolation (British Cardiac Society 1998). 
In order to achieve this hospital and coiumunity based clinical settings were encouraged to work 
together and integrate care developing new strategies for prevention and delivery of CHD care.
2.6.1 Joint British Guidelines
As a result of observing the work of European colleagues who published joint guidelines in 1994 
(Wood et al 1998), the first Joint British Guidelines (British Cardiac Society et al 1998) were 
published in 1998. These joint guidelines were compiled by the British Cardiac Society, British 
Hyperlipidaemia Association, British Hypertension Society and endorsed by the British Diabetic 
Association. The purpose of the guidelines was to achieve a common consensus on the
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management of patients with CHD. The guidelines provided an overview of the best current 
treatment based on the strength of results from large clinical and laboratory trials. Treatment 
targets for coronary risk factors were recommended as detailed below in table one.
Table 1 Treatment targets for modifiable risk factors
R isk factor Target
Systolic blood pressure (SBP) 
mmHg
<140
Diastolic blood pressure (DBF) 
mmHg
<85
Total cholesterol mmol/1 <5.2
BMI <25
Smoking Total cessation
In addition to the above, recommendations for treatment with prophylactic medication were 
given, again based on the best evidence available from large clinical and laboratory trials at this 
time. These are discussed in more detail in section 2.7.
Incorporated into the guidelines was information regarding the use of risk prediction charts 
(Anderson et al 1991;Wood et al 1998), which allow clinicians to evaluate a patients relative risk 
of developing CHD. A number of risk prediction tools exist and have emerged as a result of large 
epidemiological studies, for example, infonnation gathered over the last sixty years from the 
Framingham Study (Woodbury, et al 1979).
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It is important to recognise that these charts were designed with the intention of use in primaiy 
prevention of CHD and must be used with caution in secondary prevention. Many of the 
recommendations for treatment in primary prevention, set out in the guidelines, are equally 
relevant in the secondaiy prevention management of patients with CHD. However, treatment 
targets for those with known CHD are set at a lower level.
2.6.2 Scottish Intercollegiate Guidelines Network (SIGN)
The Scottish Intercollegiate Guidelines Network (SIGN) was established in 1993, and has 
published a wide variety of guidelines developed by multidisciplinary groups across Scotland. 
Guidelines produced are as a result of systematic review and critical appraisal of current literature 
available. The recommendations set out in the guidelines are graded according to the strength of 
the evidence available and allows practitioners the opportunity to prioritise depending on local 
need. The purpose of producing such guidelines is to improve the quality of care and endeavour 
to standardise practice across Scotland.
The introduction of SIGN publications not only reassures practitioners that are they prioritizing 
key areas of importance, but also they are working to evidence based guidelines. Guidelines are 
distributed to general practices as they become available, however it is difficult to laiow how 
widely used these guidelines are, and in what context. Specific guidelines for the use in CHD 
(Scottish Intercollegiate Guidelines Network (SIGN) 2001; Scottish Intercollegiate Guidelines 
Network (SIGN) 2002) are available and provide a clear and comprehensive approach to 
managing patients with CHD.
2.6.3 National Service Framework (NSF)
Although not specific to Scotland, the first National Service Framework (Department of Health. 
2000) published in 2000 set out twelve standards for prevention and treatment of CHD, each
27
ChojUrr 1 Wo I iii m lur t  lirvicw
supported by evidence from clinical trials including the role of primary care in secondary 
prevention. Standards one to four highlight the need for implementing policies that will monitor, 
treat and reduce CHD both in primary and secondary prevention, with emphasis on managing 
CHD in Primary care. This like SIGN proposed to improve the quality of care patients with CHD 
were receiving and also minimise the variation in both practice and outcome across England. 
Despite this publication being specific to England and CHD priorities, much of this is easily 
transferable to the Scottish population.
Patients admitted to hospital with a coronary heart disease (CHD) event should be invited to 
participate in a multidisciplinary programme of secondary prevention and cardiac rehabilitation, 
as recommended in Standard 12 of the National Service Framework for Coronary Heart Disease 
(NSF) (Department of Health. 2000). In addition, a large proportion of CHD patients who are 
managed in general practice and/or on a hospital outpatient basis and who may not have had the 
opportunity to attend fonnal cardiac rehabilitation programmes would benefit from appropriate 
secondary prevention. Cardiac rehabilitation programmes vaiy across the UK in terms of the 
patient groups who are eligible to join. Many limit access to post-myocardial infarction patients 
and post-coronaiy arteiy bypass patients only (Bethell et al, 2001; Thompson et al, 1997).
2.7 Overview of current practice
As previously discussed, a great deal of research in CHD management has been undertaken 
demonstrating the evidence base for best practice. Guidelines are widely accessible yet surveys 
continue to report sub optimal management in patients with CHD. In this thesis two key papers 
are used for reference and comparison. Both papers report on findings from retrospective 
casenote review and discuss risk factor assessment and management, and implementation of 
prophylactic medication.
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As a result of changing national health priorities and new general practitioner (GP) contract 
(Department of Health 2003) there are now established criteria practices should work towards. In 
Glasgow a new chronic disease management (CDM) programme has been established, clearly 
identifying CHD as a priority area. Practices are being encouraged to implement structured 
comprehensive secondary prevention measures and regular external audit is being undertaken to 
assess whether practices are achieving targets set out in their contracts.
2.7.1 Suiweys of secondaiy prevention management
Action on Secondaiy Prevention through Intei-vention to Reduce Events (ASPIRE) (Aspire 
Steering Group 1996) investigators undertook a retrospective and prospective cross sectional 
suiwey of patients medical records and patient interviews to measure how effectively CHD risk 
factors were being assessed and managed. The study looked at 2,583 patients aged 70 years and 
under using a stratified random sample of 12 specialist cardiac centres and 12 district general 
hospitals in the UK. Patients were grouped by gender and one of the following four main 
categories: Coronary Artery Bypass Graft; Percutaneous Coronary Angioplasty; admission with 
Myocardial Infarction and admission with Myocardial ischaemia without evidence of infarct. 
Review of medical casenotes involved documentation of risk factors and management prior to the 
CHD event and approximately six months after the CHD event. Medical note review was 
restricted to the hospital records, which may not give a true representation of documentation, 
however, results obtained from the inteiviews after the event summate this. Interviews and 
assessments were carried out at the General Practices and in the main study 83% attended. 
Findings revealed that documentation and management of risk factors was less than optimal.
In patients with known CHD, ASPIRE documented that 18-20% of patients surveyed were current 
smokers at the time of interview. It also noted that smoking was the most regularly documented
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risk factor but very little was documented with regard to action being taken, for example, advice 
given to patients regarding, smoking cessation. Blood pressure was also well documented,
Brady et al (Brady et al 2001) undertook the largest secondary prevention CHD survey of its time 
witliin the UK. A total of 24, 431 patients with a diagnosis of coronary heart disease had their 
casenotes reviewed. The patients were identified from computerised patient records, from a total 
of 548 general practitioners. Other practices were identified, but were excluded as they had 
previously had CHD audit undertaken, which could bias results.
Approximately a quarter of patients with CHD continued to smoke, this figure was slightly lower 
in ASPIRE, with approximately a fifth of patients documented as current smokers.
In both ASPIRE and Bradys work the amount of exercise undertaken by individuals was not 
documented.
The British Hyperlipidaemia Associations (BHA) guidelines (Betteridge et al 1993) first priority/ 
for treatment is patients with existing CHD, with a total cholesterol >5.2mmol/l. In 'Aspire 72% 
of men and 83% of women had a total cholesterol >5.2mol/l. It is important to recognise that the 
work undertaken by Brady et ai was five years later and it was disappointing that no significant 
improvements were observed.
In addition to the above research EURO ASPIRE (Wood et al 1997) undertook a comparative 
sui-vey observing similar results to both ASPIRE and Brady. This work was subsequently 
repeated and unfortunately there did not appear to be any significant improvements in either risk 
factor stratification and management or implementation of prophylactic medication. This again 
reinforced the need to answer the research questions proposed in tliis thesis.
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2.8 Prophylactic medication
The Joint British Guidelines (British Cardiac Society 1998) recommend that in addition to 
identifying and addressing known coronary risk factors, treatment for patients with IHD should 
also involve the implementation of evidence based prophylactic medication. Ideally patients 
should be prescribed all of the recommended therapies, namely antiplatelet therapy, beta blocker, 
statin and more recently angiotensin converting enzyme inhibitor (ACE I), However, in practice 
this is not always realistic due to contraindications and intolerances.
2.8.1 Antiplatelet therapy
Antiplatelet drugs are widely used in CHD and have been shown to reduce the incidence of MI 
(Antiplatelet Trialists' Collaboration 1994). The action of antiplatelet drugs is to reduce the 
aggregation of platelets in the blood, which may otheivvise lead to thromboembolism and 
subsequent MI. Research undertaken by the Antiplatelet Trialists’ Collaboration demonstrated 
significant benefit for not only those patients deemed at high risk, for example, unstable angina 
and suspected MI, but also, patients at high risk in other categories, such as peripheral vascular 
disease. Reductions in vascular events for the four main categories being examined; previous MI, 
suspected or definite acute MI, previous cerebrovascular CVD and other vascular disease, were 
each highly significant (2P<0.0000I) accounting for approximately one quarter. Wlien examining 
patients at lower risk in the primary prevention groups, this also showed significant reductions in 
both non fatal MI and other vascular events (2P<0.0005 and 2P=0.09 respectively).
Aspirin (Acetvlsalicvlic acid)
The use of aspirin, as an antiplatelet in secondaiy prevention of CHD is well recognized. For 
example, the Second International Study of Infarct Sumval (ISIS-2) (ISIS-2 (Second 
International Study of Infacrt Survival) Collaborative Group 1998) trial demonstrated a 23%
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reduction in vascular mortality when comparing aspirin with placebo. However there is evidence 
to suggest that almost a quarter of patients are not prescribed this (Aspire Steering Group 
1996;Brady et al 2001). Unless specific contra-indications or intolerances exist, aspirin 75mg 
daily is recommended for all patients with CHD (British Cardiac Society, British Hypertension 
Society, Diabetes, HEART, Primaiy Care Cardiovascular Society, & Stroke Association. 
2005;Scottish Intercollegiate Guidelines Network (SIGN) 2001). The rationale behind giving a 
lower dose of aspirin being there are fewer documented side effects and research has shown this 
to be an effective dose (Antiplatelet Trialists' Collaboration 1994).
One explanation for the low prescribing of aspirin may be due to patients buying the dmg 'over 
the counter’ (OTC). Often patients are advised to start taking aspirin, however OTC aspirin is 
significantly cheaper than purchasing it on prescription, hence a large percentage may do this. 
Examining the literature, there was little published in this area; however, two UK surveys 
supported the author’s thoughts. In a London suiwey examining post MI patients as many as 22% 
of patients on aspirin bought this over the counter (Hopper & Pierce 1998). Moreover, not 
surprisingly, those purchasing their aspirin OTC were patients who were still paying for their 
prescriptions. In another survey examining this area, 26% of patients using aspirin purchased this 
OTC (Bedson et al 2001). These figures could account for why research has previously found as 
few as 75% of CHD are prescribed aspirin. Examining the literature it is not clear whether or not 
general practice prescription records take into account only those patients paying for their 
prescriptions or if OTC aspirin is documented. This liighlights an area for the author to focus on.
Adenosine Diphosphate (ADP) receptor antagonists
More recently Clopidogrel, an ADP receptor antagonist has emerged on the market as an 
alternative or additive to aspirin. This is a more potent antiplatelet agent, although significantly 
more expensive. In a trial of Clopidogrel versus aspirin in patients at risk of ischaemic events 
(CAPRIE) (CAPRIE Steering Committee 1996) Clopidogrel was shown to provide an additional 
8.7% relative risk reduction, over and above the previously documented 25% risk reduction
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shown with aspirin. The study concluded that Clopidogrel was expected to prevent approximately 
24 major clinical events versus 19 with aspirin, for each one thousand patients treated for a year. 
However, at present Clopidogrel is only recommended in clinical practice for those patients who 
have either contraindications or previous intolerance to aspirin or deemed to be at higher risk of 
coronaiy events, for ACS, post PCI (Mehta, Yusuf, & Clopidogrel in Unstable angina to prevent 
Recurrent Events (CURE) Study Investigators. 2000).
2.8.2 Beta adrenergic blocking agents (g blockers)
Beta blockers work by decreasing the myocardial oxygen demand. This is done in a number of 
ways: reduction of the resting heart rate, reduction of the heart rate response during exercise, 
lowering blood pressure and lowering the force of ventricular contraction (The BHAT research 
group 1982). Similar to antiplatelet agents, the use of beta blockers in patients with IHD is well 
established (British Cardiac Society, British H^qiertension Society, Diabetes, HEART, Primary 
Care Cardiovascular Society, & Stroke Association. 2005;Scottish Intercollegiate Guidelines 
Network (SIGN) 2002;The BHAT research group 1982). Beta blockers play an important role in 
not only the management of stable angina but also acute coronaiy syndrome and MI (British 
Cardiac Society, British Hypertension Society, Diabetes, HEART, Primary Care Cardiovascular 
Society, & Stroke Association. 2005;Roe, Parsons, Pollack, Jr., Canto, Barron, Eveiy, Rogers, 
Peterson, & National Registry of Myocardial Infarction Investigators. 2005;The BHAT research 
group 1982). The choice of beta blocker varies between physicians, however some are known to 
be more cardio-selective than others, for example metoprolol and atenolol.
The majority of evidence supporting beta blocker usage was undertaken in patients post MI. 
Several studies undertaken in the 1980’s clearly demonstrated significant mortality reduction with 
beta blockers. A landmark study in relation to beta blocker therapy was the first International 
Study of Infarct Survival (ISIS-1), which was undertaken between 1981-1985. A total of 16 027 
patients entering 245 coronary care units (CCU) with suspected acute MI were randomised either 
to a control group or to a group receiving atenolol. This study demonstrated mortality reduction
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within the first seven days post infarct from 4.3% to 3.7% in the treatment group. Similarly, a 
13% reduction in sudden death was observed in post MI patients when propanolol was compared 
with placebo in the Beta Blocker heart attack trial (The BHAT research group 1982). 
Fuithennore, meta analysis of clinical trials has demonstrated that treatment with beta blockers in 
patients with CHD can lead to a 59% reduction in frequency of silent ischaemia .
As with Aspirin, despite this Icnowledge the percentage of patients being commenced beta 
blockers following an MI still remains low. It has been reported that as few as % patients post 
MI are commenced on a beta blocker. A number of documented side effects and 
contraindications exist for this group of dmgs and there may be reluctance fi'om physicians to 
commence beta blockers in view of their potential side effects. Also, a lack of information exists 
at present regarding those patients who have discontinued therapy as a result of undesirable side 
effects.
2.8.3 Statins
The evidence base behind the use of statin therapy has been discussed previously in this chapter, 
section 2.3.4.
2.8.4 Angiotensin Converting Enzyme Inhibitors
Angiotensin Converting Enzyme Inliibitors (ACE I) inhibit the conversion of inactive angiotensin 
I to the powerfiil vasoconstictor angiotensin II (Swanton 1989) and have historically been used in 
the management of chronic heart failure (CHF) and hypertension. More recently epidemiological 
and experimental data suggest that activation of the renin-angiotensin-aldosterone system plays an 
important role in increasing the risk of cardiovascular events and that the inliibition of 
angiotensin-converting enzyme would prevent events related to ischaemia and atherosclerosis 
(Yusuf et al 2000).
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Due to its potential therapeutic implications The Heart Outcomes Prevention Evaluation study 
(HOPE) (Arnold et al 2003b), a landmark study, concluded early due to the clear evidence of 
Ramiprils value. . The purpose of the HOPE study was to examine the benefits of using Ramipril, 
an established Ace Inliibitor and Vitamin E in patients with no evidence of left ventricular systolic 
dysfunction or heart failure in a group of patients at high risk of cardiovascular events. Aside 
from reducing cardiovascular events it was reported that Ramipril had the potential to reduce 
stroke, by lowering blood pressure, and could also avoid the complications of diabetes.
The HOPE study, a double blind, two-by-two factorial, randomised study recruited a total of 9297 
patients (aged 55 years or over) with evidence of vascular disease or diabetes plus one other 
cardiovascular risk factor. The primary outcomes for the study included (1) composite outcome 
of myocardial infarction (MI), (2) stroke or (3) death from cardiovascular causes. Secondaiy 
outcomes examined death from any cause, revascularisation, hospitalisation for unstable angina or 
heart failure and any complications associated with diabetes. Due to the large numbers used in 
the trial it was not thought feasible to undertake echocardiography on all the patients to establish 
ejection fractions, however, patients were not known to have a low ejection fraction (<0.40), 
(noiinal range >0.40) or heart failure.
Patients were assigned to Ramipril lOmg (n=4645) and placebo (n=4652). A sub study 
comparing low dose Ramipril 2.5mg with Ramipril lOmg was undertaken in the remaining 244 
patients. Follow up was six monthly.
Results reported a clear 20% reduction in the relative risk of primaiy outcomes. Following 
further analysis patients in the placebo group had a 17.7%(824) incidence of death from 
cardiovascular cause compared with 14.1%(653) in the Ramipril group, relative risk, 0.78; 
p<0.001. There were also significant reductions in the Ramipril group in contrast to the Placebo 
group, (460 v’s 567 (p<0.001) for patients with documented myocardial infarction and (157 v’s 
226 p<0.001) for documented stroke.
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In conclusion, the findings of the HOPE investigators demonstrated that Ramipril is beneficial in 
a broad spectium of patients with no known heart failure or left systolic dysfunction but who are 
at higher risk of cardiovascular events. The implications this has on physicians and practitioners 
is colossal, not only will it be recommended that Ramipril be incorporated into this group of 
patients but will in time undoubtedly become standard practice, even perhaps on a par with 
Aspirin usage.
2.9 Implementation of prophylactic medications
Following review of the literature it does appear that prescribing of aspirin, beta blockers and 
statins is sub optimal (Aspire Steering Group 1996;Brady et al 2001;Wood et al 1997). The 
current literature does not however give a clear indication of why uptake of these medications is 
poor. Computerised GP records are becoming more and more sophisticated and this may be one 
way to input more information around prescribing. Entering not only drugs prescribed but also 
drugs contraindicated or not tolerated may give a clearer picture. Owing to time constraints this is 
not an area the author will focus on in this research but certainly gives scope for further work.
2.10 Quality of Life (QOL)
Quality of life (QOL) assessment is a central element of clinical trials and associated forms of 
evaluative research. It is now an established end point used in clinical trials, however choosing 
the correct QOL measure must be carefully considered (Juniper 1998). The term QOL is often 
used vaguely and without clear definition (Beattie et al 1997).
In its broadest interpretation quality of life is a concept that should encompass all factors that 
might impact on a persons life and well being. It includes factors such as self-esteem, achieving
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lifes goals and a range of social, emotional and physical components. Evaluating observed 
changes in QOL as a result of a new healthcare intervention or treatment is mostly concerned with 
the impact on illness severity and general concepts of health status (Billingham & Jones 1999). 
This approach therefore can be variable depending on the definition of health being used, as well 
as the individuals interpretation of their status of well being. This is perhaps not surprising given 
many of the variables used in measuring QOL are subjective.
The WHO define health as '‘a state o f complete physical, mental and social well being and not 
merely the absence o f disease”. This definition has been used to develop many health related 
QOL scales and fonns the basis of the short form 36 (SF-36) instmment used in the research for 
this thesis.
Two approaches to measuring QOL exist; they are generic or disease specific. Generic measures 
such as the Short Form 36 (SF-36) (Ware & Sherboume 1992), the Sickness Impact Profile (SIP) 
(Bergner et al 1976), EuroQol (EuroQol Group 1990) and the Nottingham Health Profile (NHP) 
are designed to focus on general health and quality of life. One of the main advantages of generic 
measures is that they can be applied to a varied population in a number of disease areas and in the 
absence of disease. There are however disadvantages of generic measures. In teims of general 
health, generic measures may not always be as responsive to specific change, failing to fiilly 
represent the importance of changes made (Beattie et al 1997). For example, patients with a 
specific disease may have a small improvement in physical function. This may be very relevant 
to how this impacts on their general well being, however may be too subtle to measure.
Deciding which of the generic measures to use may be determined by a number of factors, 
scientific evidence, research questions, the population being studied and the nature of the study 
(Guyatt et al 1993; (Essink-Bot et al 1997).
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Perhaps one of the most widely recognised generic measures of QOL is the SF-36. The SF-36, 
which was adapted from the Medical Outcomes Study permits scoring of a set of eight scales 
displayed as a profile of health status concepts. These include: 1) limitations in physical activities 
because of health problems; 2) limitations in social activities because of physical or emotional 
problems; 3) limitations in usual role activities because of physical health problems; 4) bodily 
pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role 
activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health 
perceptions. The SF36 has been designed for self-administration, telephone administration or 
administration during personal interview. For the purpose of the research for this thesis the SF36 
will be used during phase II, forming part of an inteiwiew schedule (Ware & Sherboume 1992).
In a review of QOL measures used in patients with CHD (Dempster & Donnelly 2000), the SF-36 
was felt to have good psychometric properties. Similarly, a comparative study examining four 
generic health outcome measures (Essink-Bot et al 1997) identified the SF-36 as having the best 
ability to discriminate between groups, with high levels of internal consistency. It is deemed to be 
a reliable and suitable measure of health in a normal population (Jenkinson et al 1993) and for 
those with minor conditions.
Conversely, disease specific measures are designed with the intention of fonmilating questions 
around a specific disease area and its related health problems. Examples of disease specific 
measures within CHD include, the Angina Pectoris Quality of Life Questiomiaire (Marquis et al 
1995), the Minnesota Living with Heart Failure Questionnaire (Rector et al 1992) and the 
Cardiovascular Limitations Profile (CLASP) (Devlen & Maguire 1989). Disease specific 
measures are reportedly more sensitive to subtle changes in the disease area being investigated 
(Beattie et al 1997). However, as with generic measures, disease specific measures can be 
equally vague. Patients own individual experience can vaiy and this may influence how questions 
are answered. This variability in answering specific questions may not allow results to be 
generalised across the population being studied (Dempster & Donnelly 2000).
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The CLASP measure is widely used within CHD, and can be used across a spectrum of cardiac 
areas (Department of Health. 2000;Lewin et al 2002;Smith, et al 2002). The CLASP comprises 
of 37 items, incorporating nine physical and functional dimensions. Included in the functional 
dimensions are mobility, social life and leisure activities. The physical subscales include angina 
symptoms, ankle swelling and shortness of breath. Scores are given to each domain and a CLASP 
score is generated. An examination of the reliability, validity and sensitivity of CLASP (Lewin et 
al 2002) found positive correlations in the majority of parameters studied. Some of the strengths 
highlighted in favour of CLASP included an ability to measure symptoms specific to CHD, the 
measure appeared to be sensitive to changes obseiwed post intervention, and despite its length it 
was easy to complete. However, only patients with chronic angina were examined, and the 
majority of patients were, and had been stable for a number of years. Data were collected at 
baseline and 10 weeks, which is also a possible limitation in this cohort of patients. In 2000 the 
National Service Framework (Department of Health. 2000) recommended the use of CLASP as a 
suitable and reliable outcome measure in patients with CHD.
In the case of CHD, Demptser and Domielly (Dempster & Donnelly 2000), concluded the disease 
specific measures were found to be too narrowly focused on each CHD area, for example MI, 
heart failure, and may not be transferable across different CHD groups. The review also 
considered that there is currently no ‘gold standard’ available to compare QOL measures used, as 
the criterion was so variable. This therefore reinforces that the decision regarding which QOL 
measure to use must be based on a number of factors related to the research questions and the 
nature of the study (Juniper 1998).
In summary, both generic and disease specific measures may be successfully used independently. 
However, in order to supplement and reinforce the generalisability and validity of results, a 
combination of the two may be chosen (Dempster & Donnelly 2000). Additionally, the design of
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the questionnaire with regard to the type of questions being asked, length of questionnaire and 
complexity of questions are important factors.
2.11 Behavioural change
Helping patients to make change, irrespective of what the area of change may be, is often a 
common and difficult task during both nursing and medical consultations. For example, 
opportunistic screening may reveal a patient drinking excess amounts of alcohol. This may not be 
perceived as a problem by the patient, and they may not have considered the potential risks to 
their health. Discussing this as an area for attention can be both sensitive and difficult.
In view of the current health statistics in Glasgow pertaining to CHD (Section 2.2.4) much 
emphasis is now directed on health promotion and tackling issues such as smoking, obesity and 
exercise. Different models exist in describing components and concepts relating to behaviour 
change; Health Belief Model (Becker et al 1974), Social Cognitive Theory (Bandura 
2004;Suminski & Petosa 2006), Theory of Reasoned Action (Donald & Cooper 2001), Theoiy of 
Planned Behaviour (Ajzen 1991;Droomers et al 2004) and Transtheoretical Model (Prochaska, et 
al 1992). The transtheoretical model is probably the one most commonly used in both training 
and the clinical setting today. The transtheoretical model and the ‘cycle of change’ described by 
Prochaska and DiClemente (Prochaska et al 1992) are perhaps better known as motivational 
intemewing, and are discussed in more detail below.
2.11.1 Motivational interviewing
Motivational intemewing as a technique emerged in 1983 as a result of the experience of Dr R 
Miller working in the treatment of problem drinkers (Janz & Becker 1984). This initial concept 
was later expanded and described in 1991 by Dr Miller and Dr S Rollnick. However, in 1995 
owing to a number of interpretations around the concept of motivational interviewing, Miller and 
Rollnick described what they believed to be the definition of motivational interviewing;
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“a directive, client counseling style for eliciting behavior change by helping clients to explore and 
resolve ambivalence (Rollnick & Miller 1995)
Motivational inteiviewing has four basic components, empathetic listening, encouraging patients 
to state their own reasons for change, roll with resistance, and support and self efficacy 
(Prochaska et al 1992). The main aim is to assess the patients readiness for change and then 
conceptualise this in terms of a ‘stage’ or ‘cycle of change’. These individual stages of the ‘cycle 
of change’ are precontemplation, contemplation, preparation, action and maintenance. A later 
addition from Prochaska and DiClemente to the ‘cycle of change’ was ‘relapse’, suggesting that 
relapse is not defined as failure but as a normal part of the change process (Kiishner ei al 1998).
In essence, the ‘cycle of change’ model is an attitudinal model describing how people feel about 
making change rather than how they behave. The aim is not to dictate, but attempt to move 
patients through the process with the appropriate information and education in order to empower 
them to make their own choices. Success may be measured as forward movement from one stage 
to another, rather than ultimate cessation of the activity (Rollnick & Miller 1995).
2.12 Nurse-led Intei*vention
2.12.1 Introduction
The first reports of early day nursing go as far back as the early nineteenth centuiy, with most of 
us familiar with the ‘lady of the lamp’, Florence Nightingale(Nightingale 1859). Nursing roles 
undertaken at this time have continued to develop, however prior to the 1950’s evaluating these 
new models of nursing care was not routinely examined. It was not until the late 1950’s, early 
1960’s that there appeared to be a greater focus on examining these roles in terms of clinical
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effectiveness. Part of the impetus for this shift was to recognise the changing role of nurses and 
also to disseminate this information to other nurses in order to encourage practice development 
(Bigbee 2005).
2.12.2 Advanced nursing roles
A number of nurse specialist and advanced nursing posts exist in the United Kingdom, although 
as previously mentioned little attention has been given to evaluating these roles in terms of 
clinical effectiveness(Castledine 1993). With the expansion of nursing roles comes a variety of 
titles; Nurse Manager (NM); Specialist Nurse (SN); Clinical Nurse Manager (CNM); Clinical 
Nurse Specialist (CNS); Nurse Practitioner, Advanced Nurse Practitioner (ANP) and more 
recently Nurse Consultant (NC).
Newer nurse specialist (NS) roles exist in almost every area of nursing, for example, palliative 
care, stoma care, respiratory, and cardiology. Some evaluation of these roles has been undertaken 
but this is predominantly based on patient satisfaction surveys and clinical audit. Despite this lack 
of effectiveness data, nurse specialist posts continue to be developed in new areas of health care in 
response to reduction in junior doctor hours (Department of Health 1993) and recognition of 
unmet health care needs.
There is also a degree of confiision over the exact definition of the clinical nurse specialist and 
also the qualifications required to undertake such a role. In 1994 the UKCC described a NS as a 
"practitioner who exercises higher levels o f judgement and discretion in clinical care in order to 
function as a specialist nursing practitioner” (UKCC 1994). Although this gives some guidance 
it is still fairly vague and over ten years on this role is open to a variety of inteiprotations. This 
similarly applies to the nurse consultant post, which will be discussed in the next section.
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2.12.3 Nurse Consultants
In 1998, Tony Blair, the current Prime Minister, announced proposals to introduce Nurse 
Consultant (NC) roles within the NHS. This was in part proposed as a result of experienced staff 
leaving clinical posts to advance their career and increase their potential earnings (NHS Executive 
1999). Details of these proposals were outlined in "'Making a Difference: Strengthening the 
nursing, midwifery and health visiting contribution to health and healthcare” (NHS Executive 
1999) As previously discussed, many nurses are working under advanced nursing titles, but what 
makes the NC different? It would appear that this is an ongoing debate (Bryant-Lukosius et al 
2004). The UKCC differentiates the NC from other advanced practitioners stating it is the extent, 
level and complexity of their practice that makes them different. At present the remit of the NC 
posts is variable and evaluation of these posts limited. The specifications as to what postgraduate 
educational is required are unclear (McCreaddie 2006). However, there is a common feeling that 
a Masters degree, with emphasis on the research component (Woodward et al and Caring for 
Scotland 2001) is recommended. A difference in the nature of the NC role between Scotland and 
England has been observed (Manley 1997; Manley 2000) with Scottish nurse consultants 
performing a more defined “lead nurse” role than English counteiparts. Reasons for this are 
unclear, but it possible that this is due to the driving forces behind these posts, at a govermnent 
level.
2.12.4 Cardiac Nurse Specialist Roles
Within the cardiology setting there are a number of NC posts in practice, however the majority are 
in fact south of the border (McCreaddie 2006). Again, it is unclear why this exists, but may stem 
back to different political drivers. Fast track chest pain (Pottle 2005), Nurse led DC 
Cardioversion and Atrial Fibrillation Clinics (Tagney 2005) are a few examples of areas within 
cardiology where NC’s have been established. The CHD and Stroke: Strategy for Scotland, 2002 
(Scottish Executive 2002) highlighted opportunities to extend the scope of nursing practice, 
supporting local CHD initiatives. Within Glasgow, the Managed Clinical Network (MCN) for
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CHD were encouraged to develop consultant therapist and specialist nursing posts in accordance 
with service development (Scottish Executive 2002).
There are many examples of advanced nursing practice in the provision of cardiac care in both 
primaiy and secondaiy care, nurse led thrombolysis (Armstrong 2003), heart failure liaison nurses 
(Blue et al 2001), and nurse led chest pain clmics (Pottle 2005). Such advanced roles have now 
been widely established and accepted in the management of patients with coronaiy heart disease 
(Joss & Lindsay 2003). For patients awaiting coronary artery bypass graft surgery, McHugh et al 
(McHugh et al 2001) demonstrated that a specialist nurse-led programme can improve coronary 
risk factors, anxiety and depression levels, and general health and well being.
There is growing evidence of the effectiveness of nurse-led secondary prevention interventions 
for patients with CHD, with large randomised control trials also highlighting principles of good 
practice (Campbell et al 1998a; Jolly et al 1999). The following are examples of work in this area:
A randomised control trial was conducted in a Primary care setting in the North of Scotland to 
evaluate the effectiveness of nurse-led clinics at improving secondaiy prevention strategies for 
patients with CHD (Campbell et al 1998c;Campbell & Murchie 2004). Nineteen general practices 
were recruited and patients under 80 years, with a documented diagnosis of CHD were identified 
from computer databases and searches for repeat prescription of nitrate therapy. Patients 
(n=3,172) were identified and after screening for exclusion criteria (teiminal illness, severe 
mental illness) and those not wishing to participate a total of 1,343 patients agreed to take part. 
Patients were stratified by age, sex and general practice and randomised to nurse-led intervention 
(n=673) or to a control group (n=670) (usual care from their GP and practice nurse). Every 
patient was encouraged to attend one visit within the first three months. Follow up ranged from 
two to six monthly. The clinics monitored symptoms, drug treatment, blood pressure, lipids and 
behavioural risk factor changes.
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Data were collected prior to commencement of intervention, and at one year. Clinical outcome 
measures were gathered by review of medical notes. Data on Aspirin usage, diet, exercise and 
smoking were collected by means of self-administered postal questionnaires.
Significant changes in the intervention group were achieved from baseline to one year for Aspirin 
usage (taken or contraindicated be allergy or ulcer) 69.4% vs. 81%; Blood pressure 
(<160/90mniHg) 86.7% vs. 96.5%; Lipid management (<5.2mmol/l) 12% vs. 41.1%; Low fat diet 
(DINE score <30) (Roe & Strong 1994) 49% vs. 56.5%; and Exercise (index of physical activity 
>4) 37.6% vs. 42.1%. The results from this study demonstrate that intervention improved all 
aspects of secondary prevention except smoking (n=482 smoking at baseline and n=483 smoking 
at one year).
A different model was approached in the Southampton heart integrated care project (SHIP) (Jolly 
et al 1999). This also involved a randomised control study examining the impact of nurse-led 
care, the model of care delivery was however different. The study assessed the impact of 
coordinated care programmes for patients with a new diagnosis of MI and angina discharged from 
hospital. The nurses involved in the study were specialist cardiac liaison nurses, their input was 
not in providing clinical care but in coordinating care at hospital discharge. The purpose of the 
intervention was to facilitate better communication between primary and secondary care and 
provide structures follow up for the nurses in General Practice. A total of 67 GP practices in 
Southampton and southwest Hampshire were randomised, to intervention (n=33) and to control 
groups (n=34). Outcome measures of BMI, blood pressure and total cholesterol were collected 
before hospital discharge, and at the completion of the study. Those patients recanted to 
intervention were given a programme to coordinate preventive care led by the nurse specialists 
with evidence-based guidance on clinical management attached to each discharge communication. 
Communication between the nurse specialists, practice nurses and GPs was encouraged to manage 
problems. The control group were given usual care from hospital and GP.
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Both groups were followed up by self-administration questionnaires at one month, 4 months and 
one year. Anxiety and depression were assessed using HAD scales (Zigmond 1983) and the 
EuroQol (EuroQol group 1990) visual analogue scale were incorporated into the questionnaires. 
A total of 597 patients (422 with MI and 175 with Angina) were recmited to intervention (n=277) 
and to control (n=320), results were available on 502 at one year with 10% lost to follow up. 
Patients (at baseline) were similar in age, sex, smoking history, BMI, total cholesterol and blood 
pressure in both groups. Liaison nurses carried out a clinical assessment at one year. Data were 
analysed on an intention to treat basis but excluded deaths. There was no significant difference 
between the intervention and control groups in smoking (19% v 20%), lipid concentrations (5.8 v 
5.93nmioi/l), blood pressure (84 v 85mmHg), or fitness (distance walked in 6 minutes 443 v 
433m). Body mass index was slightly lower in the inteiwention group (27.4 v 28.2; p=0.08).
These results were thought to be successful from a methodological and logistic perspective, 
intervention was implemented effectively and loss to follow up small. However, the intervention 
was in ineffective in reducing risk, authors of the study indicated health promotion leaflets (issued 
to the patients in the intervention group) may be partly responsible for this lack of effect, namely 
the leaflets issued gave the wrong messages to the patients regarding recovery time. Another 
explanation for this lack of effect was ‘the liaison nursing service could not influence local service 
provision within the framework of the programme’. Each GP practice appeared to work with 
their own standards of practice, which effectively limited the potential benefit the liaison nurses 
could achieve. This possibly is one of the limitations of the study; communication with the 
particular practices prior to commencement of the inteiwention and agreeing targets and standards 
may have achieved more favourable results.
These two studies produced very different results, one advocating the implementation of nurse-led 
clinics the other demonstrating little effect from nurse-led care. The main difference appears to be 
that of the degree of clinical input from the nurses (allowing for the statistically significant 
improvements in cardiac risk factors). Patients participating in the Campbell study were reviewed
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by the nurses and were actively managed with regard to dmg initiation and titration, goal setting 
for risk factor modification, etc, with good effect, whereas the specialist cardiac nurses in the 
SHIP study had little clinical input to care and had to rely on the patients GP or practice nurse 
implementing the particular discharge care plans.
Nurses have a key role to play in promoting secondaiy prevention. Different models of care exist 
and these at present predominate within secondary care. The way foiward may be to shift the 
emphasis towards adopting integrated care pathways working across the primaiy and secondary 
care interface (Joss & Lindsay 2003). With the introduction of managed clinical networks 
(MCN), (Section 2.2.4) there is huge potential for nurses to be involved with the secondaiy 
prevention management of patients with CHD.
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2.13 Conclusion
From the literature covered there is strong evidence to support the burden coronaiy heart disease 
(CHD) has on our society. A great deal of research has been published in the literature 
contributing to our understanding of the disease process and its contributing risk factors. This, and 
evidence from clinical phannaceutical trials has been used to develop clinical guidelines for best 
practice. Despite this, the literature reviewed repeatedly demonstrates sub optimal CHD risk 
factor and medical management of patients. More effective measures of health promotion, care 
management directed to achieve risk factor targets and education are clearly reported in the 
literature.
Further, the evidence from the literature supports that nurse-led care is effective in managing 
patients with coronaiy heart disease. In this study I hope to illustrate that by integrating a Cardiac 
Nurse Specialist (CNS) between Primary and Secondaiy Care, to manage patients with CHD, 
could result in better implementation of recommended evidence based practice, reduce risk 
factors, improve quality of life and have the potential to reduce morbidity and mortality from 
CHD.
Research Questions:
• Wliat level of coronaiy risk factor documentation occurs in medical casenotes for those 
patients with known CHD?
• How effectively are patients with CHD managed in relation to reaching reconmiended 
target levels for coronary risk factors?
• What percentage of patients with CHD are prescribed evidence based prophylactic 
medication?
• Wliat is the general health of patients with CHD as determined by the presence or absence 
of coronary risk factors?
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What are the perceptions of patients with regard to their current general health?
How motivated are patients with CHD in making appropriate lifestyle changes?
How effective is a specialist cardiac nurse (in Primaiy Care) in improving and managing 
CHD in those patients motivated to make healthy lifestyle changes?
49
< lu'if'tcr Three Ijieraiuiu' rer!<uuii>p !u M eih teh
3.0 Literature Pertaining to Methods
3.1 Introduction
In this thesis a number of different research methods and tools were employed. The research was 
undertaken in two phases (see chapter four). For the purposes of this thesis a quantitative 
approach was used to evaluate the effectiveness of a cardiac nurse specialist (CNS) in the 
management of patients with coronaiy  ^heart disease (CHD). Phase I consisted of a retrospective 
descriptive casenote review of the presence of cardiac risk factors. This preceded a prospective 
observational study, which examined both the perceived health status of patients with CHD, and, 
the presence of current coronary risk factors. The postal questionnaire also identified those 
indicating motivation to make healthy lifestyle changes. Phase II employed a randomised control 
trial of a new care model. This chapter explores the importance of planning research design and 
examines the data collection tools chosen.
3.2 Research Design
To answer the research questions careful consideration must be focused on identifying an 
appropriate research design. The question of research design has been described by Parahoo 
(Parahoo 1997a) in its simplest form as the "how, when and why” data should be gathered and 
analysed. Furthermore, in categorising research design Parahoo describes three main types of 
research, namely experimental research, survey research and case study. Grimes and Shultz 
(Grimes & Schulz 2002) on the other hand describe only experimental and obseivational research. 
Both contribute to the principles underpirming research design.
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Experimental research aims to examine the relationship between the variables under study. This 
design is flirther divided into randomised and non-randomised research. Randomised control 
trials (RCT) will be discussed later in this chapter (Section 3.6). Observational research can be 
analytical, where a research question is broken down into layers in order that the researcher can 
obtain a better understanding of the subject, or descriptive. At a descriptive level there is no 
comparison group. The main purpose of the research is to explore the findings and describe what 
has been discussed about the area under study. One big advantage of descriptive studies is that 
having obtained results a hypothesis can be posed and examined by means of more stringent 
research, for example, a randomised control trial (Grimes & Schulz 2002). Other considerations 
in plamiing the research design with regard to data type are whether the data should be treated 
retrospectively, prospectively, quantitatively, qualitatively or by a mixed method. These data will 
be discussed fiirther in section 3.7. The importance of a good research design following review of 
the literature is well established; the next step is to consider the ethical implications of the 
proposed research.
3.3 Ethical considerations
Early reports of medical ethics date back to 1926, with an association called ‘l ’Association 
Professionnelle Internationale des Médicans’ (World Medical Association 2004), which as a 
result of concerns over surgical practice, was responsible for suspending surgical procedures. 
This association was in fact the beginning of a movement to protect the well being of individuals 
under the care of physicians. In 1947, it was replaced by the ‘World Medical Association’ 
(WMA) and evolved quickly. At this time, owing to the casualties of World War II, there was 
grave concern surrounding a lack of medical ethics. The WMA united and compiled ethical 
guidelines in an attempt to improve practice standards (World Medical Association 2004). From 
1947 to the late 1950’s codes of practice were being developed and the WMA continued to 
monitor and report code violations. However, as a result of the atrocities which were observed
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during the Nuremberg trials (Seidelman 1996), the WMA drafted the first ‘Declaration of 
Helsinki’ (World Medical Association 2004). The document outlines fundamental standards to be 
considered prior to undertaking a research project. The declaration clearly states "it is the duty o f  
the physician in medical research to protect the life, health, privacy, and dignity o f  the human 
subject’ (World Medical Association 2004). Tins should be key in undertaking research and 
remembered throughout the project period. It is also important to recognise that patients involved 
in research should be volunteers and adequately infomied regarding the nature of the research. 
Informed consent is discussed in the following section.
Before any research project is undertaken, it is the responsibility of the researcher to obtain ethical 
approval, which is nonnally obtained from the appropriate Local Research Ethics Committee 
(LREC). Each health board should have access and infonnation on relevant LREC’s (HMSO 
1998).
3.4 Subject recruitment and consent
In obtaining ethical approval for any study, the ethics committee needs to ensure that a number of 
important criteria pertaining to recruitment and consent are satisfied. First, the correct number of 
patients for the study should be calculated by means of undertaking a power calculation (Bland 
1990). Statisticians Gore and Altman (Altman 1980;Gore 1981) stress the need for the correct 
choice of sample size for any study. Recognising not only the statistical implications on the study 
they highlight upon the ethical implications if sample size is not careftilly considered prior to 
commencement of study. A study with an overlarge sample may be deemed unethical through 
urmecessaiy involvement of patients and increased costs incurred. By contrast a study with too 
small a sample size will be unable to detect any clinically important effects, therefore the research 
question may remain unanswered. Once the appropriate number of patients has been agreed and 
ethical approval sought the patients can be contacted.
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Patients participating in the research process must be volunteers and should be flilly infomied and 
give their consent freely, in written form (Abbott & Sapsford 2002a). Detailed in the ‘Declaration 
of Helsinki’ (World Medical Association 2004) is the importance to clearly infoim patients 
approached for any research of the aims, methods and proposed benefits of the study. It is equally 
important to highlight potential dangers which they could encounter. Patients should be allowed 
time, where applicable, to consider their decision. This may not always be ideal as occurs, for 
example, in the case of thrombolytic trials where the speed of drug delivery may detennine 
outcome(Hillegass & Brott 2005). In addition, all patients approached should be aware of their 
right to withdraw from the study at any time without it affecting their subsequent care (Connack 
et al 1998). Finally, patients should never feel threatened or coerced into agreeing to participate 
in the research.
3.5 Randomisation
Randomisation quite simply refers to allocating either patients or variables randomly to a 
particular group. For example, pulling names from a hat to decide who plays in a team. When 
applied to research the most common use of randomisation is in a randomised control trial (RCT). 
This will be discussed fiirther in the next section (Section 3.6). The process of randomisation in 
research plays a number of roles and different trial designs will require different procedures 
(Abbott & Sapsford 2002b). In undertaking randomisation it is suggested that allocating patients 
in blocks provide a better guarantee that treatment groups will be of equivalent size. In addition, 
stratifying the samples by important prognostic factors at baseline may have a cumulative effect 
of balancing allocation within strata, which may be of more potential benefit in smaller trials 
(Karlberg 2000). One of the main advantages of randomisation is that it helps the researcher to 
control possible extraneous variables, that is, it reduces the chances of allocation bias (Cormack ei 
al 1998;Parahoo 1997a).
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3.6 Randomised Control Trials
Phase II of the study employs a randomised control trial (RCT). The RCT is described by Grimes 
and Shultz (Grimes & Schulz 2002) and many others (Clancy 2002;Moher et al 1994;Parahoo 
1997a) as the "gold standard” in research. A randomised control trial (RCT) is an experiment in 
which patients are randomly allocated to one or more group. One of the many strengths of the 
RCT is that it allows one not only to observe findings but also to compare results. In allocating a 
group to control the researcher is able to determine what would have happened to the patients if 
they had not had the treatment(Karlberg 2000). As discussed in section 3.5, the control and test 
groups should have similar baseline values as any bias here may skew the actual results of the 
effect of the treatment.
Clancy (Clancy 2002) is however sceptical of the RCT suggesting that they are expensive and 
artificial. By the latter is implied that treatment given to patients in these trials is superior to that 
given in the real world of health care, and cannot be replicated in nonnal practice.
3.7 Data collection methods
As mentioned in section 3.2, there are many ways to collect data. For this thesis a mixed method 
of data collection was used. The following subsections explore the different methods of data 
collection used in undertaking this thesis.
3.7.1 Reliability and Validity
If research is to be of value, then it must address the issues of reliability and validity (Cormack et 
al 1998). Reliability refers to the issue of whether or not a method of measurement works
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consistently in producing similar results in similar situations (Abbott & Sapsford 2002b).for 
example, in this thesis blood pressure will be measured, two nurses taking the blood pressure 
within a short space of time should obtain the same or very similar result.
Parahoo (Parahoo 1997a) defines a method as valid when it measures what it sets out to measure. 
Pre testing and pilot studies give us the opportunity to examine whether or not we get the 
expected answers. There are a number of validity tests that can be applied. For the purposes of 
the questionnaires face validity (commonly referred to as content validity) will be used. In effect, 
face validity involves giving the questionnaire to anyone, not necessarily an expert on the subject, 
who can ‘on the face of it’ assess whether the questions reflect the phenomena being studied. 
Similarly, by administering the questioimaire to others this enables them to comment on the user 
friendliness. It also allows suggestions to be considered for possible changes and/or alterations to 
design prior to commencing the main study.
3.7.2 Retrospective and Prospective Data
In the design of this thesis both retrospective and prospective data were collected. In gathering 
retrospective data the researcher is able to understand what has happened in the past and in the 
particular area of interest. For example, a retrospective casenote analysis examining the 
documentation around breaking bad news (Barnett et al 2002) reported that although practitioners 
recorded that patients had been spoken to, little other information was documented. One of the 
main disadvantages of this design is the lack of control over the way in which data were 
previously collected (Parahoo 1997a). Data may be missing or illegible and documentation may 
be recorded out of context. In the example used above, staff may have indeed covered all the 
relevant areas pertaining to this event, however it camiot be assumed. This therefore can lead to 
misinterpretation of the facts. Conversely, in prospective data a greater control over data 
collection is achievable. The researcher is able to pre-detemiine the variables to be collected with
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a greater assurance of having complete data. With prospective data the subject selection can also 
be tighter.
3.7.3 Quantitative and Qualitative Research
Data may be generated using a variety of methods and quantitative and qualitative research is 
often described in the literature. For the purpose of this study quantitative research has 
predominantly been chosen, but to illustrate why this method has been chosen, both methods are 
discussed below.
The main methods employed in quantitative research are predetermined, namely the research 
questions and design are fixed prior to commencing the study; structured, variables to be studied 
are decided in advance, minimising the work to the researcher and participant, and finally, 
standardised', each participant is asked the same questions in the same fonnat (Parahoo 1997a). 
Unlike qualitative research, which is more open to change, quantitative research is ordered and 
predictable in its delivery. Quantitative research is typically conducted within the context of 
previous knowledge (Cormack et al 1998). In quantitative research the aim is to measure a 
particular phenomenon. Values or scores are attached to each variable being studied, which 
allows statistical analysis to be undertaken. Qualitative research, by contrast, is more holistic and 
open to the inteipretation of the individual researcher. Quantitative results are more frequently 
described in terms of patterns and themes “observed” rather than “measured” as in a quantitative 
design.
Both methods of research are open to scrutiny and disadvantages to each are proposed. One of 
the main limitations of qualitative research is the subjective nature of the research, which is felt to 
be subject to researcher bias. In addition, it is argued that it lacks reproducibility and 
generalisability (Mays & Pope 1995). Undoubtedly there are disadvantages in quantitative 
research. It may be limited as a result of the inflexible structure, and according to its critics, the
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quantitative approach yields useftil but limited data and provides only a partial view of the 
phenomena being investigated (Parahoo 1997a).
The ultimate decision should be determined by the researcher, and again reinforces the need for 
careâil consideration in research design. Both methods are capable of providing valid results, but, 
for the purposes of this thesis it was felt that a quantitative method would yield the best results. 
Owing to the design of the interview schedule employed in phase II there is little opportunity for 
qualitative data to be collected. This has been chosen specifically due to the time constraints on 
the appointments and volume of patients being studied. In phase I part B, the postal questionnaire 
(appendix VII) gives the opportunity for qualitative data to be gathered and this is presented in 
chapter 5.
3.8 Introduction to Data Collection Tools
Of equal importance in the research design is the correct choice of data collection tools. This 
phase in the research process offers a variety of possibilities. Each data collection tool has its 
limitations (Cormack et al 1998) and therefore it is important to choose the one which best meets 
the needs of answering the research question. The following subsections discuss the data 
collection tools chosen for this thesis.
3.8.1 Questionnaires
One of the most common methods of undertaking research involves the use of questiomiaires 
(Walonick 2005). Structured self-reported data are usually collected in a quantitative study by 
this means. A questiomiaire may be defined as a formal written document (Polit and Hunglar
1997) and is an umbrella term for different instruments (Cormack et al 1998). When
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administered to be completed by the patients themselves, for example, postal questionnaires, this 
is referred to as a questionnaire. Alternatively, when the questions are asked face-to-face with 
the patients this may be referred to as an interview schedule (Abbott & Sapsford 2002a;Parahoo 
1997a). A postal questionnaire will be employed in phase I part B of this thesis (appendix VII) 
and an interview schedule will be administered in phase II (appendix VIII).
Parahoo describes the questionnaire as a ‘research method when it is designed and administered 
solely for the purpose o f collecting data as part o f a research study’ifsadhoo 1997a). In 
constructing the questionnaire, questions must be relevant, clearly presented to minimise 
misinterpretation or bias and must be easy to inteipret and analyse. The questionnaire should 
contain specifically designed questions which will answer the research questions.
3.8.2 Postal questionnaires
Many of us have had experience of completing questionnaires and some may have experience of 
postal questionnaires. Postal questiomiaires offer many advantages to the researcher and are a 
useflil method of reaching a wide population (Connack et al 1998). In addition they incur less 
time and cost and patients are able to answer in their own time and at their convenience. Another 
advantage with this method is the knowledge that there is no intemewer bias (Walonick 2005). 
Undoubtedly there are limitations to the postal questionnaire. Questionnaires may not be 
completed in their entirety and there is no assurance as to who has completed the questionnaire. It 
should also be remembered that literacy levels and language barriers exist and could have an 
impact on how questionnaires are completed and their resultant response rate.
Response rate is a major concern in administering postal questiomiaires and low response rates 
may affect the reliability of the data, introducing bias (Edwards 2005) High response rates are 
reportedly more difficult to achieve with the literature suggesting higher response rates occurring 
as a result of a well-designed questionnaire (Walonick 2005).
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3.8.3 Intei*view Schedules
Due to the time and cost involved in undertaking inteiviews a smaller sample of patients is 
normally investigated. In undertaking a face-to-face interview there is scope for the interviewer 
and inteiviewee to be more flexible. Although in the case of quantitative research the questions 
are delivered in the same format each time, there are possibilities for the respondents to add 
qualitative data in support of their answers. The interview schedule should be planned in such a 
way that the process is standardised fulfilling its role as a scientific instrument (Cormack et al
1998). The quality of the data colleeted during the course of the interview is veiy much 
dependent on the maimer of the interviewer. The main advantage the interview schedule has over 
the postal questionnaire is its ability to reduce the veiy limitations postal questioimaires pose. For 
example, there is less chance of questions being omitted, and clarification of ambiguous questions 
can be addressed. Moreover, the researcher can be assured responses are not contaminated by 
outside influences, for example, questions answered by a partner or friend. In a suivey undertaken 
by the government it was reported that up to 10 percent of the responses were completed by 
someone other than that intended. Finally, the interviewer is able to assist with minimising 
language and literacy barriers.
As with all areas of the research process, limitations to this method exist. In interviews, 
interviewers can read the body language and take it as cues to probe further, if appropriate 
(Coimack et al 1998). Critics will also argue that the interviewers may use voice inflections and 
body language to influence the way a question may be answered.
3.9 Construction of questions
The decision regarding question foimat is very much dependent on the type of data the researcher 
wishes to gather (Parahoo 1997a). In constmcting the questions the aim is to collect valid and
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reliable data, which can be easily administered and analysed. Question formats include, open, 
closed and rating scales. The merits of each are discussed below.
3.9.1 Open questions
Open questions are designed in such a way that they allow the subject to answer in their own 
words. They allow more flexibility in answering, but make analysis of these responses more 
difficult and time consuming (Cormack et al 1998). An example of an open question is;
Wliat areas of nursing research do you feel are important?
Patients may give short or lengthy responses or may indeed be unwilling to answer at all. In the 
case of postal questionnaires this is undoubtedly a disadvantage as questionnaires may be returned 
incomplete, or indeed not returned. Open questions are ideally suited to qualitative research 
studies, and in particular their use in interviews.
3.9.2 Closed questions
In contrast, closed questions have the advantage of restricting the response alternatives. The 
purpose of using questions with such a high degree of structure is to ensure comparability of 
responses and to facilitate analysis (Parahoo 1997a).
The format of closed questions can be restricted to one of two options {dichotomoiis) for example: 
Do you own a car: yes/no?
Nurse led care is effective: agree/disagree
Closed questions can however be constructed to allow more freedom of choice in responses 
{alternative statements) and can also allow respondents to give one or more answer, for example: 
Wliat factors influence where you work:
Staffing levels ( )
Work pattern ( )
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Travel time ( )
Wages ( )
Another advantage of the closed question fonnat is the speed in which the questiomiaire can be 
completed, therefore minimising the risk of respondent fatigue (Cormack et al 1998). Closed 
questions do however have the disadvantage of being more difficult to constmct and the major 
drawback is that the researcher may overlook important features when constructing question 
design. In addition, owing to the restrieted options of responses the patients are obligated to 
choose the one that best suits them but may not truly represent their feelings
Both a postal questionnaire and interview schedule are employed in this thesis (see chapter 4) and 
are constructed with predominantly closed questions, and few open-ended questions. As 
discussed in section 3.7.2, this decision was made due to time constraints.
3.9.3 Rating scales
People’s attitudes are said to be composed of affective, cognitive and behavioural components 
(Spooncer 1992). Measuring individuals’ attitudes through obseiwation is difficult therefore 
another method should be applied. Rating scales are considered to be a reliable and valid method 
of collecting information about patients attitudes and beliefs (Connack et al 1998;Parahoo 
1997a). A number of different rating scales exist but for the puiposes of this thesis the Likert 
method (Likert 1932) and Semantic differential (Osgood 1957) have been chosen.
Likert scales
The Likert method will be used in phase I part B of this thesis (Section 4,13.1). Likert scales are 
widely recognised in all areas of research, for example, these scales are often used by holiday 
companies to evaluate customer satisfaction. The likert scale consists of pre defined statements 
pertaining to a particular issue or event (Coimack et al 1998). An opinion statement is made, for 
example:
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• Nurses are adequately trained to deal with breaking bad news to relatives
The extent to which the respondent agrees or disagrees to this opinion statement is rated on the 
likert scale. The first point on the scale may read, “strongly disagree” with a decreasing range of 
negative responses, ending perhaps with “strongly disagree”. Likert scales are commonly 5 point 
scales however they have the advantage of being flexible and researchers can constmct their own 
number of possible responses to best answer the research questions.
Semantic Differential Scales
Semantic differential (SD) scales will be used in phase II of this thesis (Section 4.18) to gather 
data pertaining to patients cardiac symptoms and management of the same. According to Bowles 
(BOWLES 1986) the semantic differential model ‘is a highly acceptable and frequently used 
measure of attitude and lends itself to statistical techniques for validation purposes’. The 
semantic differential scale is a tool used to rate a given concept on a series of bipolar adjectives. 
Patients are asked to plot a point on the seven point scale that goes from one extreme to another, 
for example, angina does not affect quality of life to angina dramatically impairs quality of life. 
The SD has the advantage of being flexible and easy to constmct (Polit & Hunglar 1997). The SD 
scale and the visual analogue scale are very similar in appearance and both measure attitudes, 
however patients using the visual analogue scale have a continuous line to plot their response. 
This although easy to administer and analyse is not ideal for patients with visual impairment and 
the concept of plotting emotions and attitudes like tliis if not always understood (Parahoo 1997a).
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3.10 Pre validated research tools
3.10.1 Introduction
The question of reliability and validity has been discussed (Section 3.7.1 & 3.8) and highlights the 
importance of choosing the right data collection tools to answer the research question. A number 
of ‘pre validated’ research tools exist. That is, questionnaires which have been constmcted and 
tested for their reliability, validity and generalisability (Long & Johnson 2000). For the purposes 
of this thesis the short form 36 (SF36) (Ware & Sherboume 1992) discussed below, was chosen as 
the most robust tool to examine quality of life.
3.10.2 Short form 36 (SF36)
As previously discussed m section 2.9, instmments designed to measure health related quality of 
life (QOL) can be divided into two categories, disease specific and generic. In order that the 
scores are of practicable benefit to clinicians they must produce valid data. In the case of the SF- 
36 (Ware & Sherboume 1992), several studies have been undertaken examining the validity and 
reliability in both normal patient groups and across differing patient groups with regard to 
diagnosis and socio-demograpliic characteristics (Jenkinson eta l 1993).
The Short Fomi 36 (SF36) permits scoring of a set of eight scales displayed as a profile of health 
status concepts: 1) limitations in physical activities because of health problems; 2) limitations in 
social activities because of physical or emotional problems; 3) limitations in usual role activities 
because of physical health problems; 4) bodily pain; 5) general mental health (psychological 
distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) 
vitality (energy and fatigue); and 8) general health perceptions. The SF36 has been designed for 
self-administration, telephone administration or administration during personal interview. For the 
purpose of this study the SF36 will be used during phase II, forming part of an interview schedule 
(Ware & Sherboume 1992).
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In a review comparing generic measures in patients with IHD, it was concluded the SF-36 was 
most favoured (Dempster & Donnely 2000). This was found to have good psychometric 
properties and appeared to have better constmct validity in the field of IHD. In addition, higher 
internal consistency coefficients were found allowing clearer evidence of discriminative validity.
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4.0 Materials and Methods
4.1 Introduction
This chapter details the measures and methods employed in the design, preparation and 
undertaking of this project. The main points discussed are the research questions, study design, 
etliical consideration, patient selection, recmitment, research and administration of data tools and 
the process of the patient interviews and assessment.
4.2 Study Aims
The research has two main aims. First to investigate the extent to winch secondaiy prevention 
measures for CHD patients are managed in a contemporary West of Scotland setting and, second 
to evaluate a new healthcare model for the secondary prevention of CHD, with the care to be 
provided be a cardiac nurse specialist (CNS) working with patients and the healthcare team across 
the primary and secondary care interface.
4.3 Study objectives
• To identify the extent to wiiich evidence based practice is applied to the management of 
patients with CHD.
• To examine the perceived health status of CHD patients and their motivation to make 
healthy lifestyle changes.
• To evaluate the impact of a cardiac nurse specialist (CNS) in the management of patients 
with CHD.
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4.4 Research Questions
• Wliat level of coronary risk factor documentation occurs in medical casenotes for those 
patients with known CHD?
• How effectively are patients with CHD managed in relation to reaching reconunended 
target levels for coronary risk factors?
• Wliat percentage of patients with CHD are prescribed evidence based prophylactic 
medication?
• What is the general health of patients with CHD as determined by the presence or absence 
of coronary risk factors?
• What are the perceptions of patients with regard to their current general health?
• How motivated are patients with CHD in making appropriate lifestyle changes?
• How effective is a specialist cardiac nurse (in Primary Care) in improving and managing 
CHD in those patients motivated to make healthy lifestyle changes?
4.5 Study Design
In an attempt to answer the research questions and achieve the study aims the project was 
designed and undertaken in two phases. A quantitative approach predominates in the design of 
the study. Phase one was undertaken in two parts. Phase I, part A was a retrospective descriptive 
survey of patient casenotes using a profoima for data collection. Phase I, part B was a prospective 
observational study, in the form of a self-completed postal questionnaire.
Phase 11 was a one-year randomised control intervention study. This incorporated both clinical 
and semi-stmctured interview methods for the intervention group and usual care for the control
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group. The differences between both groups are discussed in detail in section 4.18-4.19. A
cardiac nurse specialist, namely the researcher, delivered intervention. Time allocated for the 
study included study design, ethical approval, pre-testing, pilot work and the main randomised 
control trial (RCT). Therefore, it was anticipated that the work would be undertaken over a
period of 36 months. A breakdown of the timetable of work and study design is given below in
table 2.
T able 2 Tim e plan o f  study
J J A S O N D J F M A M J J A S O N D J F I V 1 A M J J A S O N D J F M A 1 V 1
Pilot
work
Phase I 
-  part A
Phase I 
-  part B
Phase II
Data 
entry 
and 
analysis
Study undertaken over 36 months
4.6 Sample Source
The sample was obtained from three general practices within the Strathkelvin Local Health 
Cooperative (SLHCC) located in the north of Glasgow. The practices cover an approximate total 
practice population of 25,000 patients.
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4.7 Subject Number
A power analysis, undertaken by the Research and Development department at Stobhill Hospital, 
was used to estimate the number of patients needed for the RCT (Section 3.4). For the purposes 
of this thesis objective outcome measures such as cholesterol, blood pressure and weight were 
used for the power calculation as opposed to the subjective measures such as quality of life and 
symptom control scores. Following consultation with the hospital research and development 
department, a two-sided test at 80% power, with a significance level of 5% (alpha 0.05) using 
Microsoft Excel was used to establish the sample size required. Although the standard 90% 
power (Altman 1980) is known to be more sensitive it was felt that as only one researcher was 
undertaking the work a test at 80% would be more appropriate. Mean values for cholesterol, 
blood pressure and weight, obtained in phase I (part A) of the study (section 5.4) were used for 
the power calculation. Data from current epidemiological research and guidelines (Aspire 
Steering Group 1996;British Cardiac Society 1998;Wood et al 1997) were used to obtain the 
values for the minimal important difference (Diamond & Jeffries 2004). Results of the numbers 
produced are presented in table 3. The study was not powered to demonstrate a statistically 
significant difference in weight. Allowing for attrition rates, for example non respondents, a total 
of 45-50 patients was advised for each group.
Table 3 N um bers identified by m eans o f  p ow er calculation for R C T
Variable Mean Standard
Deviation
Minimal important 
difference
Estimated sample 
size per group
Cholesterol (mmol/1) 5.5 1.11 1 21
Systolic blood pressure (inmHg) 138.6 20.66 15 31
Diastolic blood pressure (mmHg) 79.6 10.76 10 20
Weight 77.8 14.98 10 37
Weight 77.8 14.98 5 142
Two sided test, at 80% power, with a significance value of 5% (alpha 0.05)
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4.8 Sampling Procedure
All of the practices involved had General Practice Administration System for Scotland (GPASS). 
This is a computer database disease register, which originates from Information Services 
Department (ISD) Scotland. Patients are allocated standardised ‘read eodes’ according to 
information contained in their medical records. Coding patients’ records in this way allows 
practices to search for particular patient groups for clinical and audit purposes. In order to obtain 
the study sample for phase I, part A, a template incorporating the inclusion criteria for the project 
was compiled by the researcher using the appropriate read codes. The same inclusion criteria 
were also used for phase I part B and phase II of the research.
4.8.1 Inclusion criteria
The rationale for choosing this particular cohort of patients was based on the Joint British Cardiac 
Society Guidelines (British Cardiac Society 1998) which were based on the current evidenee base 
for best practiee. The inclusion criteria reflect the target population studied in these guidelines.
Males and females 
Patients aged 75 years and under 
Patients with a diagnosis of angina 
Patients post myocardial infarction (MI)
Patients post angioplasty
Patients post eoronaiy artery bypass grafting (CABG)
4.8.2 Exclusion criteria
For phase I part A the only exclusion criteria set was:
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• No firm evidence of CHD
For phase I part B and phase II the following additional exclusion criteria existed:
• Terminally ill
• Mentally impaired (impairing patient to make own decision regarding care)
• Housebound
• Patients who the GP felt should not be contacted due to other eircumstances
Having performed the search using the inclusion criteria, the GPASS software then generated a 
list of potentially suitable patients for the project (n=531). The researcher wished to compare 
targets in the study sample with targets from the guidelines,
Following completion of phase I, part A suitable patients were then selected for phase I, part B as 
discussed in section 4.14.1 (n=475). The decision was made to undertake the RCT at one GP 
practice alone; the rationale for this is discussed later in this chapter (Section 4.17). Patients for 
the RCT came from the original cohort of patients in phase I. Following completion of phase I, 
parts A and B at this practice patients were then assessed for their suitability to participate in the 
RCT(n=147).
4.9 Research Setting
Rooms were made available at each of the GP practices for the duration of the study. Data entry 
and analysis was carried out in the cardiology department at Stobhill Hospital.
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4.10 Ethical Consideration
It was considered that in many ways the project was an extension of the cardiac rehabilitation 
process, focussing on education and health promotion. The main focus of the project was in 
acliieving recommended target levels for blood pressure, cholesterol, weight and smoking. In 
addition the project focused on improving and maintaining diet, exercise and quality of life. Any 
changes in medication or blood samples obtained were in fact in accordance with the current 
guidelines and were the supposed best practice. Data collected were entered using unique 
identification numbers to ensure confidentiality for the patients. An application for ethical 
approval was prepared and submitted to the Local Research Etliics Committee (LREC) at Stobhill 
Hospital (appendix IV). Following assessment of the proposal, ethical approval was granted.
4.11 Informed Consent
Permission to review the patients’ casenotes for phase I part A was sought and received from the 
relevant general practitioners at the practices. Pennission was also granted to contact the patients 
for phase I part B and phase II. The issue of accessing patients casenotes without the patients 
prior permission was discussed with the LREC and in the context of the research this was not felt 
to be unethical providing the relevant general practitioners were in agreement.
Patients approached for phase I part B and phase II were fiilly informed from the outset regarding 
the nature of the study. They were assured of confidentiality and their right to withdraw from the 
study at any stage without it affectmg their future treatment. Consent was obtained from the 
patients and general practitioners where appropriate. A written infoimation sheet (appendix IV) 
and consent form (appendix IV) was prepared by the researcher to provide details of the study. 
Patients were reassured that the infoimation collected would be available only to the researcher.
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general practitioners and project supervisors and that anonymity would be ensured. It was 
explained that data collection during the study would be entered onto computer database and 
access, confidentiality and security maintained aceording to the regulations outlined under the 
Data Protection Act (Her Majesty's Stationery Office 1998).
4.12 Phase I -  Preparation of data collection tools
Data collection tools for phase I of the study were compiled by the researcher and composed in 
the following formats; a proforma and a patient-completed questionnaire sent to the patients at 
home and completed by the patient.
4.13 Phase I -  part A
4.13.1 Proforma
A profonna taking into account the content and layout of the medical casenotes was used to 
collect the appropriate data. Tliis enabled the researcher to identify relevant data and provide a 
systematic and comprehensive method of data collection. Prior to piloting the profoima, the 
content was discussed with both junior and senior medical cardiology colleagues at the hospital. 
Infoimation collected on the proforma (appendix V) included the following:
• Patient demographics
• Past medical histoiy
• Prescribed medication
• CHD risk factors and date last documented
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4.13.2 Pilot phase I -  part A
The researcher undertook all research for the study. In order to reduce any personal bias, two 
separate trained health professionals (Research Nurse and GP) were asked to complete proformas 
on 10 casesheets previously reviewed by the researcher.
4.13.3 Evaluation of pilot phase I -  part A
Time taken to review casesheets varied considerably dependent on the patients past medical 
history. Encouragingly, the data collected matched that of the data collected by the author. This 
reinforced the accuracy of data being collected but also demonstrated the proforma was a 
comprehensible data collection tool.
The main changes made to the proforma were the actual number of data collected. The first draft 
of the proforma was rather ambitious and perhaps had strayed slightly from the research 
questions. The initial draft had plamied to examine details surrounding the primary diagnosis of 
CHD, which were not needed to answer the research questions. It also became evident that in 
order to answer the research questions the proforma should incorporate finther fields regarding 
documentation of risk factors, which was done.
Forms for the data entry of this phase were also altered. Initially the author had anticipated 
coding answers. However, following discussion with the research and development department 
they suggested a more reliable method was to enter a “yes”, “no” response where possible. This 
was hoped to minimise errors in typing leading to errors in data.
Following changes to the proforma, as a result of the initial pilot, a further 10 casesheets were 
piloted with a revised profonna.
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4.14 Phase I -  part B
4.14.1 Postal Questionnaire
As described above, a postal questionnaire (appendix VII) was compiled by the researcher and 
designed for self-completion by the patients. The questionnaire incorporated both open and 
closed questions. In addition, likert scales (Parahoo 1997b) were incoiporated to evaluate patients 
perceptions of health and motivation to make lifestyle changes.
The questionnaire was designed to collect data in the following categories of infoimation:
• Patient details
• Past cardiological histoiy
• Current angina symptoms and management
• Knowledge and understanding of CHD risk factors
• Perceived health and fitness
• Attitude to making healthy lifestyle changes
4.14.2 Pilot Phase I -  part B
In order to test how robust such a questionnaire was, the tool was piloted on 20 random in­
patients in the author’s cardiology ward. Of interest to the author was not only how complete 
were the questionnaires returned but also how long had the questionnaire taken to answer. Time 
was taken to talk to each of the 20 patients and gather their suggestions for potential changes to be 
made.
4.14.3 Evaluation of pilot Phase I -  part B
Patients participating in piloting the postal questionnaire were encouraged to give both negative 
and positive thoughts about the content and layout. Time taken to complete the questionnaire 
varied from 5-20 minutes witli only two changes requiring to be made. The author had
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inadveiteiitly given patients the option to select, “don’t know” to current smoking, which one of 
the patients had been amused to answer! The other change was regarding the wording of a 
question regarding hospital admissions. Patients liked the layout and understood the questions 
being asked of them. Only two patients did not fully complete the questionnaire and this was due 
to them being unaware of what their current medication was. Piloting the questionnaire in this 
manner proved invaluable and the appropriate changes were made prior to the main study being 
undertaken.
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4.15 Phase I -  Main Study
4.15.1 Administration of Proforma
Having identified patients from the GPASS system (n=531) a retrospective review of casenotes 
was undertaken by the author to examine current practice for management of CHD patients. On 
completion of the proforma patients were then categorised into one of three groups, low to high 
risk. This was done to allow the author to undertake fLirther analysis regarding the motivation of 
patients. Data collected regarding the ‘General Status of the Patient at Present’ (see pg 171) were 
used to categorise patients. Those found not to be at the recommended target level for a particular 
coronary risk factor, or where recommended monitoring was not undertaken according to the 
recommended guidelines, were used as parameters. Patients were placed in the low risk group if 
they had 0-1 of the above factors, for example, current smoker. Patients with 2 - 3  of the above 
factors, for example, current smoker, bloods not obtained in the last year and cholesterol 
6.4mmol/l were placed in the medium risk group, and finally, high risk patients had to have 4 or 
more of the above factors. Of interest was whether or not those patients considered to be at higher 
risk in phase I (part A) were likely to respond to the questionnaire. By reviewing all the casenotes 
of those initially identified it ensured that only patients with a firm documentation of CHD 
(n=475) were then considered for not only the next stages of the study but also for data entry. 
Following review of each casenote, a preliminary decision utilising the exclusion criteria (Section 
4.8.2) was made by the researcher to either include or exclude the patient in the phase I part B of 
the study.
The final decision regarding contacting the patients for the study was left with the GP, as it was 
felt that they were in the best position to know the suitability of their own patients. In order to do 
this individual GP lists were generated following casenote review. A standardised form 
(appendix VI) compiled by the CNS was given to GPs along with the patients casenotes. The 
relevant GP then intimated whether or not individual patients could be contacted. For those the
76
(luiplcr h'our Malcriiü: and Mciluxh
GP felt were unsuitable a written explanation was requested justifying their decision. Appropriate 
data were collected on those patients deemed unsuitable (n=99) for further contact in recognition 
of the need to account for all initial patients.
4.15.2 Administration of Postal Questionnaire
Having identified patients suitable for contact (n=376), this cohort of patients were then taken 
forward to the next stage of the study. This involved the completion of the self-completed postal 
questionnaire. Postal questionnaires were then sent to all suitable patients with a covering letter 
from their practice (appendix IV). The reason for the letter was to reassure patients that their GP 
was aware of the research and as such was supporting it. In addition to this, return stamped 
addressed envelopes were supplied to minimise the inconvenience to the patient and increase 
return of the questionnaires. A Microsoft Access computer database was set up by the researcher 
to record the number of questiomiaires sent and returned.
Following completion and return of the questionnaires data were then entered into a Microsoft 
Access database. All data were entered however only those patients expressing an interest to 
make appropriate lifestyle changes were to be contacted for phase II. Patients responding to the 
questionnaire not wishing to make lifestyle changes were not taken any ftirther in the study; 
however, if there was any aspect of their CHD management that required attention this was 
addressed with the relevant GP.
4.16 Phase II -  preparation of data collection tools
The interview schedule (appendix VIII) for phase II compiled and completed by tlie researcher 
consisted of three data collection tools. A clinical assessment record was constmcted to collect 
infomiation; name, address, post code, date of birth, current medication and compliance, blood 
pressure, weight and height, smoking history, cholesterol and alcohol consumption. In addition to
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the above record the schedule combined the use of the pre-validated SF36 (Ware et al 1992) as 
described in section 3.10.2. Semantic differential scales were also incorporated into the schedule 
to measure the patients’ current symptoms of chest pain and dyspnoea, as described in section 
3.9.3.
4.16.1 Pilot of Phase II data collection tools
Prior to commencing onto the main study of phase II data collection tools were again piloted on a 
random group of patients from our cardiology ward. Due to the volume of data being collected 
only 10 patients were asked to participate. The time taken by the author to complete the schedule 
was between 35 minutes and 1 hour and 20 minutes.
4.16.2 Changes to Interview Schedule following pilot
Only minor changes were made to the interview schedule which involved altering the layout of 
information being gathered in order to allow inteiviews to flow in a more logical order. Time 
taken to complete the interview schedule was significantly longer than had been expected and as 
such it was decided that one-hour should be allocated for the baseline visit proposed for the main 
study.
4.17 Pilot study of intervention
Following discussion with the practices it was agreed that a pilot of the intervention would be 
undertaken prior to the RCT. With consent from the GPs at Springfield Medical Practice a pilot 
study was carried out to assess the feasibility and practicality of the proposed intervention 
method. The anticipated time to undertake the pilot work was nine months. This time included
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collecting data for phase I, parts A and B, in addition to making any necessary changes to the 
intervention method. Obviously due to the time constraints on the project there was a degree of 
overlap with both the pilot of the intervention method and main study for phase II (see table 2). 
Patients participating in the pilot of phase II received only inteivention.
4.17.1 Evaluation of intervention method following pilot study
Undertaking a pilot of the intervention method allowed clearer insight into the time taken to 
undertake assessments in the setting of general practice, and also examine administration time. 
This proved an extremely valuable exercise as the researcher was able to document time taken to 
contact patients, make appointments and collect and action any changes as a result of either the 
assessment or blood results. Results for the pilot work of intervention were presented at the 
European Society of Cardiology and the abstract presented is displayed in appendix X.
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4.18 Phase II Main study
Only the patients from Peel View Medical Practice were used for the RCT. The reason for this 
was due to time and travel constraints and also patients would be from a similar socio-economic 
spread. For phase II only motivated patients, as described in section 4.14.2 were selected.
Prior to contacting patients GPASS records were checked to ensure patients were still alive, this 
was decided to be the most accurate method of clarifying patient status.
Potential patients for phase II of the study were contacted regarding the proposed research by 
telephone. A brief description of the study and what the visit would entail was discussed. 
Telephone contact was chosen as it was thought to be more personal than a letter and also allowed 
for a mutually suitable appointment time to be made. This was hoped to reduce missed 
appointments and/or cancellations. The researcher undertook patient assessments.
4.18.1 Baseline Visit
All patients agreeing to participate in the RCT were invited into the practice for a baseline visit 
prior to randomisation. A dedicated room was made available at the general practice and 
appointments were stinctured in clinic format. One hour was allocated for each baseline visit, 
however this took into consideration time obtaining consent. On arrival to the interview room 
patients were introduced to the researcher and reassured that the assessment process was infonnal. 
Patients were offered a cup of tea or coffee prior to the assessment commencing and a note of the 
start time was recorded. Interview times varied between 35 minutes to 1 hour and 5 minutes. 
Patients participating in the study were given a full explanation of both the inteiwention and 
control arms of the study and were asked to give infomied consent prior to commencement.
An individualised approach was taken in the management of patients. Patients were given a brief 
description of clinical measures (see section 4.17.2) to be undertaken along with the rationale
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behind each. A detailed record of current medications were recorded and compared with that of 
their GPASS computer record. Patients were asked to provide details of their smoking history, 
alcohol consumption, exercise activity, and dietary habits. Any inactive medications were 
discussed and removed from the computer following discussion with the relevant GP. General 
health was measured using the SF36 (Section 3.10.2) and symptom control was measured using 
semantic differential scales. Time was allocated for the provision of information and education 
relating to the underlying causes of heart disease, the resultant symptoms of angina and 
breathlessness and its management, with time set aside for questions. The principles underlying 
motivational interviewing were used to guide conduction of the intemews and behavioural 
change (Prochaska et al 1992).
A verbal summaiy reinforcing points mentioned during the interview concluded the history taking 
aspect of the interview schedule. Individual specific risk factors, medical management and 
investigations were discussed. Patients were informed of possible medication changes and also 
aspects of diet, exercise, stress and smoking cessation intervention, which were thought to be 
beneficial. Patients decided on the areas of their lifestyle that they wished to concentrate on 
making changes to. Agreed goals were not necessarily set but patients were encouraged to 
consider relevant lifestyle changes. Where relevant, referral to health promotion initiatives such 
as smoking cessation, GP exercise referral and community dietician were offered to all patients. 
Patients were also encouraged to utilise the use of health promotion leaflets made available for the 
study.
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4.18.2 Clinical Measures
In addition to collecting the infomiation described above in section 4.17.1 appropriate clinical 
measurements were obtained in accordance with local and national guidelines (British Cardiac 
Society 1998).
4.18.3 Blood Pressure
Blood pressure was recorded towards the end of each assessment, as it was hoped patients would 
be more relaxed and a more realistic blood pressure would be obtained. The method of obtaining 
blood pressure was in accordance with the British Hypertension Society guidelines (Petrie et al 
1986). A mercury sphygmomanometer was used for recording blood pressure, the 
sphygmomanometer was both validated and calibrated through the pharmacy department at 
Stobhill Hospital. Patients were seated, using their left arm (for consistency) at heart level an 
adult cuff selected according to arm circumference, small (9 x 18cm), medium (12 x 23cm) and 
large (15 x 33 cm). The sphygmomanometer was placed on the desk and patients were instructed 
that two recordings would be obtained. The stethoscope was applied over the brachial arteiy just 
below the cuff and then the cuff was inflated to the point of occluding the radial pulse and then 
deflated at 2mm/s. The systolic measure was recorded as the emergence of sounds ( Korotkov 
phase I) and the diastolic on the disappearance of sounds (Korotkov phase V), with blood pressure 
recorded to the nearest 2mniHg. A minimum of two blood pressures were recorded at each visit. 
Documentation of blood pressure was recorded in the intei"view schedule, patient’s casesheets and 
hand held record.
4.18.4 Body Mass Index
A set of Salter mechanical scales were used solely for the purpose of the study, with regular 
calibration of the scales undertaken at the general practice to ensure accuracy of the recordings 
obtained. Weight was measured to the nearest 0.1kg with patient standing, outdoor clothing and 
shoes were removed. The patients height was recorded using a wall fitted height metre validated
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at the general practice prior to the study commencing, this mstrument was used throughout the 
duration of the baseline visits. Height was recorded in cm. Having obtained both recordings the 
patients BMI was then calculated as weight (kg) divided by height (m^). Documentation of 
weight, height and BMI was recorded in the interview schedule, patients casesheets and hand held 
record.
4.18.5 Venous blood sampling
Prior to the joint guidelines (British Cardiac Society, British Hyperlipidaemia Association, British 
H^'pertension Society, & endorsed by the British Diabetic Association 1998) being produced it 
was standard practice to obtain a full lipid profile, which required a fasting blood sample. The 
joint guidelines supported the collection of a random plasma serum cholesterol which did not 
require the patient to be fasted which was ultimately less inconvenient for patients attending. In 
addition to cholesterol random bloods were obtained for analysis of urea, creatmine, liver funtion, 
blood glucose and a full blood count. In the event of a patient being diabetic an HbAiC was 
obtained. A venous blood sample was obtained in accordance with local Stobhill Hospital 
venepucture standard. The preferred site for access was the ante-cubital fossa however if this was 
unsuccessful the cephalic vein at the dorsal arch of the hand was attempted. The chosen arm was 
supported and a tourniquet applied 2 -  4” above the chosen site of venepucture to allow venous 
stasis and dilate the vien. Once the required samples of blood (10-13ml) were obtained into the 
appropriate biochemistry and haematology vacutainers the tourniquet was released and pressure 
applied over the puncture site for one minute, or until bleeding had stopped. Shaips were safely 
disposed of, bottles were labelled and bloods were then transported for analysis. All blood 
analyses were undertaken at Stobhill Hospital, using standardised protocols with internationally 
agreed quality assurance procedures.
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4.18.6 Randomisation for phase n
The baseline visit was identical for all patients and randomisation of the patients took place only 
after these visits were concluded. A computer software programme (SPSS), was used to produce 
random numbers, which ensured equal groups, and that allocation was free from personal biases. 
To further remove any personal bias, following stratification for age and sex (due to the relatively 
small cohort of patients) a member of our hospital research and development department 
undertook the randomisation process.
Following randomisation, the patients were divided into the two arms of the study, namely 
intei-vention or control. Differences in the two arms are discussed below.
4.19 Intervention group
Patients randomised to the inteivention group were assigned to nurse led care from the cardiac 
nurse specialist (CNS), namely the researcher. Following the baseline visit patients in the 
intei-vention group were then telephoned by the CNS to discuss subsequent management and 
inform them of the results of investigations undertaken during tire baseline visit. Individual 
record cards were compiled by the CNS and sent out to the patients to allow them to document 
and follow progress (appendix IX). This was undertaken in an attempt to encourage the patients 
to take some responsibility for their health. Subsequent blood results or confirmation of changes 
in medical management were discussed by telephone within two to three days of assessment. A 
letter confirming results and changes made was sent to the patient within a week of the telephone 
conversation.
Scheduled appointments were arranged at 3, 6 and 9 months with a final assessment at 12 months. 
This totalled four formal appointments (inclusive of baseline visit) in which intervention fr om the
8 4
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CNS could take place. Patients were notified that they could continue to see their own GP and 
other members of the practice team as normal.
The format of the follow up visits was again a stmctured clinic appointment collecting relevant 
information on individual progress with risk factors, medication and symptom control. In line 
with the Joint British Guidelines (British Cardiac Society 1998) clinical measurements of blood 
pressure, weight and cholesterol were obtained. Quality of life using the SF36 was measured at 
baseline, 6 months and one year.
In addition to collecting the relevant data for the RCT, patients randomised to inteiwention were 
given education and support from the CNS.
The main aims of the education were to:
Improve patients understanding of the process of CHD 
Discuss what risk factors are and how to address them 
Highlight the relationship risk factors have on CHD
Improve patients understanding of their medication and discuss issues of compliance 
Discuss symptom control and management
Ensure patients were aware of the importance of recognising when tlieir symptoms 
required urgent hospital attention and admission
The main focus of the support mechanism involved:
• Encouraging patients to make appropriate healthy lifestyle changes
• Facilitating contact to appropriate smoking cessation interventions
• Facilitating contact to appropriate weight management interventions
• Facilitating contact to the GP Exercise Referral Scheme
• Referral to their GP if indicated
• Referral to secondary care if indicated
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Access to contact -  patients could phone the CNS to discuss any aspects of the study 
and/or their CHD management
4.20 Control group
Followmg the baseline interviews a written summary of the assessment and decisions made was 
documented in the interview schedule and the patients’ medical casenotes. Patients in the control 
group were contacted by telephone by the CNS with the relevant blood results and their individual 
GPs were alerted to the findings of the baseline visit. For example GPs were aware of a patients 
elevated cholesterol or blood pressure measurement. Patients were advised to seek advice from 
their GP regarding elevated findings as it was in the patients best interest to address these areas. It 
was also deemed unethical to ignore these factors.
Following this interaction from the CNS patients received no fluther interaction with the CNS 
until the final visit for the RCT at 12 months. Patients in the control group received only usual 
care given by their GP and practice team. Again patients were mformed during the baseline visit 
that they should continue to see their GP and other health care professionals as normal.
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4.21 Data Management and Analysis
All data collected for each patient were entered onto Microsoft Access data forms compiled by the 
author, and stored electronically. Data analysis was undertaken using both Microsoft Access and 
Minitab. Data collected, stored and extracted for presentation were managed in accordance with 
the data protection act (HMSO 1998). Further information regarding the data collected and 
methods of analyses are detailed below.
4.21.1 Phase I
Information collected for phase I combined both discrete and continuous variables and produced 
data on 475 patients.
4.21.2 Phase II
The fundamental issues to be dealt with in analysing the data collected over the study period was 
based on the following key questions of interest:
• Are the two groups comparable in tenns of their risk factors at baseline
• Is there a significant difference between the inteiwention and control groups in terms of 
the changes in risk factors from baseline to 12month follow up
• Is there a significant difference between the intei-vention and control groups in teims of 
symptoms, prophylactic medication and health related quality of life.
The primary hypothesis that there will be a significant difference between the intei-vention and 
control groups was tested using students t test and chi-square (Diamond & Jeffries 2004).
Following discussion with a statistician (Harper Giimour, University of Glasgow), it was agreed 
that additional analysis on an intention to treat basis could be undertaken. This involved analysing
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data on those patients who failed to complete the 12month follow up as people who made no 
change.
4.22 Data Analysis
This next section will explore the type of data being produced in the study and examine methods 
of data analysis.
4.22.1 Variables
It is important to ascertain what data are available for analysis. The main types of data produced 
are called variables (Diamond & Jeffries 2004). There are numerous variables of interest that can 
be studied and to ease the process variables can be separated into two main groups, continuous 
and discrete. Continuous variables for example, “cholesterol level” can potentially adopt any 
value within a given range, and discrete variables for example “gender -  male/female”, have no 
numerical value. Discrete variables may be assigned a value such as “very poor health = 5” but 
the value of the numbers are irrelevant.
4.22.2 Summaiy Statistics 
Averages and percentiles
There are three main averages, which we commonly use to analyse and present data (Swinscow); 
Mean', to calculate the mean we add together all the values of the observations and divide by the 
sample size. The mean is probably the most frequently used measure of the average. The 
disadvantage of using the mean is that it is dependent on all the values and therefore is sensitive to 
outliers (points well outside the main body of data).
( ’hnplcr h'our .\ faierial;: niid S Irlhodr
In statistical terminology the mean is calculated as follows:
M ean  =  2]% 
n
Mode; the mode is the value, which occurs most frequently in the sample. If there are two values 
for which this is the case then the distribution is said to be bimodal. Median; in contrast to the 
mean and mode, the median is the middle observation in the dataset. The data require to be 
ordered to calculate the median, however, all the data values are not required. To calculate the 
median on an odd dataset simply requires adding the two mid points and dividing by two. The 
formula for calculating the median is as follows:
M edian  =  n±_l th  observation  
2
Dispersion
In order to know the distribution of the data we can employ frirther measures namely the range, 
the interquartile range and the standard deviation. These measures allow us to frirther analyse the 
data and examine how evenly or otherwise the data are distributed. The range reports the lowest 
and highest values of the dataset. Again, like the median the range is very sensitive to outliers 
and can therefore be somewhat deceptive.
Interquartile range
Perhaps a better description of the variance of data is to measure the interquartile range. To 
calculate this we must know the median, the lower quartile represents the midpoint between the 
median and the lowest value. The upper quartile represents the midpoint between median and the 
highest value. The remaining portion of data is described as the interquartile range (mid-spread). 
Because the interquartile range does not use all the observations in the dataset it is not so affected
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by outliers, as is therefore more robust than using the standard deviation. The interquartile range 
should be used as a measure of spread when the median is being used as a measure of average.
Standard deviation
The standard deviation (SD) is most commonly used where data are not too skewed or when as in 
the interquartile range, where the mean is being used as a measure of the average. The standard 
deviation measures the average amount by which all the values deviate from the mean. It informs 
us about the size of the difference between a particular observation and the mean (residuals). 
Standard deviation is calculated as the square root of the sum of the squared residuals. The larger 
the standard deviation, the greater is the spread of the data.
4.22.3 Normal distribution
Data can be described as either normally distributed, or skewed. Data that are normally 
distributed when displayed on a histogram or graph are symmetrical and are distributed m a 'bell- 
shape’ this reveals the mean and median are in fact equal. On the other hand data that are skewed 
indicates the values of the mean and median are different due to the mean being affected by 
extreme values found in the dataset. Data can be positively or negatively skewed. Positively 
skewed data are concentrated at the lower end of the range and conversely negatively skewed data 
are concentrated at the higher end of the range. The normal distribution is the most important 
statistical distribution (Diamond & Jeffries 2004).
4.22.4 Hypothesis
Normal distribution of data helps us evaluate the probability of something happening. This can be 
taken frirther by introducing a study hypothesis. For the purpose of phase II of the study we are 
interested in the whether or not the specialist cardiac nurse is better than usual care for the patients 
in managing CHD risk factors. Most studies are designed to prove a hypothesis held by the
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researcher, firstly we must intimate what we expect to happen if the statement is true. This is 
known as the null hypothesis or Ho.
4.22.5 Intention to Treat
This method of analysis by intention to treat is an extremely paramount issue in this study. 
Generally, in clinical trials like this, it is perhaps somewhat expected that not all of the patients 
will comply with the original protocol. Some may for whatever reason fail to attend an 
appointment or even stop attending entirely. The approach is used in this trial so far limits the 
analysis to include only those patients who complied ie those patients who attended all 
appointments, and omits those who did not.
The general rule in clinical trials is that treatment groups should be compared as they were formed 
by randomisation, regardless of what happens to the patients tlnoughout the trail. In doing so, the 
patients are then analysed not according to how they were treated, but rather according to how it 
was intended they should be treated.
These two methods can very often produce different conclusions, mainly due to the fact that they 
are answering different questions.
Furtheimore, accounting for all patients involved in the study will undoubtedly avoid possible 
bias. Consequently it is crucial to carry out the analysis using the ‘intention to treat’ approach in 
addition to the method already applied to the data, to ensure accurate results and conclusions are 
reached.
4.22.6 Presentation of results
Results for this thesis will be presented using a number of different methods and will in part be 
generated with the aid of a computer software programme, namely Minitab (Minitab statistical
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software 2005). Tables, figures, pie charts, box plots and histograms will be used to present the 
data as appropriate.
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5.0 Results -  Phase I
5.1 Introduction
In this chapter results for phase I are presented in two parts; A and B. Data were collected in 
order to answer the following research questions:
Part A
• What level of coronary risk factor documentation occurs in medical casenotes for those 
patients with known CHD?
• How effectively are patients with CHD managed in relation to reaching recommended 
target levels for coronary risk factors?
• What percentage of patients with CHD are prescribed evidence based prophylactic 
medication?
• What is the general health of patients with CHD as determined by the presence or absence 
of coronary risk factors?
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5.2 Patient selection
Casenotes o f patients with a diagnosis o f IHD, from three general practices in the North Glasgow 
area were studied. The total practice population for the three practices is approximately 23,700.
Figure 1 methods employed in the identification and selection of patient numbers for 
Phase I - part A
P h a s e  I - p a r t  A
P a t i e n t s  I d e n t i f i e d  ( n = 5 3 1 )
C a s e n o t e  r e v i e w  ( n = 5 3 1 )
E x c l u d e d  n o  e v i d e n c e  o f  C H D  
( n = 5 6 )
S u i t a b l e  f o r  p a r t  A  
C a s e n o t e  d a t a  e n t e r e d  
( n = 4 7 5 )
As highlighted in figure 1, following casenote review (Section 4.13.1) 10.5% (n=56) were found 
to have no firm diagnosis o f IHD, and were excluded from data entiy . Results herein are 
therefore based on 475 patients unless otherwise stated.
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5.2.1 Age and gender
In the overall study population there were more males, 67% (n=319) than females 33% (n=156), 
with males on average being younger than females (mean 63yrs+/- SD 7.9 (m) versus mean 65yrs 
+/- SD 7.9 (f)). The age range was 36 to 75 years.
5.3 Past M edical History
Data were gathered from casenotes to explore the nature o f relevant past medical history and 
identify what percentage o f patients had previously sustained a cardiac event ie MI. Figure 2 
presents data for patients found to have one or more o f the pre-defined IHD criteria.
Figure 2 Percentage of patients with documentation of one or more IHD diagnosis, as 
retrieved from casenote analysis
I diagnosis
angina PTCA
Only 5% of patients had undergone PTCA, which is likely to be a reflection o f management at 
this time.
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5.4 Risk factors
The last recorded measurement for each o f the risk factors being examined was obtained from 
casenotes. Data were examined to evaluate how frequently patients had their risk factors 
recorded, in accordance with current guidelines and a comparison made with results reported in 
the ASPIRE survey. Percentages are used to present the data gathered (figure 3).
Figure 3 Comparison of the % of patients found in ASPIRE and in the current study with 
documentation or coronary risk factors
□  c/notes - ever 
I ASPIRE - ever
□  c/notes • last 12 mnths
CHOL Weight
Practices achieved higher rates o f risk factor documentation in comparison to findings from 
ASPIRE, however examining those risk factors obtained within the last 12 months show that these 
measurements are not being routinely updated in accordance with current guidelines, ie annual 
recording.
Data were then analysed to determine what percentage o f patients achieved recommended target 
levels in accordance with current guidelines. Results are presented as mean measurements, actual 
numbers and percentages (table 4).
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Table 4 Summary statistics for modifiable risk factors Phase I part A
Variable Mean
(SD)
Range Target n above target 
(%)
SBPmmHg 138.57 80-200 <140 185
(99) (39.3)
DBPmmHg 79.18 50-130 <85 114
(10.9) (24)
Total chol 5.45 2.5-9.7 <5.2 259
mmol/1 (1.11) (57)
BMI 27.85 15-50 <25 280
(4.84) (72.5)
Results reveal a lower percentage of patients, 61% (n=290) achieve systolic blood pressure target 
(< 140mmHg) compared with 76% (n=361) achieving diastolic blood pressure target (< 
85mmHg). Both mean cholesterol and BMI were recorded above target level, which was echoed 
in the percentages acliieving target overall, 45.5% (n=216) and 27.5% (n=106) respectively. 
Although weight was routinely documented in the casenotes, 93% (n=443), height was not 
available for 19% (n=89), which is essential for calculating BMI.
Assessment of smoking status ever recorded revealed two percent (n=10) of patients had no 
documentation of smoking habit. Of the 98% of notes with smoking status recorded 23.5% 
(n=109) were current smokers, 40.5% (n=188) ex-smokers and 36% (n=168) life long non- 
smokers. ASPIRE results reported a total of 88% had smoking status ever recorded.
Findings show that smoking status is well documented, with higher percentage being recorded 
within practices compared with ASPIRE. Written advice regarding smoking cessation was not 
formally collected, however, it was obseiwed by the author that casenote documentation regarding 
this was veiy infrequent.
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5.5 Prophylactic evidence based medication
Data obtained from prescribing summaries were used to determine the extent to wliich patients 
were prescribed the recommended evidence based coronary medications, namely Aspirin, Beta 
Blocker and Statin.
This revealed a total of 77.5% (n=368) of patients were prescribed Aspirin, 48% (n=228) Beta 
Blocker and 56% (n=266) Statin. Information regarding patients buying ‘over the counter’ (OTC) 
Aspirin and for those whom medications were contraindicated for was not routinely available.
Of the post MI patients (n=242), 84% (n=203), 46.3% (n=112) and 61.6% (n=149) were 
prescribed Aspirin, Beta Blocker and Statin respectively, with 24% (n=58) post MI patients being 
prescribed all three. Of the non MI patients (n=233), 40% (n=93) were prescribed both Aspirin 
and Statin.
From these results there is clear evidence that both individual prescribing is sub-optimal for the 
overall group and the combined prescribing of all recommended prophylactic evidence based 
medications is veiy poor.
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5.6 Part B
Wliat are the perceptions of patients with regard to their current general health? 
How motivated are patients with CHD in making appropriate lifestyle changes?
5.7 Patient selection
Patients selected for phase I part B were obtained from the original cohort of patients identified at 
the outset of the study. Following consultation with GPs (see 4.14.1), 99 were deemed unsuitable 
for the self completed postal questiomiaire -  questionnaire A (see appendix VII), this left 376 
(79% of the original cohort) patients eligible for participation in part B.
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Part B
Figure 4 Methods employed in identification and selection of patient numbers for Phase I
- part B
Phase I - part B
Postal questionnaire sent 
(n=376)
Postal questionnaire 
data entered 
(n=285)
Postal questionnaire 
not returned
(n=91)
Postal questionnaire 
returned
(n=285)
Excluded - G P /Card iac Nurse Specia list decision
(n=99)
Screened for suitability 
(n=475)
Patients considered for phase I part B 
(n=475)
O f the 76% (n=285) responding to questionnaire A, 67% were male, and 33% female, mean age 
63yrs +/- SD 8.0. Results herein are based on the 285 responding to postal questionnaire unless 
otherwise stated.
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5,8 Questionnaire responses
Patients were asked to answer questions regarding past and/or current medical history, in relation 
to heart disease, eg “Have you ever had a heart attack?”, “Yes”, “No” or “Don’t Know”
Fifty five percent (n=156) of patients recorded having sustained an MI in the past with 15% 
(n=42) stating they “didn’t know”. 37% (n=106) reported having hypertension with 16% (n=44) 
stating “didn’t know”. 9% (n=26) reported having a diagnosis of diabetes, with 6% (n=16) stating 
“didn’t know”.
Fifteen percent (n=43) admitted to being current smokers. 95% (n=265) of patients reported 
having their cholesterol checked in the past, with 46% (n=130) stating they had knowledge of the 
“result”. Of those aware of the result, answers ranged from ‘have no cholesterol! ’ to 7.6mmol/l.
In order to assess the patients knowledge of their past histoiy it was important to compare this 
with what was documented in the casenotes. The findings of this analysis are displayed as 
percentages in figure 5. It is evident from this that patients on the whole are well infoimed about 
their health.
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Figure 5 Comparison of patient % with documentation of diagnosis in casenote retrieval 
versus patients own reporting in postal questionnaire
I c/note 
lyes
diabetes chol check
5.9 M edication
Patients were asked to give a list o f all the medication they were currently taking.
78% (n=223) reported taking Aspirin, compared with 77.5% (n=368/475) found on casenote 
review. This would suggest that the majority o f patients were prescribed their aspirin even if  they 
bought it ‘over the counter’. . 15% (n=44) admitted to occasionally missing their medication 
however, only 3% (n=8) stated that they found taking medication difficult.
5.10 Perceptions o f general health and fitness
Patients were asked to rate their perceived level o f general health, fitness and diet on a five-point 
scale. The responses are illustrated in figure six.
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Figure 6 Distributions of responses of patients perceptions of level of health, fitness and 
diet
□  h e a lth
□  f i t n e s s
□  d ie t
As can be seen patients were more likely to rate aspects o f their health as average or above 
average (good-very good).
5.11 Motivation to change
Patients were asked whether or not they felt they could improve aspects o f their lifestyle.
All patients responded to this question regarding lifestyle changes, 66% (n=189) indicated they 
felt they could improve aspects o f their lifestyle. A further 9.5% (n=27) indicated they had ‘never 
thought about it’. Patients were then asked what aspects o f their lifestyle they could change, with 
particular relevance to coronary risk factors. Patients were encouraged to tick all relevant fields; 
figure seven displays the frequency o f all the responses given for this particular question.
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Figure 7 Percentage of patients responding to postal questionnaire indicating areas of 
lifestyle they wish to address
I risk factor
smoking diet exercise aicohoi
As illustrated 81% (n=35) o f current smokers identified this as an area for improvement with 
exercise being the next highest priority identified at 72.5% (n=137).
O f the 96 patients not wishing to make lifestyle changes, 72% (n=69) reported that their ‘lifestyle 
was healthy’.
Patient were asked why they wished to make lifestyle changes, from a list o f reasons selected by 
the author, again, patients were encouraged to tick all relevant fields. Figure eight displays the 
frequency o f all o f the responses given for this particular question.
Figure 8 Actual numbers of patients reporting reasons for wishing to make lifestyle 
changes
□  health
■  fitness
□  money
□  self confidence
■  challenge
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As can be seen, health and fitness were most frequently selected, 81.5% (n=154) and 64.5% 
(n=122) respectively.
5.12 Education
Patients were asked if they had ever received education about healthy living or heart disease, and 
if  so, where this information came from (figure 9).
Figure 9 Indicates where patients source their educational information, data are presented 
as % and patients may have identified more than one area
o th e r
B o o k s  & M ag
P ra c  N u r se
C ar R e h a b
H O S P
20 40 60 80
%
100
A total o f 77% patients (n=219) reported they had previously received or obtained information 
regarding healthy living or heart disease. O f this group 76.7% (n=168) received education from 
their general practitioner, 22% (n=49) received information from the practice nurse.
For the patients indicating they had received their education from other sources, they were asked 
to state examples. Answers for this included ‘TV ’, ‘video’, ‘internet’, ‘Hospital Consultant’ and 
‘the wife’.
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5.13 Conclusion
The data produced for phase I, parts A and B present an overview of how CHD patients are 
managed in accordance with their documentation and management of modifiable risk factors and 
implementation of prophylactic evidence based medication. It also gives us an insight into how 
knowledgeable patients are regarding their health and how motivated they are to making 
appropriate changes. The following key points simimarise the conclusions for phase I.
Part A
Documentation and management of modifiable risk factors, was superior to findings in 
Aspire, however, remains sub-optimal
Implementation of prophylactie evidence based medication was also found to be sub- 
optimal with regard to achieving risk factor targets and initiating all appropriate therapies
Part B
Patients who are perceived to require the most intervention are less likely to respond to 
the offer of help
Patients were well informed of their past and present medical histoiy and had received or 
obtained relevant education about their health
The majority of patients were motivated to make changes to their health where it was 
deemed necessary
1 0 6
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6.0 Results -  Phase II
6.1 Introduction
In this chapter the results for phase II are presented. Data were collected in order to answer the 
following research question;
How effective is a specialist cardiac nurse (in Primary Care) in improving CHD risk 
factors, and what is the impact of the specialist cardiac nurse in the management of these 
patients?
6.2 Patient selection
Patients for phase II of the project were obtained from one of the three general practices involved 
in phase I (Section 4.17). Figure 10 illustrates the number of patients identified for phase II of the 
project, and their subsequent follow up. Patients from this practice were a sub-group of the 
original cohort of patients in phase I and as such data gathered from casenote review and postal 
questionnaire (questionnaire A) for this group are reported as part of the total population of phase 
I (ehapter 5).
276 patients were identified from this practice using the pre-defmed IHD criteria (Section 4.7.1). 
A total of 35 were excluded from data entry (figure 10). Of the population being studied for 
phase II, there were more males, 61% (n=148) than females 39% (n=93), with males on average
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being younger than females (mean 63yrs+/- SD 8.5 (m) versus mean 65yrs +/- SD 8.7 (f)). The 
age range was 36 to 75 years.
Figure 10 Methods employed in identification and follow up of patient numbers for Phase 
II
P hase II
Identified for project 
(n = 2 7 6 )
screened for suitability 
for phase II 
random ised control trial-
no further follow up
147 returned  
grp 1 = 2 1  
grp 2 »  27  
grp 3 = 99
no further follow up 6 6  not returned  grp 1 = 24 grp 2 = 2 0  
grp 3 = 2 2
excluded - no evidence of 
IH D  
(n = 35 )
excluded from questionnaire A - 
G P  decision 
(n = 28 )
questionnaire A  sent 
(n = 213 )
12.6% (n=35) were found to have no evidence o f IHD and as such their data were not entered. 
This left 241 (87.4% o f the original cohort) patients eligible for participation in phase II -  
randomised control trial, and as such their casenote data were entered.
6.3 Questionnaire A response rate
A further 10% (n=28) were excluded from progressing further in the project, as they fitted into 
one or more o f the pre-defined exclusion criteria (Section 4.14.1). Questionnaire A was therefore 
administered as described in figure 10 to 77% (n=213) patients.
A response rate o f 69% (n=l47) was achieved from questionnaire A at this practice. Table 5 
below presents the absolute numbers o f patients responding and failing to return questionnaires
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and how this correlates to the risk groups (Section 4.14.1) patients were allocated following 
casenote review.
Table 5 Postal questionnaire response in actual numbers
Questionnaire A Risk Group (n=)
One Two Three
Questionnaires not returned (n= 66) 24 20 22
Questionnaires returned (n= 147) 21 27 99
Total 45 47 121
Chi-Square at 5% significance level with 2 degrees of freedom was applied to the data
A significant difference (p=0.000) was found between the groups, and it is therefore likely that 
more patients in the higher risk groups, ie Group One did not return the questionnaire A.
6.4 Patient selection
Data for patients responding to questionnaire A (n=147) were then entered and analysed to assess 
the suitability of these patients to progress to the RCT. Figure 11 illustrates the actual numbers of 
patients screened for suitability for the RCT and their subsequent follow up.
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F IG U R E  11 M e t h o d s  e m p l o y e d  in  t h e  id e n t if ic a t io n  a n d  s e l e c t io n  o f  PATiENT
NUMBERS FOR PHASE II - RANDOMISED CONTROL TRIAL
Selecting patien ts for random ised control trial
motivated
(n=96)
willing to participate 
(n=91)
follow up a t 12m nths incom plete 
(n=4)
declined invite 
(n=5)
follow up at 12m nths incom plete 
(n=7)
control group 
(n=46)
no further follow up
lifestyle healthy/not in terested  
(n=51)
intervention group 
{n=45)
Q uestionnaire A returned  (n=147)
grp 2 = 27 
grp 3 = 99
As figure 11 illustrates, 34.7% (n=51) indicated in the questionnaire that either their lifestyle was 
healthy or they were not interested in improving aspects o f their lifestyle. Data from the postal 
questionnaire were entered for this group however there was no further follow up. This left 
65.3% (n=96) o f those responding to the questionnaire who were deemed suitable for inclusion 
into the RCT.
Five patients declined the invitation to attend for the project and were not followed up further. 
This left 91 patients who were invited to participate in phase II o f the project (RCT). Following 
randomisation (4.17), 45 were allocated to intervention and 46 to control.
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6.5 Summary of baseline characteristics for randomised control trial
Baseline characteristics for the two groups are summarised in table 6. In order to assess the two 
groups at baseline a two sample t test was imdertaken to ensure there were no significant 
differences between the groups.
Table 6 Control and intervention groups at baseline
VARIABLE CONTROL GROUP INTERVENTION GROUP p value
Number of patients 46 45 NS
Males 26 26 NS
Females 20 19 NS
Age (years) 62.5 62.1 0.725
Range (42-75) (45-75)
SBPmmHg 136.54 136.71 0.973
Range (85-190) (95-200)
DBFmmHg 81.54 81.56 0.996
Range (60-105) (55-110)
Weight(kg) 80.2 79.4 0.797'
(49-118) (40-118)
BMI(kg/m^) 28.7 27.9 0.862
(21.7-40.1) (17-40.5)
Number of smokers 10 10 0.986
Total cholesterol mmol/1 5.26 5.35 0.708
Range (3.7-7.8) (3.6-8.7)
Alcohol -  numbers in
each category
(categories 1- 39 37 NS
4) 7 8
(categories 5-
8)
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Table 6 clearly demonstrates that the two groups were extremely well matched and no 
statistically significant differences were found in any of the parameters being examined. 
Absolute numbers and percentages were used to examine how comparable the two groups were at 
baseline with regard to current prescribed prophylactic medication and risk factor targets (table 7). 
It is of note that when analysing cholesterol levels, both 5.2mmol/i and 5.0mmol/l have been 
examined, this is due to a change in the guidelines which took place during the course of the 
project.
Table 7 Baseline characteristics for intervention and control in relation to risk factor 
targets and prescribing
Variable Inteiwention
n==45
Control
n=46
%2
test
n = (%) n = (%) p value
Aspirin 42 (93) 42 (91) 0.716
Beta Blocker 23 (51) 22 (48) 0.754
Statin 29 (64) 26 (57) 0.44
SBP < 140 27 (60) 26 (57) 0.737
DBF < 85 30 (66) 36 (78) 0.215
BP < 140/85 24 (53) 24 (52) 0.912
B M I < 2 5 13 (29) 9 (20) 0.299
Current smoker 10 (22) 10 (22) 0.956
TC < 5.2mmoI/l 27 (60) 19 (41) 0.075
TC < 5.0mmol/l 20 (44) 16 (35) 0.346
A cohol
Males > 28units/wk 3 (6) 1 (2) 0.296
Females > 21units/wk 0 (0) 0 (0) NA
Chi-square at 5% significance level, with 1 degree of freedom was used to calculate 
statistical difference.
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Again, it is clear from table 7 that there are no statistically significant differences between the 
groups. It is observed though that a higher percentage of patients in the intervention group have 
cholesterol level at target.
Table 8 illustrates the total numbers and percentages found in the two groups with IHD diagnosis. 
Patients may indeed have had one or more of the CHD diagnoses being examined.
T able 8 B reakdow n  o f  %  o f  patien ts docum ented in bo th  groups w ith  one o r m ore  IH D  
diagnosis
Intervention Control X2
Diagnosis 11= (% ) 11= (% ) p value
A ngina 16 (35.5) 24 (52) 0.110
M I 24 (53) 24 (52) 0.912
C A B G 8 (18) 9 (19  5) 0.827
C hi-Square tests  at 5%  significance level, w ith  1 degree o f  freedom  w ere  again adop ted  to  
ob tain  statistical significance
Results demonstrate that there are no significant differences between the two groups at baseline 
and reinforces how well the two groups are matched at baseline.
6.6 Follow up of patients
Patients in the intervention group were invited for assessment eveiy three months, attending for a 
potential of five visits in total, ie baseline, 3 , 6 , 9  and 12 months. Patients in the control group 
were invited for a potential two visits.
A total of 11 patients were not able to complete the 12 month assessment, however, their follow 
up status was identified as presented in figure 12.
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F igure  12 D etails ou tcom e o f  patien ts unable to  com plete 12 m onth  R C T
INTERVENTION In -  71 CONTROL (n= 41
• 2 DIED (1 FROM CARDIAC CAUSE) • 2 DIED
• 2 MOVED FROM AREA • 2 MOVED FROM AREA
• 1 ALIVE BUT UNCONTACT ABLE • 1 LOST TO FOLLOW UP
• 1 TERMINAL ILLNESS
• 1 DECLINED FOLLOW UP FOR
PERSONAL REASONS coit
changes over the 12months, these patients data were removed from analysis.
6.7 Changes from baseline to 12months
A total of 84.5% (n=38) and 91.3% (n=42) completed the 12 months for intervention and control 
respectively. Basic descriptive summaiy statistics and two sample t tests were undertaken to 
examine mean differences between baseline and 12 month follow up for the two groups. 
Inteiwention and control were compared using two sample t tests. Table 9 displays the results of 
mean changes and any statistical significance found within variables.
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Table 9 Illustrates th e  changes found  betw een  the tw o  groups at 12 m onths
VARIABLE INTERVENTION CONTROL p value
Number of patients 38 42 N S
Males 26 26 N S
Females 19 20 N S
Age (years) 62 63
Range (45-75) (42-75) N S
Variable Mean difference 
between baseline and 
12months 
Intervention 
Control
95% Confidence Interval for 
Mean Difference
(Inteiwention -  Control)
p value
SBPmmHg 17.97 5.43 (3.22,21.87) 0.009
DBPmmHg 13.13 6.36 (1.98, 11.57) 0.006
Weight (KG) 0.16 0.06 (-1.36, 1.81) 0.782
BMI 0.14 0.01 (-0.45. 0.72) 0.643
SMOKING (no. ofcigs) 1.74 1.07 (0.922, 4.70) 0.004
Total cholesterol mmol/1 0.74 0.19 (-0.10, 1.01) 0.002
T w o sam ple t  tests  w ere  undertaken  to  com pare the  difference betw een  in tervention  and 
con tro l findings at 12 m onths
Results reveal that changes in the main modifiable coronaiy risk factors, namely, blood pressure 
(p< 0.00), and cholesterol (p=0.018) show statistically significant improvements within the 
inteivention group. Although no statistical significance is obseived in smoking cessation the total 
number of cigarettes smoked between the two groups showed a statistically significant (p=0.004) 
reduction in the number of cigarettes smoked in the intervention group.
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6.8 Percentage o f patients reaching target levels in accordance with current 
guidelines
In addition to examining mean changes between the two study groups, it was also o f importance 
to assess if a higher percentage o f patients in the intervention group reached target levels 
recommended in current guidelines. As previously mentioned, the cholesterol target changed 
during the project and as such the author has chosen to use the new cholesterol target o f 
5.0mmol/l for the purposes o f analysis. Figure 14 illustrate the percentages o f patients in both the 
intervention and control group reaching target both at baseline and 12 months.
Figure 13 Percentage of patients in both groups reaching target blood pressure at 0 and 12 
months
% AT TARGET BLOOD PRESSURE 0-12MONTHS
INT CONT
BLOOD PRESSURE <=140/85
BASELINE
12MONTHS
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Figure 14 Percentage of patients in both groups reaching target cholesterol at 0 and 12 
months
% AT TARGET TOTAL CHOLESTEROL 0-12MONTHS
% 40
BASELINE
I12MONTHS
INT CONT
TOTAL CHOLESTEROL <=5.0m m ol/l
Figure 15 Percentage of patients in both groups reaching target BMI at 0 and 12 months 
% AT TARGET BODY MASS INDEX 0-12MONTHS
BASELINE
12MONTHS
INT CONT
BODY MASS INDEX <=25
It is evident from figures 13-15 that in all variables a higher percentage o f patients reach target in 
the intervention group than in the study group.
In order to examine this further Chi-Square tests at 5% significance level, with 1 degree o f 
freedom were undertaken on each variable to obtain statistical significance (table 10).
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T able 10 D em onstra tes statistical significance found betw een  groups at 0 and 12 m onths
p  value
Variable Baseline 12months
BP < 140/85 0.912 0.000
TC < 5.0mmol/l 0.346 0.002
BMI < 25 0.299 0.025
Results displayed in table 10 show that in each variable there is a statistically significant change 
between the groups from baseline to 12 months. Of interest BMI is statistically significant (p= 
0.025) for percentages reaching target despite the mean changes between inteiwention and control 
being non-statistically significant (p= 0.643) at 12 months.
6.9 Prophylactic evidence based medication
The same approach was adopted to analyse changes found in prescribing of prophylactic evidence 
based medication. The findings are displayed below in figures 16-19. As with cholesterol, 
changes in the guidelines recommended patients with specific criteria (2.6.4) were commenced 
ACE inliibitors in response to the HOPE study, as such this was implemented and is included in 
the analysis.
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Figure 16 Percentage of patients prescribed Aspirin at 0 and 12 months 
% PRESCRIBED ASPIRIN 0-12MONTHS
BASELINE
I12MONTHS
INT CONT
ASPIRIN
Figure 17 Percentage of patients prescribed Beta Blocker at 0 and 12 months 
% PRESCRIBED BETA BLOCKER 0-12MONTHS
I BASELINE 
I12MONTHS
INT CONT
BETA BLOCKER
Figure 18 Percentage of patients prescribed Statin at 0 and 12 months
% PRESCRIBED STATIN 0-12MONTHS
BASELINE
12MONTHS
INT CONT
STATIN
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Figure 19 Percentage of patients prescribed Ace Inhibitor at 0 and 12 months
% PRESCRIBED ACE INHIBITOR 0-12MONTHS
[BASELINE
I12M0NTHS
INT CONT
ACE INHIBITOR
Beta Blocker prescribing was slightly reduced in the intervention group, compared with an 
increase in the control group. In contrast to this. Aspirin, Statin and Ace inhibitor prescribing 
improved in the intervention group in comparison to the control group.
Actual numbers are presented for these findings in table 11 below, in addition to, Chi-Square tests 
at 5% significance level, with 1 degree o f freedom, which were undertaken to establish statistical 
significance.
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Table 11 Changes found in prescribing between the two groups at baseline and 12 month 
follow up
Variable
Baseline 12 month follow up
Intervention
(n-45)
Control
(n=46)
Intervention
(n=38)
Control
(n=42)
n= n= p  value n= n= p  value
(%) (%) (%) (%)
Aspirin 42 42 0.627 36 39 0.729
(93) (91) (95) (93)
Beta Blocker 23 22 0.754 18 21 0.814
(51) (48) (47) (50)
Statin 29 26 0.597 33 30 0.092
(64) (57) (87) (71)
ACE Inhibitor 10 7 0.391 16 6 0.005*
(22) (13) (42) (14)
Probability of a difference oeeurring by chance calculated by using Chi square test at 5% 
significance level with one degree of freedom 
* statistically significant
As an additive to results presented in figs 16-19, table 11 confirms that. Beta Blocker prescribing 
did indeed increase in the control group, but this was not found to be statistically significant 
(p=0.814).
As previously noted, the prescribing of Aspirin, Statin and Ace inliibitor increased in the 
intervention group, p=0.729, p=0.092 and p=0.005 respectively, with Ace inhibitor found to be 
statistically significant.
6.10 Short Form 36 health survey (SF-36)
General health status was examined using the SF36 (Section 3.10.2). Table 12 displays the mean 
scores for the eight SF-36 domains for both groups at baseline and 12 months.
121
( lu ip lrr ju \ ‘ nil,' : Pha.'c 11
Table 12 Mean (SD) Short Form 36 health survey (SF-36) scores at baseline and 12 
months and mean changes in scores between baseline and 12 months in intervention and 
control groups
Group:
Intenfention
(n=^ 45)
Control
(n=46)
Mean (SD) score Mean 
change 
in score
P
value
SF-36 domain Baseline Final
Physical function Intervention 68.2(18) 75.3(16) 7.1 0.06
Control 69.4(24) 71.2(24) 1.8 0.72
Physical role limitation Intervention 73.3(43) 83.6(34) 10.3 0.23
Control 66.9(44) 75.6(42) 8.7 0.34
Emotional role limitation Intervention 85.3(34) 85.0(34) -0.3 0.97
Control 80.4(39) 82.5(36) 2.1 0.79
Social functioning Intervention 85.0(23) 88.6(21) 3.6 0.47
Control 88.2(21) 82.6(28) -5.6 0.29
Mental health Intervention 69.3(24) 73.7(20) 4.4 0.36
Control 74.6(23) 74.6(22) 0 0.99
Energy and vitality Intervention 43.1(24) 50.4(20) 7.3 0.13
Control 46.5(24) 49.0(26) 2.5 0.64
Pain Intervention 70.2(27) 76.4(21) 6.2 0.24
Control 76.8(25) 78.0(27) 1.2 0.84
General health perception Intervention 55.6(20) 61.6(23) 6 0.21
Control 59.0(24) 62.4(25) 3.4 0.51
The mean scores for the SF-36 domains for both groups do not alter greatly over the 12 
months of follow up.
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6.11 Alcohol Status
Changes over the year for patient’s alcohol consumption were observed in both groups. Patients 
who reduced their alcohol consumption over the 12 months are presented as ‘improved’. A 
summaiy of the change in patients units of alcohol a week over the 12 months is illustrated in 
table 13.
Table 13 Trends in alcohol consumption over the study period - figures are presented in 
actual numbers
WORSENED NO CHANGE IMPROVED TOTAL
INTERVENTION 1 30 7 38
CONTROL 7 30 5 42
TOTAL 8 59 12 79
y l  at 5% significance level, with 2 cegrees o f freedom was performed on alcohol data
Numbers ‘improved’ in both groups are small, after performing chi-square on the data it can be 
concluded that there is not a statistically significant difference between the groups, p=0.389.
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6.12 Analysis by Intention to Treat
Analysis of data so far examines whether the intervention is effective according to the study 
protocol, rather than focussing on how this may impact the total CHD population being studied. 
Again, applying two sample t-tests for each variable will allow formal comparisons for 
intei*vention and control in tenns of mean improvements in risk factors over the 12 months (table 
14).
It is important to recognise that in each test, the mean difference of baseline and 12 month value 
for the control group was subtracted from the mean difference of baseline and 12 month value for 
the inteiwention group.
Table 14 Summary of results o f two sample t-tests fusing analysis bv intention to treat)
Variable Mean difference 
between 0-12 month 
INT. CONT.
Mean change 
in score
p  value 95%CI for 
mean diff 
INT CONT
Nature of 
inteiwal
SBP 15.18 4.96 10.22 0.017 (1.91, 18.54) POSITIVE
DBP 11.09 5.80 5.28 0.021 (0.83, 9.74) POSITIVE
BMI 0.12 0.00 0.12 0.657 (-0.40, 0.63) Contains Zero
SMOK 1.47 -0.98 2.45 0.004 (0.79, 4.10) POSITIVE
CHOL 0.62 0.16 0.46 0.025 (0.06, 0.86) POSITIVE
95% Confidence Inteiwals for average difference in improvement over the year between the two 
groups
As demonstrated in table 14, the variables for blood pressure, smoking and total cholesterol all 
show statistically significant p-values and confidence intervals that do not contain zero. In 
contrast BMI is non significant and the confidence interval contains zero. From this we can see 
that it is highly probable that patients in the intervention group experience more of an 
improvement over the year than the control group.
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6.13 Trends in risk factors over 12 months for the intei'vention group only
Previous analysis confirms that patients in the intervention group show significant improvement 
in a number of risk factors. In order to examine at what time point patients appear to reach target 
levels and how long these changes are maintained data were transformed into boxplots (figures 
20-23) displaying mean recordings. These boxplots are used to summarise the data at each of the 
five time points, namely baseline, 3 ,6 ,9  and 12 months (final).
6.13.1 Blood pressure
Figure 20 Presents the mean recording of systolic blood pressure (SBP) in the 
intervention group at 3. 6. 9 and 12 months
Changes in SBP over 12 months
200
SBP
100
month 3 6 90 12
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Figure 21 Presents the mean recording o f diastolic blood pressure (DBPl in the 
intervention group at 3, 6, 9 and 12 months
Changes in DBP over 12 months
110 -
month
As with systolic blood pressure, the initial descent of the diastolic blood pressure is most 
noticeable from baseline to 3 months. Again, it is observed that mean diastolic blood pressure 
remains below target level for the duration of the study.
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6.13.2 Body mass index (BMI)
Figure 22 Presents the mean recording o f body mass index fBMI"! in the intervention 
group at 3. 6. 9 and 12 months
Changes in BMI over 12 months
4 0 -
3 0 -
2 0 -
month
It can be seen from figure 22 that mean body mass index (BMI) does not alter greatly at 
any o f the protocol time points. There appears to be an initial downward trend in mean 
BMI, however this is not sustained.
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6.13.3 Cholesterol
Figure 23 Presents the mean recording of total cholesterol in the intervention group at 3, 
6. 9 and 12 months
Changes in cholesterol over 12 months
9 - f
7 -
20
o-g 5 -
3 -
month 0 3 6 g 12
Mean total cholesterol values follow a similar pattern to blood pressure, displaying a rapid drop 
from 0-3 months, with mean total cholesterol remaining below target level for the duration of the 
project.
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( y.iy l i ia yc  ii
6.14 Conclusion
The data produced for phase II, randomised control trial, present an overview of the impact the 
cardiac nurse specialist (CNS) can make on patients with eoronaiy heart disease (CHD), who are 
motivated to make healthy lifestyle changes. Implementing the appropriate management of 
modifiable risk factors and prophylactic evidence based medication. It also gives us an insight 
into the time frame in which this can be achieved. The following key points siumnarise the 
conclusions for phase II.
Phase II
The CNS significantly improved outcomes in secondary prevention management of 
motivated patients with CHD.
This model of care is effective in improving risk factor modification in a group most 
likely to benefit from such intervention.
This model of care demonstrates a stmetured comprehensive care pathway, which could 
be reproducible
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Chapter 7.0 Discussion
7.1 Introduction
To set the scene, the thesis began with a suinmaiy of the evidence-base underpinning secondaiy 
prevention measures for patients with established coronaiy heart disease (CHD). A review of the 
current recommendations for treatment was presented together with literature, which identified 
deficiencies in the secondary prevention management in patients with CHD. The studies 
undertaken in this thesis were designed with this background in mind. This chapter presents an 
overview of the research findings and their contribution to the existing literature. Theoretical and 
practical implications are discussed and areas of fiiither research are proposed.
7.2 Research Aims and Questions
The aims of this thesis were first to investigate the extent to which secondary prevention measures 
for CHD patients are managed in a eontemporaiy West of Scotland setting, and second, to 
evaluate a new healthcare model for the seeondaiy prevention of CHD, with the care to be 
provided by a cardiac nurse specialist (CNS) working with patients and the healthcare team across 
the primary and secondaiy care interface.
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7.3 Answering the research questions
This chapter aims to answer the research questions, which were constructed at the outset of the 
research in order to achieve the aims set out in this thesis. The research questions were:
• Wlrat level of coronary risk factor documentation occurs in medical casenotes for those 
patients with known CHD?
• How effectively are patients with CHD managed in relation to reaching recommended 
target levels for coronary risk factors?
• Wliat percentage of patients with CHD is prescribed evidence based prophylactic 
medication?
• Wliat is the general health of patients with CHD as determined by the presence or absence 
of coronary risk factors?
• What are the perceptions of patients with regard to their current general health?
• How motivated are patients with CHD in making appropriate lifestyle changes?
• How effective is a specialist cardiac nurse (in Primary Care) in improving and managing 
CHD in those patients motivated to make healthy lifestyle changes?
7.4 Observed levels of coronary risk factor documentation in medical casenotes for 
those patients with known CHD
Work undertaken by a range of researchers demonstrates a clear reduction in morbidity and 
mortality from coronaiy heart disease where appropriate treatment is implemented (Capewell, et 
al 1999). The recommendations as outlined in the Joint British Guidelines (British Cardiac 
Society 1998) advocate addressing known coronary risk factors, for example blood pressure,
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cholesterol and smoking. In addition, they recommend at least amiual review of patients with 
CHD to collect and manage coronary risk factors. Therefore, it was important to establish to what 
extent evidence based practice was being applied to the management of patients with coronary 
heart disease locally, and how this compared to work undertaken for other similar surveys 
examining risk factor documentation in secondary prevention (Aspire Steering Group 
I996;Brady, et al 2001;Wood et al 1997).
Research work for this study was commenced in 1999 and completed early in 2002, and therefore 
the findings were clinically relevant and comparable to the work undertaken by the researchers 
above.
The phase 1 study group consisted of 475 patients of which approximately two thirds were male 
with an average age of 63yrs and a third were female with an average age of 65yrs. These findings 
were similar to the age and gender balance present in other demographic surveys of CHD patients 
(Aspire Steering Group 1996;Brady, eta l 2001).
A comparison of results in the present study with those presented in ASPIRE was made for blood 
pressure, smoking, cholesterol and body mass index (BMl). Casenotes were examined for any 
documentary evidence of these coronary risk factors. Blood pressure and smoking were the most 
frequently recorded factors for both studies. These finding are consistent with both ASPIRE and 
Brady et al (Brady, et al 2001). By contrast to Aspire, an improvement in documentation for 
cholesterol and weight was observed in the current study (Section 5.4, Figure 3). However, 
despite 93% of patients having a documented weight in the current study, almost a fifth (19%) had 
no record of height thereby making it impossible to calculate the BMI or make an assessment of 
their degree of obesity.
In addition to collecting the above data, data from casenotes were collected to examine if annual 
recording of risk factors was being undertaken in clinical practice. The results were
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disappointing. From an initial review of the results it appeared that coronary risk factors in the 
current study were well documented, and indeed demonstrated an improvement from the ASPIRE 
and Brady eî al data. On closer inspection, the results revealed amiual risk factor documentation 
was not being undertaken (Section 5.4, Fig 3), concurring with other similar studies 
(EUROASPIRE II Study Group. 200I;Wood et al 1997). As few as 40% had annual blood 
pressure recorded, despite previous findings that blood pressure was the most commonly recorded 
variable (98%). Similar findings were observed for cholesterol and BMI. This may reinforce the 
opinion that risk factor screening is often opportunistic. It is perhaps obvious that patients, who 
are not routinely reviewed, i.e. annually, do not achieve the recommended target levels for 
coronary risk factors.
7.5 To what extent are patients with CHD managed in relation to reaching 
recommended target levels for coronai*y risk factors?
For a number of years the Scottish Executive has identified CHD as an area of high priority with 
financial incentives being offered to general practice for achieving pre-defmed targets regarding 
risk factor documentation and management. With the introduction of the new GP contract 
(Department of Health 2003), practices are now not only being rewarded for having coronaiy^ risk 
factors documented but are also required to prove that they have been obtained within a pre­
defined time. Further incentives within the contract provide financial rewards for practices 
achieving target levels, and tliis will undoubtedly have an impact on fiiture research in this area.
The research for this thesis pre dates the new GP contract (Department of Health 2003) and has 
demonstrated that implementing evidence based practice and managing patients to target is 
achievable. During the time course of the work being undertaken for this thesis, the 
reeommendations and target levels changed, for example ACE iniiibitor therapy was 
recommended to certain groups of patients with CHD (Arnold et al 2003a), and this is likely to
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happen with the GP contract. CHD has clearly been identified as a priority area within the new 
GP contract and this should be an ongoing process, evolving with the emergence of new research.
The SIGN guidelines (Scottish Intercollegiate Guidelines Network (SIGN) 2002) and the Joint 
British Guidelines (British Cardiac Society 1998) clearly define the evidence base which has led 
to the recommended target levels presented in Table 1.
In phase I of the current study, the percentage of patients at target levels for CHD risk factors 
were compared with findings in ASPIRE (Aspire Steering Group 1996). Like ASPIRE, a 
substantial percentage of patients did not achieve target levels (Section 5.4, Table 3). For 
example, in phase I of the study only 43% of patients achieved a target cholesterol level (< 
5.2mmol/l). Cholesterol management is relatively straightforward (Brady, et al 2001), and statin 
therapy is better tolerated (Evans 2004).
In phase II (RCT) of this research the mean baseline blood pressure and cholesterol were within 
target levels (Section 6.5). This does however mask the extent of unmet needs as on fiirther 
analysis as few as 53% of patients were at the recommended target level of blood pressure 
<140/85mmHg, and only 40% of patients were at a target cholesterol level of < 5.0mmol/l (this 
target level had changed during the course of the study). Blood pressure is often difficult to 
manage and patients often require two or three antihypertensive agents to control their blood 
pressure (Hansson et al 1998).
It is possible that the reason for measuring any of the coronaiy risk factors is often opportunistic 
and not systematic, and the consultation will often bear no relationship to CHD. It is likely that 
any measurement obtained opportunistically is not the priority at that particular consultation. 
Subsequently, this may not be followed up and acted upon. This being the case, then it may not 
be surprising that patients do no achieve target levels.
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7.6 Prescribing trends for the implementation of evidence based prophylactic 
medication in patients with CHD
Landmark studies such as 4S (Scandinavian Simvastatin Survival Study Gri'oup 1994), ISIS I 
(First International Study of Infarct Survival Collaborative Group 1986) and HOPE (HOPE study 
investigators 2000) are examples of large clinical phannaceutical trials which have contributed to 
a significant reduction in coronaiy mortality and coronary event rates. Recommendations for best 
evidence base treatment emerge from the work undertaken in these studies and are subsequently 
incorporated into the CHD guidelines (British Cardiac Society, British Hypertension Society, 
Diabetes, HEART, Primaiy Care Cardiovascular Society, & Stroke Association. 2005;Scottish 
Intercollegiate Guidelines Network (SIGN) 2002). The use of Aspirin, or alternative antiplatelet, 
statins, beta blockers and angiotensin converting enzyme inhibitors (ACE I) are recommended in 
the secondaiy prevention management of patients with CHD ((British Cardiac Society, British 
Hypertension Society, Diabetes, HEART, Primaiy Care Cardiovascular Society, & Stroke 
Association. 2005).
To date surveys such as Aspire (Aspire Steering Group 1996), Brady et al (Brady et al 2001) and 
Euroaspire II (EUROASPIRE II Study Group. 2001) continue to report sub optimal prescribing of 
these medications. It is important to recognise that data collected for Aspire were gathered 
approximately three years prior to this thesis. Wlien results in this thesis for phase I (part A) were 
compared to Aspire and Brady et al, there did not appear to have been any real improvement in 
the medical management of those patients with CHD. In some areas prescribing trends did in fact 
appear worse. For example, in phase I of this thesis Aspirin was prescribed in 76% of all patients 
with known CHD, versus 86% in Aspire. The research undertaken in phase I (part B) indicated 
that where some patients may have bought their aspirin over the counter (OTC), this was still 
being recorded on the practice database as being prescribed, which is important when undertaking 
audit. Although we cannot assume the patients not prescribed Aspirm were buying this OTC, 
from the results it would suggest that this is not the case.
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By contrast, statin prescribing was improved in this research with 56% of CHD patients being 
prescribed statin compared to only 16% in Aspire and 18-20% in Brady et al. This increase may 
be contributed to the dissemination of CHD guidelines such as SIGN(Scottish Intercollegiate 
Guidelines Network (SIGN) 2001) and the Joint British Societies Guidelines (British Cardiac 
Society, British Hypertension Society, Diabetes, HEART, Primary Care Cardiovascular Society, 
& Stroke Association. 2005). Statins are well tolerated with good safety and efficacy profiles 
(Evans M 2004). This increase is encouraging however perhaps more work needs to be focused 
on patients being prescribed not only the appropriate medication but also at an appropriate dose as 
less than half the patients were found to be at the recommended target level (Section 5.4, Table 3). 
Similar trends were observed for beta blocker and ACE I therapy. These results concur with other 
suiveys of this nature and may support a different approach to CHD management.
7.7 Sub optimal management does not appear to affect patients perceptions of 
general health
Risk scores for patients with CHD are routinely used in clinical practice (TIMI study group 2006). 
Prior to undertaking the casenote review for phase I (part A) of the thesis, the CNS compiled risk 
groups in an attempt to categorise patients into low (low risk factor profile) to high (high risk 
factor profile) risk groups (Section 6.3, table 4). This was undertaken to identify whether patients 
found to be in a higher risk factor categoiy were less likely to respond to the postal questiomiaire 
and randomised control trial (RCT). Another aspect of the research undertaken in phase I (part B) 
of this thesis was to examine patients perceptions of general health (Section 4.14.1). Patients 
answering these questions were more likely to indicate their health was average or above, hi 
phase II (RCT) the short fomi 36 (SF36) (Ware & Sherboume 1992) was used to measure quality 
of life. Mean baseline scores in both groups were found to be similar to that of normative data 
from a large community sample (Jenkinson, et al 1993) (Section 6.10, table 11). This data
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gathered for phase I and II of this thesis may imply that the cohort of patients being studied were 
generally reporting good health. No statistically significant change in SF36 scores was observed 
in either group at 12 months following the RCT.
7.8 Patient motivation to make healthy lifestyle changes
It has been cited in this thesis, that perhaps one of the biggest barriers to achieving risk factor 
targets and making appropriate lifestyle changes, is patient motivation. Patient compliance to 
particular interventions are often very much dependent on their own health beliefs, perceptions 
and understanding of the particular condition or topic.
In phase I (part B) of tliis thesis the postal questionnaire achieved a 76% rate. Tins may indicate 
that this was a motivated group of patients who responded. It is possible that this could be a 
reflection of the postal questionnaire and supporting letter being well constmcted (Appendix VII 
and IV) making it easier for patients to understand and respond to (Walonick 2005). This 
supporting letter informed the patient of the purpose and rationale of the study in addition to 
highlighting that by responding they might be asked to contribute further with the research in 
participation with the RCT. This may also support the health belief model demonstrating that 
when patients understand what is being investigated they are more motivated to comply (Hiatt, 
,Schectman ).
Patients responding to the postal questiomiaire in phase I (part B) were asked to indicate their 
motivation to make healthy lifestyle changes. Of those responding 66% indicated they felt they 
could improve aspects of their lifestyle, with a further 9.5% stating they had ‘never thought about 
it’ (Section 5.10, figure 6).
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The research for phase II (RCT) of this thesis was targeted only at those patients indicating a 
response to make changes or as above, who had ‘never thought about it’. The patients who 
indicated they were ‘not interested’ were not contacted fiirther. This could perhaps be considered 
as a study limitation and will be discussed fiirther later in this chapter.
Wliat was interesting about the questionnaire responses was the reason patients were motivated to 
make healthy lifestyle changes (Section 5.11, figure 8), almost all of the respondents indicated 
health and fitness as the key reason. In phase II (RCT), there was an obseived dip in body mass 
index (BMI) in the summer months, this could perhaps suggest that patients were attempting 
weight loss prior to a summer holiday, or that patients feel better in the summer months due to the 
longer days and weather.
7,9 The impact of the CNS in improving and managing CHD in those patients 
motivated to make healthy lifestyle changes
The National Seivice Framework (NSF) (Department of Health. 2000) states that prior to 
leaving hospital, all patients with heart disease should be invited to participate in a 
multidisciplinary programme of cardiac rehabilitation which includes implementation of 
secondary prevention measures. Patients participating in the research project presented in this 
thesis would probably be suitable for phase 3 or 4 of the new SIGN guidelines for cardiac 
rehabilitation (Scottish Intercollegiate Guidelines Network 2002), however the research pre dates 
this. Nevertheless, cardiac rehabilitation guidelines have been established for a number of years, 
but often as recommended above, they are targeted at patients on discharge from hospital. The 
majority of patients participating in this research study may never have had a hospital admission.
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SIGN 57 (Cardiac Rehabilitation) guidelines (Scottish Intercollegiate Guidelines Network 2002) 
emphasise the importance of managing secondaiy prevention of CHD in the community, with 
input from the primary care team. In order to facilitate this, incentives such as the General 
Practice Exercise Referral Scheme (GPERS) and GRASSP were piloted. These programmes 
promoted management of coronary risk factors within the community. Work for both of the above 
was in it’s infancy at the time of the work being undertaken for the research presented in this 
thesis. Following consultation with the Public Health department within the Greater Glasgow 
National Health Seivice Board (GGNHSB), it was agreed that intervention patients participating 
in the research for this thesis could access the GPERS. Evaluation of this programme was not 
available on completion of the research, however anecdotal evidence suggested that this was a 
veiy positive service for patients with CHD.
Since the completion of this thesis other similar programmes promoting health have been 
established within GGNHSB, for example, the “Hearty Eating Programme” and the introduction 
of smoking cessation programmes. Secondary care may be unaware of the services available to 
patients with CHD in their community. The implementation of a CNS integrating care between 
primaiy and secondaiy care may help to facilitate appropriate referrals to these programmes, 
reinforcing positive health promotion.
Clinical guidelines for the management of CHD (British Cardiac Society, British H^qiertension 
Society, Diabetes, HEART, Primaiy  ^ Care Cardiovascular Society, & Stroke Association. 
2005;Scottish Intercollegiate Guidelines Network (SIGN) 2001) are widely accessible in both 
primaiy and secondaiy care yet as described earlier in tliis chapter, patients continue to receive 
sub optimal management.
Different approaches to the promotion of secondary prevention of CHD have been evaluated 
(Campbell et al 1998a;Jolly et a /1999) with varying degrees of success. Work undertaken by 
Campbell et al, in the Grampian region of Scotland, and Jolly et al , in Southampton in England
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(ths SHIP Study), was compared with the findings of phase II (RCT) of this thesis. To summarise, 
a different model of care was delivered in all three studies. No significant improvements were 
made in the CHD management of patients studied in the SHIP (Jolly et al 1999) study, however 
the study was felt to be successful fiom a methodological viewpoint.
Patients in the inteivention group in Grampion region (Campbell et al 1998a) were seen once at 
baseline and then encouraged to attend for follow up anything from 2 to 6 monthly. In the current 
study (phase II (RCT)), a structured approach was used and fixed 3 monthly reviews were made 
with patients recmited to the inteiwention group. Patients in the SHIP (Jolly et al 1999) study 
were not seen by the CNS, follow up was by self-administered questionnaire. The nurse 
specialists worked as a liaison seivice, this model may have improved communication however 
did not have any impact on patient care.
Within the inteivention group of the current study 79% of patients reached a target cholesterol 
level of < 5.0mmol/l compared to 41% with a target level of < 5.2mmol/l in the inteivention group 
in Grampion (Campbell et al 1998a). Both the current study and Grampion study(Campbell et al 
1998a) achieved improvement in the percentage of patients achieving target blood pressure, 
however the target level in the current study was lower, 97% (I40/85mmHg), versus, 96.5% 
(I60/90mmHg) in the Grampion study (Campbell et al 1998a). The target levels for cholesterol 
and blood pressure outcomes were lower in the current study, this may be a reflection of the time 
in which Campbells work was undertaken.
The most striking observation when all three studies were analysed was the difference in smoking 
habits in the current study compared to the others. Neither the Grampion study (Campbell et al 
1998a) or SHIP (Jolly et al 1999) were able to impact on smoking (Grampion, smokers at baseline 
11= 482, 12 months n= 482), (SHIP, smokers at baseline 19%, 12 months 20%). In the current 
work, 21 % of patients studied m phase II (RCT) were smokers at baseline, at 12 months 40% of 
patients in the intervention group ceased to smoke, with a fiirther statistically significant reduction
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in the number of cigarettes smoked (p=0.004). Observed baseline figures for smoking in 
Grampion (19%) were slightly lower than that found in StllP and the current study (21)% in 
phase II (RCT). This could suggest that this group of smokers were long-tenn smokers who may 
not see smoking as a priority area to address.
In addition to the above, prescribing trends were compared with the work undertaken by SHIP 
(Jolly et al 1999) and in Grampion (Campbell et al 1998a). The SHIP study (Jolly et al 1999) did 
not examine prescribing trends. Patients within the intervention group in Grampion group 
(Campbell et al 1998a) achieved improvements in Aspirin prescribing 69.4% - 81%. Within the 
current study, Aspirin prescribing in patients at baseline for both groups was in fact excellent 
were (93% intervention, versus 91% control). Patients within both group groups achieved further 
non significant improvement in Aspirin prescribing.
As described previously, statin therapy is relatively straightfomard (Brady, et al 2001) and statins 
on the whole are well tolerated (Evans 2004). Patients recmited to the intervention group 
achieved better cholesterol management, compared with the control group. Cholesterol levels 
were obtained from patients in both groups at baseline, yet the inteivention group achieved better 
results in prescribing of statins and also in the percentage of patients reaching target cholesterol 
level. Both patients and their GPs in the control group were told their baseline cholesterol level 
and advised by the CNS to address this. The reasons why patients in the control group did not 
achieve better results is outwith the scope of this study. It is possible that patients were 
commenced statin therapy or existing therapy was increased following the baseline reading. 
There is evidence to suggest that as many as 50% of patients will have stopped taking their 
medication at one month. Patients in both groups at baseline were felt to be motivated and 
perhaps more likely to make appropriate changes. It is therefore difficult to understand why 
patients in the control group may not have been motivated to make the recommended changes. 
The diflFerences observed between the control and intervention groups in the current study may 
support the model of care evaluated in the RCT.
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The evidence in the literature reports patients are receiving sub optimal care (Brady et al 2001) 
and perhaps the existing models of care need to be re-evaluated. It may be that the majority of 
patients with CHD receive usual care from their health care team in both primary and secondaiy 
care, but is this enough?
Other models of care may exist however as yet there is little evidence to suggest secondary 
prevention management is improving. The new model of care evaluated in phase II of this study 
was successfiil, possible explanations for this include; appropriate time allocated to appointments 
to incorporate appropriate education and support; regular follow up at clinics reinforcing the same 
key health messages, which may then be recognised by the patients as important areas of their 
health to consider; using motivational interviewing techniques to move patients from one stage of 
change to the next; and delivering a model of care using a structured comprehensive approach 
therefore ensurmg all the relevant areas are covered.
Moreover, with the advent of the new GP contract (Department of Health 2003) there is perhaps 
scope for this role to be undertaken at a Nurse Consultant level. Implementation of Nurse 
Consultant clinics for chest pain (Pottle 2005) and atrial fibrillation (Tagney 2005) have 
demonstrated success. Using the model in this thesis a Nurse Consultant could help to facilitate 
the aims and objectives set out in the GP contract.
Finally, using an intergrated approach offering the patients ‘specialised’ care delivered by the 
CNS may improve outcomes. This model of care may provide improved outcomes for patients 
with CHD.
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7.10 Study limitations
• In phase I (part A) of the research, a retrospective casenote analysis was undertaken to 
collect data to examine the extent to which secondary prevention treatment is achieved in 
patients with CHD. Although the CNS made every effort to collect all the relevant data it 
cannot be assumed that data not found to be recorded in the casenotes had not previously 
been obtained. It is possible that information is collected and recorded in a different 
format.
• In phase I (part B) of this research, the postal questionnaire sent to patients with CHD
asked patients to indicate their motivation to make healthy lifestyle changes. For those 
patients who responded indicating they were ‘not interested’, the CNS made no fliither 
contact. This model set out to examine whether the model of care being evaluated could 
be effective in patients motivated to make healthy lifestyle changes. As described in 
section 7.11 further research in the group of patients apparently poorly motivated would 
be valuable.
• In phase II (RCT) a sole researcher, namely the CNS, undertook the study. To reduce any
personal bias the CNS had to ensure that the research methods were robust. For this
reason the CNS was not involved in the randomisation process, this was undertaken using 
computerised random number tables, and was executed by a member of the hospital 
research and development team. Also, randomisation of the patients was undertaken after 
the baseline visit to further reduce personal bias.
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7.11 Recommendation for further research
The research conducted for this thesis has emphasised that the management of patients with CHD 
is sub optimal but can be significantly improved with a comprehensive and stmctured approach 
using CNS-led clinics. The CNS is ideally suited to delivering this model of care however the 
research in this thesis has highlighted further questions, which at present are unanswered. Further 
research should; explore whether the same model of care delivered by the CNS can be replicated 
in all GP practices and identify what the potential barriers to delivering this model of care may be. 
This could be undertaken by means of a RCT of CNS intervention compared to usual care in a 
wider group of GP practices, for example a Local Health Care Co-operative (LHCC). Practices 
would ideally be stratified for socio-economic status. Future research could also explore whether 
other health professionals could deliver this model of care, namely the practice nurse and general 
practitioner, achieving improved secondary prevention management for patients with CHD.
The question of choosing only motivated patients could be examined. It would be of interest to 
attempt to intervene on the group of patients who appeared not to be motivated to make healthy 
lifestyle changes.
It had been anticipated by the CNS that a cost analysis of the model of care delivered in this thesis 
would be undertaken. Unfortunately due to other commitments the advisor involved was not able 
to fiilfil this request. In the current environment where financial implications are a major 
consideration this would be an area where fiirther research may strengthen the argument for the 
CNS.
Obesity (section 2.4.5) and inactivity (2.4.6) are recognised risk factors contributing to CHD. 
Although patients were asked about their exercise capacity no formal validated instrument was 
used to evaluate this. With the introduction of the Physical Activity Strategy (ref), it is hoped that 
by 2021 50% of the Scottish population will be achieving 30minutes of moderate activity on most
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days. Exercise is known to be of benefit to patients with CHD and further research specifically 
measuring exercise habits would be of interest.
Finally, as clinically significant changes in cardiac event rates are not expected within the time 
frame of the research for the thesis, it would be interesting to follow up this cohort of patients 5 
years from the initial contact to examine further outcome measures. The ultimate goal is for 
survival and a reduction of cardiac event rates.
7.12 General conclusions
Sub-optimal risk factor documentation and management of patients with CHD continues to exist 
in current practice. The CNS model of care significantly improved outcomes in the secondary  ^
prevention management of patients with CHD motivated to make lifestyle changes. 
Improvements were observed in smoking, cholesterol, and blood pressure. Improvements 
although not significant were made in weight management. Prescribing trends in prophylactic 
medication were also improved for the majority of medications which are recommended for the 
secondary prevention of patients with CHD. Further research may wish to examine whether this 
model of care can be effective in patient groups considered to be poorly motivated with higher 
levels of risk factors present. This thesis has demonstrated that a model of care, based in primary  ^
care, delivered by a CNS in partnership with the GP practice team is effective in improving risk 
factor modification in a group most likely to benefit from such intervention.
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7.13 Full Circle
This research began with the identification of sub optimal treatment for the secondaiy prevention 
management of patients with CHD. Different models of care have previously been examined but 
the research in this thesis aimed to test the impact of a new model of care in primary care, 
delivered by a CNS from secondaiy care. The results from this thesis have demonstrated that this 
model of care is effective in improving risk factor modification in a group most likely to benefit 
from such intei-vention. In addition to this, the new model of care demonstrated a stmctured 
comprehensive care pathway, which could be reproducible.
On completion of the work undertaken for this thesis, a secondary prevention project was 
proposed within the Local Health Care Co-operative, (LHCC) where the CNS was working. In 
line with best practice, and in response to national and local health priorities. Priority Projects 
were being established. These projects were in many ways pilot studies in anticipation of a 
chronic disease management (CDM) programme which has now been established by the Greater 
Glasgow National Health Service Board (GGNHSB). Practices involved in the Priority Projects 
chose an area of health felt to be of particular relevance to their practice populations needs.
Strathkelvin LHCC, in the North of Glasgow, chose “Secondaiy Prevention of heart attacks and 
stroke” as the focus for their “Priority Project”. The project aimed to provide optimal care in 
accordance with current evidence-based guidelines and reduce morbidity and mortality from CHD 
and CVD.
As a result of the outcomes achieved in the research presented in this thesis, the CNS was invited 
to project manage the Priority Project. The model of care used in this thesis was replicated in all 
patients with coronaiy heart disease and cerebrovascular disease. One of the main barriers to
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delivering the care to patients was in fact a shortage of nurses. In many practices the Practice 
Nurses were unable to take on the extra commitment of the secondary prevention clinics. The 
concept of integrating nurses from secondaiy/ care to primary care was proposed to the practices. 
Practices were aware that the integrated model of care had previously worked with the 
randomised control trial in this thesis, so were receptive to the idea. In six of the twelve practices 
a cardiac nurse specialist (CNS) from secondary care undertook the secondary prevention clinics. 
Nurses integrated well, and although the project has now concluded, some of the nurses continue 
to undertake clinics on a weekly basis. This hopefully demonstrates this new model of care, 
delivering a structured comprehensive care pathway, can be reproducible.
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ABCD Treatment algorhytlim for hypertension
The British Hypertension Society recommendations for 
 combining blood pressure lowering drugs
Younger (e.g.<6Syr) Older (e.Q.èSSyr)and Non Black o r  Black
Stop 1 A(orB ') CorD
Step 2
Stop 3
Stop 4
Resistant
Hypertension
I A (orB^) i [V] I C o rD  
*
__________ JL___________
f Adel: either a-b loekaror spironolactone o r  o ther diuretic |
A; ACE inhibitor o r anQlotensIn receptor blocker 
C; Calcium Chantwi Blocker
B: blocker
D; Diuretic (thiazide)
'  r.o rtib lim E lnrt l i w l v l n g  0  rant! D n i n v l i n i n g n ' t i m  r.iviiiiiHt.'tl iU lfjtii)iR Pc< iriW rm iri5 ri l l i e ia H m t
Adjptea reference <5
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Source: Williams et al 2004
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Body Mass Index Calculation
Body Mass Index (BMl)
To take account o f the expected differences in weights in adults ofdifferent 
heights, a simple index o f weight-for-height has been devised as the body 
mass index (BMI). This is calculated as;
BM l - Weight kg Height n f
An adult o f 70 kg with a height o f 175 cm has a BM l of: 
70
1 .7 5 : - 2 2 .9
The internationally accepted ra n g e s^ 'o f  BMIs are as follows: 
Underweight: < 18.5
Normal: 18.5-24.9
Overweight: 25.0-29.9
Obesity: 30.0-39.9
Extreme obesity: >40
A BMI <17.5 has bccti taken as one criterion o f anorexia nervosa" '^-'.
Source: Scottish Collegiate Guidelines Networkfwww. sign.ac.uk)
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Proposal submitted to Local Research Ethics Committee
1. RESPONSIBLE INVESTIGATORS
K a ty  Joss 
F rank  D unn
2. TITLE OF PROJECT
C oronary  H eart D isease In teg rated  C are P ro ject
Stobhill N H S T rust w ith  G eneral P ractitioners -  N o rth  G lasgow
3. SUMMARY OF AIM AND BACKGROUND
Coronary Heart Disease (CHD) remains the major cause of morbidity and mortality in the Western 
World with event rate and mortality being particularly high in the West of Scotland in both men 
and women. Concern remains about the implementation of the evidence based practices in patients 
with coronaiy arteiy disease. In addition more effective methods of health promotion and 
education are required. The concept of specially trained nurses in providing the link between 
primary and secondaiy care is being explored in a number of areas and this may be one way to 
integrate care for patients with coronary artery disease,
A  num ber o f  articles have recently  appeared in the m edical literatu re to  suggest 
that the  concept o f  m anaged care perform ed by specially trained  nurses could be a 
step in the right d irection fo r patients. I f  positive results are obtained, designated  
nurses could have a m ajor ro le  to  play in risk facto r screening and m anagem ent 
fo r patients w ith coronary  a rte iy  disease. This also m ay lead to  a m ajor beneficial 
effect on  ou r overall delivery o f  health  care and costs.
4. SUMMARY OF METHODOLOGY
W e w ould  aim to  visit th ree  M edical P ractices in the N o rth  o f  G lasgow . W ith  
consent from  th e  G eneral P ractitioners w e w ish to  obtain inform ation from  their 
database (a  tem plate  will be com piled to  identify patients w ith  established o r 
suspected  coronary  artery  disease). O nce w e have identified th e  patien ts suitable 
fo r th e  study w e will then, w ith  the patients consent, obtain  inform ation on  their 
curren t m edical trea tm ent and investigate their risk factors fo r CHD.
T he follow ing variables will be assessed:
•  Physical w ellbeing
•  Incidences o f  chest pain
•  Sm oking
• B lood  P ressure
•  Lipid analysis
•  W eight
•  E xercise
•  GP appointm ents and ou tpatien t appointm ents
•  H ospital adm issions w ith  suspected  cardiac problem
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P osta l Q uestionnaires have been designed fo r patients to  com plete. P atien ts 
responding  to  questionnaire will be random ly allocated into tw o  g roups fo r either 
contro l o r intervention. H aving evaluated all the inform ation on  the  in tervention  
group, a  m anaged care program m e will be structu red  fo r individual patients 
covering their specific needs. T he patients will then  be closely m onitored  w ith  
respect to  the above points a t th ree  m onthly intervals fo r tw elve m onths. P atien ts 
in the contro l group  will be assessed once, given appropriate  health  education  and 
health  p rom otion  leaflets and a fu rther final assessm ent will tak e  p lace at tw elve 
m onths.
5. ANTICIPATED DURATION OF THE PROJECT
2 years
6. DRUGS TO BE ADMINISTERED FOR EXPERIMENTAL PURPOSES
N one
7. NON-STANDARD PRODUCTS TO BE ADMINISTERED FOR 
EXPERIMENTAL PURPOSES
N one
8. THE USE OF RADIOACTIVE MATERIALS
N one
9. CERTIFICATE OF INDEMNITY
N o t A pplicable
10. If the project is grant aided confirmation that the source of the grant accepts 
liability must be provided
N o t A pplicable
11 APPROPRIATE CLINICAL TRIALS CERTIFICATE/EXEMPTION 
FORM
N o t Applicable
12 CONFIRMATION OF CURRENT MEMBERSHIP OF A MEDICAL 
DEFENCE UNION
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D r F rank  D unn  Y E S
M s K aty  Joss N o t A pplicable
13 PERSONAL EXPERIENCE
D r F G  D unn  has undertaken  considerable research in the field o f  coronary  heart 
disease
K aty  Joss is a cardiology sister w ith  extensive clinical experience in the 
m anagem ent o f  co ronary  heart disease.
14 PATIENT CONSENT AND INFORMATION FORM
See enclosed
15 FINANCIAL IMPLICATIONS
N il
16. DECLARATION
E nclosed
14. Patient Information
~ B elow  contact le tte r fo r Q uestionnaire
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Dear
We have been approached by the Cardiology Department at Stobliill 
Hospital and asked to work with them on a project which aims to identify 
and reduce risk factors for individual patients with a known or suspected 
history of Coronary heart disease.
These risk factors, which include blood pressure, cholesterol, smoking, 
alcohol, diet, exercise and stress are probably known to you tlirough 
discussions with ourselves or the hospital, but this project plans to go one 
step fiirther.
In this respect, the Cardiology Department has seconded a nurse with 
specialist Cardiology training, Katy Joss, to work with the Practice on this 
new initiative.
As someone who has been selected as suitable for inclusion, we would ask 
you to fill in this simple questiomiaire. It should take about 15 minutes to 
complete.
You may also be contacted with regard to attending a short interview at the 
Practice. Tins interview will be part of the ftiller project and Katy will 
telephone you personally to discuss this.
There is, of com se, no pressure on you to do this, but we hope you will feel 
able to take part. If you agree to take part in the study it may be of little 
benefit to you personally. However, the results may help other patients in 
the friture. Should you not wish to take part this will not affect your usual 
treatment in any way. Information collected will remam confidential.
If you have any queries, please contact us at the Surgery.
Thank you
Yours sincerely
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14. Patient Information continued..
~ B elow  contact le tte r fo r interview /assessm ent
Dear
I would like to thank you for taking the time to complete the recent 
questionnaire regarding your heart and health, which Katy and I have 
now had a chance to review.
In the light of your answers, we feel it would be appropriate for you to 
come into the Practice for the interview we mentioned. Patients being 
invited to attend for interview will be randomly selected into two 
groups.
Group one - patients in tliis group will be assessed and followed up by 
Katy every tliree months for one year.
Group two “ patients in tliis group will be assessed and given relevant 
health promotion and health education. They will then be assessed 
again by Katy at one year.
The assessment will take approximately one hour and will involve the 
following:
Looking together at your risk factors for heart disease
Obtaining an up-to-date record of your blood pressure, weight, 
diet, cholesterol, smoking history, etc
Discussing any questions you may have regarding your 
heart/health
To arrange tliis interview, Katy will contact you by telephone and 
invite you into the Practice at a time suitable to you both. As before, 
we hope you will want to take part in the study, but you are under no 
obligation to do so.
Please feel free to contact me at the Practice should you have any 
questions.
Yours sincerely
1 7 2
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CONSENT FORM
Coronary Heart Disease Integrated Care Project Stobhill NHS Trust with General
Practitioners -  North Glasgow
I .................................................. o f ......................................................................... .
have had the opportunity to discuss the study with Katy Joss and understand that 
participation in this research is voluntary and I can withdraw at any time without it 
affecting my treatment.
I hereby consent to the participation in the above study.
Signed .............................    Date
PRINT N A M E....................................................(Patient)
Signed......................................................... Date
PRINT N A M E.....................................................(Research Nurse)
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CHD Integrated Care Project 
Stobhill NHS Tnist with General Practitioners - North Glasgow
PROFORMA FROM PATIENTS CASENOTES
GP Practice: CHI no. GP:
Patient name: Date of Birth:
Address:
Postcode:
Sex:
PAST MEDICAL HISTORY
Cardiac Non cardiac Not recorded □
FAMILY HISTORY OF HEART DISEASE: Yes □  No □  Not recorded □
CURRENT MEDICATION
Medication Dose Frequency Date of most recent rec.
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Who did patient first present to with possible cardiac symptoms;
Hospital □  GP □
What year did they first present:........................................
REFERALLS
Cardiology Clinic Yes □  No □
No. o f times attended =
Fast track Yes □  No □
Exercise testing Yes □  No □
No. o f times exercised =
Echo Yes □  No □
No. o f echos carried out =
Cardiac Rehab Yes □  No □
Angiography Yes □  No □
No. of Angios carried out ==
Angioplasty Yes □  No □
No. o f times angioplasty carried out
CABG
No. ofCABGs =
Yes □  No □Thallium
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GENERAL STATUS OF PATIENT AT PRESENT
Recording Date last 
recorded
Recording Action
required
Rec in last year 
Yes Q N o □
Blood Pressure
Yes □  No □
Cholesterol
Yes □  No □
Weight
Yes □  No □
Smoking
Yes □  No □
Bloods
Yes □  No □
Medication
Yes □  No □
Patients H eig h t.......................(in cm)
B M I-
Identified Risk Factors
Not recorded □  
Not recorded □
Hypertension ^Cholesterol Smoking Obesity Diabetes
Attends Cardiovascular Clinic □
Attends Hypertension Clinic □
Attends Diabetic Clinic □
No. o f times patient has attended GP in the last year =
No. of hospital admissions with possible cardiac symptoms in the last year =
ACTION PLAN -
Would like to send out questionnaire Yes □  No □  GROUP:
If No, state reason
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Appendix VI: GP consent forms for contacting patient by postal questionnaire
178
. ippe in l iy i  ’/  • ( i l ’ conxe/H Jorin far  ( oiilcu im p  prUicni: hv  pa.'i til  (pir.' Hainiain
Dear Dr
RE: CHD Integrated Care Project, Stobhill NHS Trust with General 
Practitioners - North Glasgow
Could you please indicate with a tick your consent for me to contact the patients 
below with regard to sending them a postal questionnaire for the above project?
Please remember patients contacted may then be asked to participate in the 
randomised control study.
Many thanks,
Katy Joss
PATIENTS
NAME
DOB ADDRESS For Contact 
YES
For contact 
NO
If no, please 
state reason
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Appendix VII: Postal questionnaire
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Coronary Heart Disease Integrated Care Project 
Stobhill NHS Trust with General Practitioners-North Glasgow
Please complete the following questionnaire which will be treated in strictest confidence. 
A space for additional comments has been left at the end. Please feel free to add any 
comments you feel are relevant.
Thank you for taking the time to complete this questionnaire.
Name:...
Address:.
Date of Birth: 
S e x :................
Postcode
Living arrangements
Live alone: O  Live with partner: \U
Live with your young children: CH Live with your son/daughter and family: CH
Live in sheltered housing: CH Live in a nursing home: CD 
How many people are there in your household.............
1 If you have ever had chest pain, when did you first see your GP about it?
Within the last 3 months EH Within the last 6 months CD Within last year CD 
Over one year ago CD 2-5years ago CD 5-8years ago CD
8-10 years ago O  >10years ago O  Not relevant O
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2 I f  you get chest pain how often does it occur?
Every day Cl 2-3 times a week CD□
2-3 times a month CD Once a month CD
Never □
Once a week
Very rarely CD
3 How often do you use your nitrate spray or nitrate tablet under tongue?
2-3 times a week CD Once a weekEvery day CD □
2-3 times a month Cl Once a month CD Very rarely CD
Never □
4 If  you never use a nitrate spray or tablet is this because:
You never have pain O You have pain, but you can’t use it CD 
You have pain but you don’t have a nitrate spray or tablet CD
5 Do you have any family history o f Angina or Heart Attack? Cl YCS CD No
6 That you are aware of, which of the following family members have had Angina/Heart 
Attack?
Father Mother
Brother Sister
Aunt Uncle
Son Daughter
182
7 Have you ever had a heart attack? 
Do you have high Blood Pressure?
Do you have diabetes?
Do you Smoke?
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□  Yes □  No □  Don’t know
□  Yes □  No □  D on’t know
□  Yes □  No □  D on’t know
□  Yes □  No
Have you ever had your cholesterol checked? O Yes CD No CD D on’t knOW
Do you know what your cholesterol level is? CD YeS O No
If Yes, what is your cholesterol level reading ................................................
8 What is your weekly alcohol consumption? Please list the number o f drinks you would be 
likely to have on an average week. For example, you could list what you had last week:
Day of Week Number of drinks Type of drink
eg Monday Three pints Beer
Monday
Tuesday
Wednesday
Thursday
Friday
Saturday
Sunday
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About your medication
9 Are you taking any medication at the moment? D Y cS  CD N o
10 If  Yes, please list below;
Medication Dose What times of day
11 Do you ever miss taking your medication? CD YeS CD No
12 Do you find it difficult taking your medication? CD YcS CU No
13 In the last year have you been admitted to hospital with your heart condition?
□  Yes □  No
14 If  Yes, how many times in the last year have you been admitted;
Once CD Twice CU Three times CD Four times CD
Five times CD Five to ten times CD More than ten times CD
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About your General Health
15 H o w  w ould  you ra te  your general health?
V ery  G ood □ G ood □
A verage □ P o o r □
V ery P o o r □
16 H o w  w ould  you ra te  y o u r general fitness?
V ery  G ood □ G ood □
A verage □ P o o r □
V eiy  P o o r □
17 H o w  w ould  you ra te  y o u r diet?
V ery G ood □ G ood □
A verage □ P o o r □
V ery  P o o r □
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18 D o  you feel you could  im prove aspects o f  your lifestyle? [ ]  Y c S - g O  tO  q u e s t i o n  1 9
□  No-go to question 21
19 I f  Y es, w ha t aspects could  you change?
Sm oking □
D iet □
E xercise □
A lcohol □
20 W hy do you feel you  w ant to  change these aspects?
H ealth  □
F itness □
M oney  □
S elf confidence □
C hallenge □
21 I f  N o , is this because?
Y o u r lifestyle is healthy □
Y ou are n o t in terested □
Y o u  have never th ough t about it □
22 W hat encourages you  to  m ake changes in your lifestyle?
Fam ily support CD W ant to  feel fitter CD
M edical reasons CD G oing on holiday! CD
W ant to  save m oney CD Personal reasons CD
A ny o ther r e a s o n s .....................................................................................................
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23 In  th e  past have you been  given any education  about healthy living o r heart disease?
□ Y e s □  No
24 I f  Y es, then  w here did you  get your advice? T ick as m any as applicable.
G eneral P rac titioner
H osp ita l D o c to r
P rac tice  N urse
C ardiac R ehab  (H osp)
B o o k s and M agazines
O ther (please state)
T hank you  again for tak ing  th e  tim e to  fill in this questionnaire.
P lease use th e  space below  to  add any additional com m ents you feel are relevant.
P lease re tu rn  th e  com pleted  questionnaire in th e  envelope provided to: 
K aty  Joss
Peel V iew  M edical P ractice 
45-53 U nion S treet 
K IR K IN T IL L O C H  
G L A S G O W  
G 66 ID L
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Appendix VIII: Interview Schedule
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Coronary Heart Disease Integrated Care Project 
Stobhill NHS Trust with General Practitioners-North Glasgow
FIRST ASSESSMENT RECORD
Today’s Date :Patient Details :
Past Medical History :
Current Medication taken by patient :
FrequencyDoseMedication
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Observation Recording Date next due Signed
BP on arrival
BP after 5 mins
Weight in KG
Height in cm
If Smoker - amount
Cholesterol
If no chol then obtain
Todays date
Observation Recording Date next due Signed
BP on arrival
BP after 5 mins
Weight in KG
Height in cm
If Smoker - amount
Cholesterol
If no chol then obtain
Todays date
Observation Recording Date next due Signed
BP on arrival
BP after 5 mins
Weight in KG
Height in cm
If Smoker - amount
Cholesterol
If no chol then obtain
Todays date
Observation Recording Date next due Signed
BP on arrival
BP after 5 mins
Weight in KG
Height in cm
If Smoker - amount
Cholesterol
If no chol then obtain
Todays date
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Medication compliance
From the questionnaire does there appear to be compliance with medication: Yes/No 
If there appears to be non compliance, what appears to be the problem:
Doesn’t know which tablets to take
Takes too many tablets
Doesn’t collect prescriptions
Doesn’t take any tablets
Takes only some of prescribed tablets
Other, please state
Alcohol
State answer from the questiomiaire :
Does there appear to be a problem : Yes/No 
Smoking
Do you smoke : Yes/No
If no, have you ever smoked : Yes/No
How many do you smoke a day =
What type of cigarettes do you smoke:
Low Tar
Medium Tar
Noimal Tar
Extra Strong
Cigars
If Cigars, do you inhale
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1 In general, would you say your health is
□  excellent □  very good □  good □  fair □  poor
2 Compared to a year ago, how would you rate your health in general now
□  Much better now than one year ago
□  Somewhat better than a year ago
□  About the same
□  Somewhat worse than a year ago
□  Much worse than one year ago
3 The following questions are about activities you might do during a typical day. Does your health 
limit you in these activities? If so, how much?
Yes, Yes, No, not
limited a limited a limited at 
lot little all
a) Vigorous activities, such as running, lifting heavy objects, 
participating in strenuous sports
b) Moderate activities, such as moving a table, pushing a 
vacuum cleaner, bowling or playing golf
c) Lifting or carryhig groceries
d) Clhnbmg several flights of stairs
e) Climbing one flight of stairs
f) Bending, kneeling or stooping
g) Walking more than a mile
h) Walking half a mile
i) Walking a 100 yards
j) Bathing and dressing yourself
4 During the past 4 weeks, have you had any of the followmg problems with your work or other 
regular daily activities as a result of vour physical health?
Answer Yes or No to each question.
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□ Yes □ No
□ Yes □ No
□ Yes □ No
□ Yes □ No
a) Cut down on the amount of time you spent on work or other activities
b) Accomplished less than you would like
c) Were limited in the kind of work or other activities
d) Had difficulty perfonning the work or other activities 
(eg it took extra effort)
5 Durhig the‘past 4 weeks, have you had any of the following problems with your work or other 
regular activities as a result of any emotional problems (such as feeling depressed or anxious)?
Answer Yes or No to each question.
a) Cut down on the amount of time you spent on work or other activities
b) Accomplished less than you would like
c) Didn’t do work or other activities as carefully as usual
6 During the past 4 weeks, to what extent has your physical health or emotional problems interfered 
with your normal social activities with family, friends, neighbours or groups:
□Not at all □  Slightly □  Moderately □  Quite a bit □  Exti'emely
□ Yes □ No
□ Yes □ No
□ Yes □ No
7 How much bodily pain have you had during the past 4 weeks?
□  None □  Veiy mild DMild □  Moderate DSevere □  Very
severe
8 During the past 4 weeks, how much did pain interfere with your normal work (mcluding work both 
outside the home and housework)?
□  Not at all □  A little bit □Moderately □  Quite a bit □  Extremely
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9 These questions are about how you feel and how things have been with you during the past month.
(For each question, please indicate the one answer that comes closest to the way you have been 
feeling.)
How much time during the past month
a) did you feel full of life?
b) have you been a very nervous person?
c) have you felt so down in the dumps that 
nothing could cheer you up?
d) have you felt calm and peaceful?
e) did you have a lot of energy?
f) have you felt downhearted and low?
g) did you feel worn out?
h) have you been a happy person?
i) did you feel tired?
j) has your healtli limited your social
activities (like visiting friends or close 
relatives)?
All of Most of A good Some A little None
the the bit of of the of the of
time time the time time the
time time
□ □ □ □ □ □
□ □ □ □ □ □
□ □ □ □ □ □
□ □ □ □ □ □
□ □ □ □ □ □
□ □ □ □ □ □
o □ □ □ □ □
□ □ □ □ □ a
□ □ □ □ □ □
□ □ □ □ □ □
10 Please choose the answer tliat best describes how tme or false each of the following statements is 
for you.
Please tick one box on each Ime 
a) I seem to get ill more easily than
Definitely Mostly Not
true tme sure
Mostly Definitely 
false false
other people □ □ □ □ □
I am as healthy as anybody I know □ □ □ □ □
I expect my health to get worse □ □ □ □ □
My health is excellent □ □ □ □ □
194
7// Inh rr i rv ,  ,‘x l u ’dnii
Angina
Visual Analogue Scale
Zero represents no affect to overall health and well being
Seven represents complete disability, discomfort and restriction to life
Place a cross on the scale which represents your Anginal symptoms best
Breathlessness 0  ^ #  t  §  #  —#  $  ^  7
Place a cross on the scale which represents how well you manage your Anginal symptoms:
Breathlessness 0 # — #— #------#— e — #— # — »  7
How often do you use your GTN sublingual spray ......................per day
......................per week
What things tend to bring on your angina symptoms: circle all that apply 
Exercise Cold weather Heavy meals
Stress Lying flat Walking uphill
Other (please state) ............................................................
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Summary of assessment 
Observations :
Medication compliance : 
Alcohol :
Smoking ;
Diet :
Exercise:
General Health : 
Angina/Breathlessness : 
Education on heart disease: 
Brief evaluation of assessment
ACTION PLAN
Suggestion Discussed with GP Date discussed Action to be taken
Extracts from this questiomiahe are taken from The Short Form 36 Health Survey 
Reproduced by kind pennission of the Health Outcomes Institute, Mimieapolis, USA
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Appendix IX: Patient held record cards
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^STOBHILL
 n n sT r u st  —
stobhill NHS Trust, Cardiology Dept. 
133 Balornock Rd. Glasgow G 21 3UW 
Tel: 0141 201 3058
CORONARY HEART DISEASE
INTEGRATED CARE PROJECT
Name:........................... ...... ............
Address:.............. ............................
Date of B irth:...................................
Please cany this card with you. 
Nurse: KATY JOSS
Contact No: 0141 772 4744 (SMP) 
0141 201 3000 
page:4227 Stobhill Hospital
D r:................................................... .
BLOOD PRESSURE 
systolic diastolic
CHOLESTEROLDATE WEIGHT NEXT APPOINTMENT is 
Date Time Place
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Appendix X: Abstract accepted for poster presentation at the European Society of 
Cardiology 2000, Amsterdam, The Netherlands 26-30 August 2000
199
. ! p p c iu i ix X  . ! nru t p r c y n u n i  In Xiirop'cm; ! <x jt o l  (
SECONDARY PREVENTION OF CORONARY HEART DISEASE - AN 
INTEGRATED APPROACH 
KA Joss; GM Lindsay; FG Dunn
Stobhill Hospital, Balornock Road, Glasgow, Scotland, G21 3UW
Introduction Recent studies have demonstrated that follow up and treatment for patients 
with Coronary Heart Disease (CHD) remains clearly deficient and that more effective 
methods o f health promotion and education are required to reduce cardiovascular 
morbidity and mortality. The concept o f hospital trained cardiac nurses in providing the 
link between primary and secondaiy care may be one way to integrate care in patients 
with CHD.
Method As part of a prospective intervention study being undertaken in the North of 
Glasgow, patients with CHD were identified and contacted. Patients were invited to the 
General Practice premises for a one to one assessment of risk factors and medical 
treatment. Advice was given regarding risk factor modification and appropriate changes 
to medical management initiated by the nurse specialist. Patients were followed up on a 
three monthly basis to monitor progress.
Results Complete data on Cholesterol, Systolic Blood Pressure (SBP), Body Mass Index 
(BMI) and Smoking was available for 59 patients, on entry to study and at three and nine 
months o f follow up.
There was a progressive reduction in random serum cholesterol over the study period. 
Mean cholesterol at baseline, three and nine months being 5.6, 4.9 and 4.8mmol/l 
respectively. The percentage o f patients with a random serum cholesterol o f >5.0mmol/l 
was 71%(42/59), 40.6%(24/59) to 28.8%(17/59) over the same period.
SBP also reduced over the study period. Mean SBP being 138, 128 and 124mm/Hg 
respectively. The percentage of patients with a SBP >140mm/Hg was 37%(22/59), 
16.9%(10/59) and 8.5%(5/59) over the same period.
BMI did not significantly change. Mean BMI being 27.54, 27.27 and 27.75 respectively. 
The percentage o f patients with a BMI >30 was 27% (16/59), 23.7%(14/59) to 
22%(13/59) over the same period.
The percentage o f patients smoking was 22%(13/59), 22%(13/59) to 18.6%(11/59) over 
the same period with 8 reducing their smoking habit.
A paired 2 tailed t-test was used to compare results at baseline to nine months. BMI was 
not significantly different p=0.47. Smoking was significantly reduced p=0.007. The 
reduction in cholesterol and SBP was highly statistically significant p<0.001.
Conclusion The two major barriers to successful risk factor modification in General 
Practice are lack o f time and specialist input. We have demonstrated that a Nurse 
Specialist integrating care between the Primary and Secondary interface does 
significantly improve risk factor modification in a group most likely to benefit from such 
intervention.
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Appendix XI: Professional Nurse: Nurse-led interventions contribute to cutting the 
risks for heart disease
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Professional Nurse
Nurse-led intei-ventions contribute to cutting the risks for heart disease 
VOLJ8, NO 11, 01July2003
Katy Joss, RN, Cardiac Nurse Specialist, Stobhill Hospital, Glasgow; GmzQ L indsay, BSc 
(Hons), RN, RM, MN, PhD, Reader in Clinical Nursing Research, Glasgow Caledonian 
University/North Glasgo University NHS Tmst, Glasgow
Patients admitted to hospital with a coronaiy heart disease (CHD) event should be invited to 
participate in a multidisciplinary programme of secondaiy prevention and cardiac rehabilitation, 
as recommended in Standard 12 of the National SeiMce Framework for Coronary Heart Disease 
(NSF) (DoH, 2000).
In addition, a large proportion of CHD patients who are managed in general practice and/or on a 
hospital outpatient basis and who may not have had the opportunity to attend formal cardiac 
rehabilitation programmes would benefit from appropriate secondaiy prevention. Cardiac 
rehabilitation programmes vary across the UK in terms of the patient groups who are eligible to 
join. Many limit access to post-myocardial infarction patients and post-coronaiy arteiy bypass 
patients only (Bethell et al, 2001; Thompson et al, 1997).
The aims of cardiac rehabilitation and secondaiy prevention measures are to reduce the risk of 
subsequent cardiac problems and promote a return to a flill and normal life. This paper focuses on 
the impact of nurse-led initiatives in the provision of secondaiy preventive care for a range of 
patient groups with CHD.
A growing body of research-based evidence has shown in recent years that a range of 
inteiventions can lead to a reduction in the mortality of patients with CHD (SIGN, 2002).
Prophylactic medication
Aspirin has been shown to significantly reduce vascular events - vascular death, non-fatal stroke 
and myocardial infarction (MI) - by 13-42% in a range of patient groups who have suffered, or are 
at high risk of, vascular events (Antiplatelet Trialists' Collaboration, 1994; SIGN, 1999).
A meta-analysis of studies involving more than 20 000 patients on long-term beta-blocker therapy 
following an MI showed a 23% reduction on all-cause mortality and a 32% reduetion in sudden 
death (Held and Yusuf, 1993).
Ace inhibitors In addition to aspirin, long-term angiotensin-converting-enzyme (ACE) inliibitors 
should be considered for patients following MI with or without left ventricular dysflinction 
(HOPE, 2001).
CHD risk-factor reduction
Treatment to target major CHD risk factors, namely hypertension (BP >140/90mmHg) (Browner 
and Hulley, 1989) and hyperlipidaemia (total cholesterol >5mmol/L) (Scandinavian Simvastatin 
Survival Study Group, 1994; Heart Protection Study, 2002) has shown reductions in mortality of 
30%. The promotion of healthy lifestyles - including smoking cessation (Cupples and McKnight, 
1994; Wilhelmsson, 1988), havmg a diet high in finit, vegetables, nuts, grains and fish oils (Burr 
et al, 1989; De Lorgeril et al, 1994; Moher, 1995), and, in obese patients, weight loss (Katzel et al. 
1995) and increased physical exercise (Wenger, 1995) - can have a significant effect on the 
prevention of CElD events.
However, despite the evidenee of the benefits of these changes in lifestyle they are not necessarily 
implemented in practice, and suboptimal treatment of CHD patients with prophylactic 
medications and achievement of risk factor targets have been reported (Brady, et al, 2001)
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Nurse-Ied initiatives
There is growing evidence of the effeetiveness of nurse-led secondaiy inteiwentions for patients 
with CHD, particularly in primary care settings. The results of large-scale randomised controlled 
trials highlight principles of good practice.
Different approaches to the promotion of secondaiy prevention of CHD in primary care have been 
evaluated. The results of a large trial conducted in 21 GP practices that included 1906 CHD 
patients aged 55-75 years, reported a difference in the effectiveness of three different methods of 
promoting secondary prevention.
The methods included an audit of patients' medical notes, with feedback to the primary health­
care team, compared with two groups with systematic recall to either GP follow-up or a nurse-led 
clinic (Moher et al, 2001). 'Adequate assessment' of serum cholesterol, blood pressure and 
smoking status was compared in terms of risk factors being recorded in the notes and follow-up 
assessment within a two-year period.
Adequate assessment of all three risk factors was much more common in the nurse and GP recall 
groups (85% and 76% respectively) than the audit group (52%) The systematic recall system for 
patients with CHD led to better patient assessment, although only small improvements in 
treatment or reduction in risk-factor levels were noted. After adjustment for baseline levels, the 
advantage of the nurse recall group, in terms of percentage of patients with appropriate 
management in smoking, cholesterol, blood pressure and antiplatelet medication, was 10% higher 
than the audit group and 8% higher compared with the GP recall group. It was noted in this study 
that nurses were good at taking patient histories but less good at exploring patients' perceptions 
and understanding of heart disease and medication (Moher et al, 2001).
In terms of the recommendations of the NSF for cardiac rehabilitation (DoH, 2000) this is an area 
where nurses should direct ftirther attention. Other studies of nurse-led interventions in primary 
care have reported improved outcomes in terms of CHD risk-factor reduction and higher levels of 
prescription of prophylactic medication. A study involving 19 general practices (involving 1173 
CHD patients) evaluated nurse-led CHD secondaiy prevention clinics where regular follow-up of 
patients (every two to six months) was undertaken compared with usual care (Campbell et al 
1998a; Campbell et al 1998b).
The patients included in the study were less than 80 years old and had been prescribed nitrates, or 
were identified by computer or manual search of pre-existing morbidity and prescribing records 
with a diagnosis of CHD. For practical purposes, a random sample of patients was identified and 
recruited in order that numbers would be limited to 150 per practice. (Tliis excluded just less than 
one-third of CHD patients identified and should be taken into account in any attempt to replicate 
this seiwice for all CHD patients in general practice.)
The inteiwention and follow-up took place over one year. The clinics included a first visit lasting 
about 45 minutes and follow-up visits of about 30 minutes' duration, with the timmg of follow-up 
determined by clinical circumstances but usually every two to six months. Clinic protocols were 
compiled by the primaiy care team, and training and education materials were available, together 
with client-held record cards.
The study concluded that nurse-led clinics improved medical secondaiy prevention outcomes 
(lowering blood pressure and cholesterol) and helped patients to make lifestyle modifications. The 
majority of patients gained at least one effective component of secondary prevention (for 
example, increasing exercise, cutting down on fatty foods and so on), although no effect on 
smoking cessation was achieved. Based on hnprovements in blood pressure and cholesterol 
levels, and a reduction in cardiac risk factors, it was estimated that a one-third reduction in 
cardiovascular events and mortality would be realised as a result of these changes.
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A four-year follow-up of this cohort of patients has now been reported (Murchie et al, 2003). This 
shows significant improvements in the intervention group at one year (as reported above) except 
for smoking cessation, and the lifestyle changes were sustained for four years, except for the 
exercise. The control group, most of whom attended clinics after the first year, improved over the 
intervening years so that at the four-year follow-up there were no significant differences in 
treatment targets. There were more deaths in the control group (18.9%) compared with the 
mtervention group (14.5%) over the mean follow-up period of 4.7 years. The authors conclude 
that nurse-led secondary prevention improved medical and lifestyle components of secondary 
prevention and this led to significant reductions in mortality over the medium temi.
Specific high-risk CHD patient groups
For patients awaiting coronary arteiy bypass graft surgery, McHugh et al (2001) showed that a 
specialist nurse-led programme can improve coronaiy risk factors, anxiety and depression levels, 
and general health and well-being. Their randomised trial compared a specialist liaison nurse and 
practice nurse shared-care programme with standard care. The health needs of intervention group 
patients were assessed by a specialist cardiac liaison nurse to detemiine the content of a 
programme of monthly health education sessions. These were carried out alternately by the liaison 
nurse in patients' homes and by the practice nurse in the practice clinic.
Interventions addressing behavioural risk factors - smoking, physical inactivity, poor diet, and 
excess alcohol - were based on an individual's readiness to change (Prochaska and Diclemente, 
1984). Those receptive to making changes were encouraged to evaluate the positive and negative 
aspects of change.
Patients in the nurse-led programme were more likely to stop smoking (25% compared with 2%), 
reduce obesity (24.5% compared with 10.2%), show improvement in anxiety levels, report an 
increase in physical activity and to maintain better blood pressure control.
Although there was a significant reduction in cholesterol levels in the intervention group there 
was no significant difference between the groups in terms of the proportion of patients with 
cholesterol levels achieving target levels. Tliis may relate to the fact that as yet nurses are unable 
to prescribe lipid-lowering therapy. Patients in the specialist nurse-led programme were in better 
general health at the point of surgeiy as measured by the self-completed SF-36 health and well­
being assessment questionnaire (Ware et al, 1993). The liaison system between specialist cardiac 
nurses, practice nurses and health visitors in combination with the use of patient-held records in 
this programme, was reported to be beneficial in promoting continuity of care.
Another study, by Jolly et al (1999), compared care directed by a specialist cardiac liaison nurse 
with standard preventive interventions provided in seeondary care to patients discharged from 
hospital after an acute episode of angina or MI. The liaison nurse's role was to provide an 
important link to facilitate communication between primary and secondaiy care settings rather 
than direct patient care.
In Jolly et al's study, the patients' practice nurse was informed of the timing of discharge and 
provided with a summaiy of important elinical information either by telephone or fax within 24 
hours. Again, eontinuity between primaiy and secondary care for post-discharge CHD patients 
was shown to have improved; however, patients demonstrated no improvement in the main 
modifiable CHD risk factors and did not report improvement in quality of life.
Conclusion
Nurses have a key role in promoting cardiac rehabilitation and secondaiy prevention. A range of 
important principles for practice associated with improved outcomes in nurse-led initiatives for 
patients with CHD are set out in Box 1.
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Since it is recognised that not all CHD patient groups will be offered a foiinal cardiac 
rehabilitation programme, and not all those invited to attend do so (Bethell et al, 2001), a wider 
range of approaches such as described in this paper should be considered in order that patients 
with established CHD are appropriately managed. Pivotal to the success of cardiac rehabilitation 
has been the multidisciplinary approach, ensuring good communication and education. The 
evidence supporting secondary prevention management of CHD is compelling and undoubtedly 
more investment in researching cardiac rehabilitation is required. Different models of cardiac 
rehabilitation exist and these at present predominate within secondaiy care. The way foiward may 
be to shift the emphasis towards adopting mtegrated care pathways working across 
primary/secondary care.
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